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ABSTRACT	  	  Generally	   Hepatitis	   C	   Virus	   tropism	   is	   limited	   to	   hepatocytes.	   This	   limited	  tropism	   is	   a	   result	   of	   the	   receptors	   HCV	   requires	   for	   cellular	   entry	   and	   other	   host	  cellular	  factors	  including,	  uniquely,	  a	  liver	  specific	  miRNA,	  miR-­‐122.	  	  The	  relationship	  between	  HCV	   and	  miR-­‐122	   is	   interesting,	   as	   commonly,	  miRNA	   are	   associated	  with	  suppression	   of	   function,	   but	   in	   the	   case	   of	   HCV,	   miR-­‐122	   actively	   promotes	   HCV	  proliferation.	   	  In-­‐depth	  studies	  have	  demonstrated	  that	  miR-­‐122	  along	  with	  the	  RNA	  induced	   silencing	   complex	   (RISC)	  protein	  Argonaute	  2	   (Ago2)	   binds	  directly	   to	   two	  seed	   sequences	   separated	   by	   8-­‐9	   nucleotides	   on	  HCV	   5’UTR.	   	   Binding	   to	   the	   5’UTR	  results	  in	  an	  increase	  in	  viral	  replication	  and	  translation.	  	  The	  method	  by	  which	  miR-­‐122	   promotes	  HCV	   translation	   and	   replication	   is	   not	   fully	   understood	   but	   evidence	  suggests	   that	   part	   of	   the	   function	   of	   miR-­‐122	   is	   to	   stabilize	   the	   HCV	   genome	   and	  protect	  it	  from	  exonuclease	  degradation	  by	  Xrn1,	  but	  other	  mechanisms	  remain	  to	  be	  identified.	  The	  reliance	  of	  HCV	  on	  miR-­‐122	  is	  best	  exemplified	  by	  the	  fact	  that	  removal	  of	   miR-­‐122	   by	   a	   miR-­‐122	   antagonist	   drastically	   impedes	   HCV	   viral	   titers	   in	  Chimpanzees	  and	  humans	  with	  no	  indication	  of	  escape	  mutants.	  The	   observation	   that	   HCV	   augmentation	   of	   the	   HCV	   life	   cycle	   by	   miR-­‐122	  requires	   Ago2	   suggests	   that	   other	   components	   downstream	   in	   the	   miRNA	  suppression	   pathway	   may	   also	   be	   part	   of	   the	   mechanism	   of	   action.	   Our	   studies	  focused	   specifically	   on	   the	   processing	   body	   (p-­‐body)	   associated	   DEAD-­‐box	   helicase	  DDX6.	  	  DDX6	  is	  essential	  for	  p-­‐body	  assembly,	  required	  for	  robust	  miRNA	  suppression	  activity	   and	   elevated	   in	   HCV	   associated	   hepatocellular	   carcinomas.	   As	   such	   we	  hypothesized	  that	  DDX6	  and	  p-­‐bodies	  were	  directly	  or	  in-­‐directly	  associated	  with	  the	  mechanism	  of	  action	  of	  miR-­‐122.	  Knocking	   down	   DDX6	   with	   siRNA	   indicated	   that	   DDX6	   augments	   both	   HCV	  replication	   and	   translation.	   To	   examine	   whether	   DDX6	   augmentation	   of	   HCV	  replication	  was	  related	  to	  the	  effects	  of	  miR-­‐122	  on	  the	  HCV	  life	  cycle,	  HCV	  replication	  and	  translation	  were	  assessed	  in	  the	  presence	  or	  absence	  of	  miR-­‐122	  when	  DDX6	  was	  knocked	   down.	   Our	   data	   indicated	   that	   HCV	   replication	   and	   translation	   were	  augmented	   equally	   by	   miR-­‐122	   whether	   DDX6	   was	   present	   or	   not.	   Our	   data	   also	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demonstrated	  that	  HCV	  replication	  and	  translation	  that	  was	  occurring	  independent	  of	  miR-­‐122	  was	  also	  still	  affected	  by	  DDX6	  knockdown.	  	  Taken	  together	  our	  observations	  strongly	  suggest	  that	  the	  role	  DDX6	  has	  on	  HCV	  is	  independent	  of	  HCV	  and	  miR-­‐122’s	  relationship.	  	  In	   order	   to	   better	   understand	   miR-­‐122’s	   relationship	   with	   HCV,	   we	  hypothesized	   that	   targeting	   the	   miR-­‐122	   binding	   region	   with	   siRNA	   would	   inhibit	  HCV	  replication	  initially,	  but	  that	  over	  the	  course	  of	  several	  rounds	  of	  treatment	  with	  the	  same	  siRNA,	  HCV	  would	  mutate	   to	  escape	   the	  siRNA,	  producing	  escape	  mutants	  that	   replicate	   without	   a	   dependency	   on	   miR-­‐122.	   	   These	   escape	   mutants	   could	   be	  evaluated	  on	  how	   they	   replicate	  without	  using	  miR-­‐122,	   shedding	   light	  on	  miR-­‐122	  and	   HCV’s	   relationship.	   Conversely	   if	   no	   escape	  mutants	   arose	   the	   siRNA	   could	   be	  further	  studied	  as	  a	  potential	  therapeutic	  for	  HCV.	  siRNA	  designed	  to	  target	  the	  miR-­‐122	  binding	  region	  inhibited	  HCV	  replication,	  confirming	   that	   the	   designed	   siRNAs	   could	   access	   the	  miR-­‐122	   binding	   region	   and	  function	  as	  an	  siRNA.	  Interestingly,	  when	  the	  siRNAs	  were	  used	  against	  a	  replication	  competent	  HCV	  RNA	  having	  a	  single	  nucleotide	  mutation	  in	  the	  first	  miR-­‐122	  binding	  site,	   instead	   of	   abolishing	   siRNA	   knockdown,	   two	   of	   the	   siRNA	   showed	   enhanced	  inhibition	   activity.	   The	   target	   sequences	   of	   these	   siRNAs	   spanned	   both	   miR-­‐122	  binding	   sites	   and	  we	   speculate	   that	   their	   inhibitory	  activity	  was	  due	   to	   competition	  for	  miR-­‐122	  binding	  to	  site	  2.	  This	  observation	  indicates	  that	  siRNA	  targeting	  the	  miR-­‐122	   binding	   region	   have	   dual	   activity,	   by	   siRNA	   induced	   cleavage,	   and	   as	   a	  competitive	  inhibitor	  of	  miR-­‐122	  binding.	  	  	  Selection	   for	   viral	   escape	   mutants	   of	   the	   miR-­‐122-­‐binding	   site	   targeting	  siRNAs	  revealed	  viral	  RNAs	  having	  mutations	  within	  the	  miR-­‐122	  binding	  sites,	  in	  the	  surrounding	  region,	  and	  to	  other	  areas	  within	  the	  HCV	  IRES.	  	  The	  mutant	  viruses	  will	  be	  used	  to	  assess	  the	  influence	  of	  miR-­‐122	  binding	  site	  mutations	  on	  HCV	  replicative	  fitness,	   and	   to	   determine	   if	   the	   virus	   can	   evolve	   to	   replicate	   independent	   from	  augmentation	  by	  miR-­‐122.	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  Membrane	  Protein-­‐Associated	  Protein	  A	  IMP-­‐1	   	   	   Insulin-­‐Like	  Growth	  Factor	  2	  mRNA	  Binding	  Protein	  1	  IFNα	   	   	   Interferon	  α	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IAV	   	   	   Influenza-­‐A	  Virus	  	  IRES	   	   	   Internal	  Ribosome	  Entry	  Site	  ITAFs	   	   	   IRES	  Trans-­‐Acting	  Factors	  JCV	   	   	   JC	  Virus	  JEV	   	   	   Japanese	  Encephalitis	  Virus	  JFH-­‐1	   	   	   Japanese	  fulminant	  Hepatitis-­‐1	  KSRP	   	   	   K	  Homology	  Splicing	  Regulatory	  Protein	  LDL	   	   	   Low-­‐Density	  Lipoprotein	  LDLR	   	   	   Low-­‐Density	  Lipoprotein	  Receptor	  LNA	   	   	   Locked	  Nucleic-­‐Acid	  LVP	   	   	   Lipoviroparticle	  miRNA	   	   Micro	  RNA	  miR-­‐122	   	   Mirco	  RNA	  122	  mRNP	  	   	   mRNA	  Ribonucleoprotein	  MW	   	   	   Membranous	  Web	  N	   	   	   Nucleocapsid	  NS-­‐1	   	   	   Non-­‐Structural	  Protein-­‐1	  NSAP1	  	   	   NS1	  associated	  protein	  1	  NPC1L1	   	   Niemann-­‐Pick	  C1-­‐Like	  1	  NP	   	   	   Nucleoprotein	  ORF	   	   	   Open	  Reading	  Frame	  PABP	   	   	   Poly(A)-­‐Binding	  Protein	  PBS	   	   	   Phosphate-­‐Buffered	  Saline	  P-­‐body	   	   Processing	  Body	  PV	   	   	   Poliovirus	  Pri-­‐miRNA	   	   Primary	  miRNA	  Pre-­‐miRNA	   	   Precurssor	  miRNA	  PFV	   	   	   Prototype	  Foamy	  Virus	  Rap55	  	   	   RNA-­‐Associate	  Protein	  55	  RLuc	   	   	   Renilla	  Luciferase	  RISC	   	   	   RNA-­‐Induced	  Silencing	  Complex	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RNP	   	   	   Ribonucleoprotein	  RRE	   	   	   Rev-­‐Response	  Element	  SGR	   	   	   Sub-­‐genomic	  Replicon	  SHAPE	   Selective	  2’Hydroxyl	  Acylation	  Analyzed	  by	  Primer	  Extension	  siRNA	   	   	   Silencing	  RNA	  SL	   	   	   Stem-­‐loop	  SR-­‐B1	   	   	   Scavenger	  Receptor	  Class	  B	  Type	  1	  SVR	   	   	   Sustained	  Virological	  Response	  TfR1	   	   	   Transferrin	  Receptor	  1	  TRBP	   	   	   HIV-­‐1	  Transactivating	  Response	  RNA-­‐Binding	  Protein	  UTR	   	   	   Untranslated	  Region	  VEGF	   	   	   Vascular	  Endothelial	  Growth	  Factor	  VLDL	   	   	   Very	  Low-­‐Density	  Lipoprotein	  WNV	   	   	   West	  Nile	  Virus	  WT	   	   	   Wild-­‐type
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1.0 INTRODUCTION	  AND	  LITERATURE	  REVIEW	  	  
 Hepatitis	  C	  virus	  introduction	  1.1 	  
1.1.1 Clinical	  characteristics	  	  Hepatitis	   C	   virus	   (HCV)	   is	   a	   global	   health	   concern.	   	   There	   are	   roughly	   150	  million	  people	  currently	  infected	  with	  the	  virus	  (1),	  with	  an	  estimated	  250	  thousand	  being	  Canadians	  (2).	   	   	  There	  are	  six	  genotypes	  of	   the	  virus	  distributed	  throughout	  the	  world,	  with	  genotype	  1	  being	  most	  prominent	  in	  North	  America	  (3).	  	  The	  virus	   is	   spread	   from	  person	   to	  person	   through	   infected	  blood	  or	  blood	  derived	   bodily	   fluid	   (4).	   	   The	   commonly	   accepted	   modes	   of	   transmission	   are	  through	  blood	  transfusions	  with	   infected	  blood,	  sharing	  needles,	  accidental	  needle	  sticks,	   sexual	   contact	   and	   mother	   to	   child	   transmission	   during	   childbirth	   (4-­‐6).	  	  Once	   infected	  with	   the	  virus,	  patients	  either	  spontaneously	  clear	   the	   infection	  and	  suffer	  few,	  if	  any	  symptoms,	  or	  develop	  a	  chronic	  hepatitis	  infection.	  	  Unfortunately	  patients	  develop	  chronic	  hepatitis	  roughly	  70%	  of	  the	  time.	  	  Those	  who	  suffer	  from	  chronic	  hepatitis	  are	  at	  risk	  of	  developing	  liver	  cirrhosis,	  hepatocellular	  carcinoma	  (HCC)	  and	  death	  (1).	  	  Due	  to	  the	  level	  of	  cirrhosis	  associated	  with	  HCV,	  its	  infections	  are	  the	  leading	  cause	  for	  liver	  transplantation	  in	  North	  America	  (7).	  Currently,	   there	   is	   no	   vaccine	   to	  prevent	  HCV	   infections.	   	   Traditionally,	   the	  treatment	   for	   those	   infected	  with	   the	   virus	  was	   a	   combination	  of	   pegylated	   IFN-­‐α	  and	  ribavirin	  (8).	   	  This	  combination	  treatment	  is	  effective	  roughly	  70	  -­‐	  80%	  of	  the	  time	  for	  genotype	  2	  and	  3	  but	  only	  50%	  effective	  against	  genotype	  1	  (9).	  Fortunately	  for	   patients	   infected	  with	   genotype	   1,	   there	   have	   recently	   been	   new	   direct-­‐acting	  antiviral	   agents	   (DAAs)	   licensed	   for	  use.	   	   In	   combination	  with	   IFN-­‐α	  and	   ribavirin	  these	  DAA	  have	  been	  demonstrated	   to	  be	  60%-­‐90%	  effective	  at	   clearing	   the	  virus	  from	  patients	  infected	  with	  genotype	  1	  (10,	  11).	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1.1.2 Molecular	  characteristics	  	  HCV	  is	  an	  enveloped	  positive	  strand	  RNA	  virus	  belonging	  to	  the	  Flaviviridae	  family.	  	  Its	  genome	  is	  9.6kb	  in	  length	  and	  encodes	  a	  single	  open	  reading	  frame	  (ORF)	  flanked	   by	   5’	   and	   3’	   untranslated	   regions	   (UTR).	   	   An	   internal	   ribosome	   entry	   site	  (IRES)	  resides	  within	  the	  5’	  UTR	  and	  directs	  cap-­‐independent	  translation	  of	  the	  HCV	  polyprotein,	   which	   is	   cleaved	   into	   ten	   individual	   proteins	   by	   both	   host,	  (endoplasmic	   reticulum	   signal	   peptidase	   and	   single	   peptide	   peptidase)	   and	   viral	  proteases.	  The	  10	  individual	  proteins	  are	  termed	  core,	  E1,	  E2,	  p7,	  NS2	  through	  NS5	  (12,	  13)	  (Fig.	  1.1).	  	  	  
1.1.2.1 Structural	  proteins	  	  	  Structural	  proteins	  core,	  E1,	  and	  E2	  are	  derived	  from	  the	  N-­‐terminal	  portion	  of	  the	  HCV	  polyprotein.	  Core	  protein	  forms	  the	  HCV	  nucleocapsid	  and	  binds	  to	  and	  surrounds	   the	   genomic	   RNA	   in	   the	   HCV	   virion.	   Core	   protein	   is	   composed	   of	   two	  domains.	   	   The	   first	   domain	   is	   predicted	   to	   interact	   with	   RNA	   while	   the	   second	  domain	  interacts	  with	  lipids	  (14).	  	  Core	  proteins’	  ability	  to	  bind	  RNA	  and	  lipids	  has	  led	  to	  it	  being	  associated	  with	  many	  host	  and	  viral	  proteins	  (15)	  but	  its	  primary	  role	  is	  as	   the	  HCV	  capsid	  protein,	   and	   it	   is	  predicted	   to	  play	  a	   large	   role	   in	  HCV	  virion	  assembly	  (16,	  17).	  The	  HCV	  envelope	  proteins	  E1	  and	  E2	  mediate	  virion	  attachment	  and	  entry	  into	  the	  cell.	  Both	  E1	  and	  E2	  proteins	  are	  ER	  anchored	  prior	   to	   incorporation	   into	  the	   viral	   particle.	   	   E2	   is	   recognized	   by	   both	   CD81	   and	   scavenger	   receptor	   class	   B	  type	  1	  (SR-­‐B1)	  and	  plays	  a	  pivotal	  role	  in	  HCV	  entry	  (18).	  	  





Figure	  1.1	  HCV	  genome,	  translation	  and	  processing.	  A	  schematic	  diagram	  of	  the	  HCV	  genome,	  highlighting	  the	  complexity	  of	  the	  5’	  and	  3’	  UTR.	  	  The	  polyprotein	  that	  is	   translated	   from	   the	  HCV	   genome,	   and	   the	   cleavage	   sites	  within	   the	  polyprotein	  that	  results	  in	  the	  individual	  HCV	  proteins.	  The	  hollow	  scissors	  represent	  the	  cleave	  of	   core	   by	   single	   peptide	   peptidase,	   the	   solid	   scissors	   represent	   cleave	   events	  performed	  by	  ER	  singnal	  peptidase	  and	  arrows	  denote	  sites	  that	  are	  cleaved	  by	  HCV	  proteases,	  either	  NS2	  or	  NS3.	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pH	  of	   the	  virion	  during	  egress	   from	  the	  cell	   (19).	   	  P7	  also	   interacts	  with	  NS2,	  and	  core,	  a	  step	  proposed	  to	  be	  important	  for	  virus	  assembly	  (20).	  During	  translation	  of	  viral	  proteins,	  NS2	  works	  as	  a	  protease	  to	  cleave	  itself	  from	  NS3	  (21).	  It	  then	  recruits	  viral,	  and	  possibly	  host	  proteins,	  required	  for	  HCV	  to	  assemble	  and	  then	  bud	  into	  the	  ER	  lumen	  (22).	  NS3	   is	   both	   a	   DEAD-­‐box	   helicase,	   a	   type	   of	   helicase	   protein	   that	   will	   be	  discussed	   in	   depth	   in	   section	   1.6	   (13),	   and	   a	   protease.	   	   NS3	   promotes	   its	   own	  cleavage	   from	   NS2	   in	   the	   polyprotein,	   and	   along	   with	   its	   co-­‐factor	   NS4A	   is	   the	  protease	  responsible	  for	  cleaving	  much	  of	  the	  HCV	  polyprotein	  (23,	  24).	  	  In	   addition	   to	   its	   role	   as	   a	   cofactor	   for	  NS3’s	  protease	   and	  helicase	   activity	  (25),	  NS4A’s	  association	  with	  NS3	  allows	   the	  complex	   to	  be	  anchored	   to	   the	  ER,	  a	  process	   that	   is	   thought	   to	   enable	   the	   two	  proteins	   to	   augment	  HCV	  assembly	   (24,	  26).	  	   NS4B	  is	  a	  hydrophobic	  protein	  with	  an	  important,	  but	  poorly	  understood	  role	  in	   the	   HCV	   life	   cycle.	   NS4B	   induces	   the	   formation	   of	   the	   HCV	   infection	   induced	  membranous	   web	   (MW),	   the	   site	   of	   the	   HCV	   replication	   complex	   and	   HCV	   RNA	  replication.	   	  Thus,	  an	  interaction	  between	  NS4B	  and	  the	  replicating	  RNA	  cannot	  be	  ruled	   out,	   and	   perhaps	   plays	   a	   role	   in	   HCV	   replication	   (27).	   	   Others	   have	   also	  demonstrated	   that	   a	  mutated	   form	   of	  NS4B	   can	   increase	  HCV	   particle	   production	  while	  not	  affecting	  replication,	  suggesting	  a	  role	  in	  virus	  assembly	  (28).	  NS5A	   has	   been	   demonstrated	   to	   affect	   HCV	   translation,	   replication	   and	  assembly.	  	  How	  NS5A	  participates	  in	  many	  of	  these	  activities	  is	  not	  known,	  but	  NS5A	  exists	   in	   two	  states,	  a	  hyperphosphorylated	  state	  and	  a	  hypophosphorylated	  state.	  Hypophosphoyrlated	   NS5A	   is	   thought	   to	   promote	   RNA	   replication	   while	  hyperphosphorylated	   NS5A	   suppresses	   replication	   (29-­‐31).	   NS5A’s	   ability	   to	  localize	  to	   lipids	  and	  interact	  with	  core	   is	  thought	  to	  be	  essential	   for	  the	  virus’	   life	  cycle	  (12,	  32,	  33).	  	  	  NS5B	   is	  an	  RNA	  dependent	  RNA	  polymerase	  and	  as	   such	   is	   responsible	   for	  the	  synthesizing	  of	  both	  the	  positive	  and	  negative	  RNA	  strands	  of	  HCV.	   	  There	  are	  also	   studies	   that	   indicate	  NS5B	   is	   required	   for	  HCV	   assembly	   but	   its	   exact	   role	   is	  unknown	  (18,	  34).	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1.1.3 HCV	  life	  cycle	  	  An	  overview	  of	   the	  entire	  HCV	   life	   cycle	   is	   summarised	   in	  Figure	  1.2	  and	  a	  summary	  of	  how	  HCV	  attaches	  and	  enters	  a	  hepatocyte	  is	  illustrated	  in	  Figure	  1.3.	  	  
1.1.3.1 	  Attachment	  and	  entry	  	  Infectious	   HCV	   virus	   particles	   are	   assembled	   in	   a	   way	   that	   makes	   them	  similar	   to	   very-­‐low	   density	   lipoprotein	   (VLDL)	   or	   low-­‐density	   lipoprotein	   (LDL).	  	  Interestingly,	   lower	   density	   HCV	   particles	   are	   more	   infectious	   to	   human	  hepatocytes.	  	  Similarities	  between	  the	  appearance	  of	  HCV	  particles	  in	  comparison	  to	  VLDLs	   and	   LDLs	   have	   led	   to	   HCV	   particles	   being	   named	   lipoviroparticles	   (LVPs).	  	  The	  composition	  of	  the	  LVP	  allows	  for	  a	  myriad	  of	  interactions	  with	  host	  receptors.	  	  As	  such,	  many	  receptors	  including,	  heparin	  sulphate	  proteoglycans	  (HSPG),	  the	  low-­‐density	   lipoprotein	  receptor	  (LDLR),	  SR-­‐B1,	  and	  Niemann-­‐Pick	  C1-­‐like	  1	  (NPC1L1)	  have	  all	  been	  identified	  to	  influence	  HCV	  attachment	  and	  subsequent	  steps	  required	  for	  entry	  by	  clathrin-­‐mediated	  endocytosis	  (35).	  The	  first	  interaction	  a	  LVP	  has	  is	  with	  HSPG	  on	  the	  host	  cell.	  	  HSPG	  is	  thought	  to	  bind	  apolipoprotein	  E	  (ApoE)	  moieties	  within	  the	  LVP	  and	  allows	  attachment	  of	  the	   virus	   but	   does	   not	   assists	   in	   cell	   entry	   (36).	   LDLR	  has	   also	   been	   suggested	   to	  assist	  in	  a	  similar	  fashion	  but	  it	  is	  not	  essential.	  In	  fact	  its	  interaction	  with	  LVPs	  has	  also	  been	  demonstrated	  to	  be	  detrimental	   to	   the	  virion,	   thus	   the	   importance	  of	   its	  interaction	   is	   not	   fully	   understood	   (37,	   38).	   	   After	   association	  with	   HSPG	   and/or	  LDLR,	   the	  LVP	  associates	  with	   SR-­‐B1.	  The	   ability	   of	   SR-­‐B1	   to	   assist	   in	   attachment	  depends	  on	  the	  composition	  of	  the	  LVP	  and	  its	  access	  to	  HCV	  E2	  (39-­‐41).	  	  SR-­‐B1	  is	  dispensable	  for	  virion	  attachment	  but	  is	  required	  for	  virus	  entry.	  	  Virion	  interaction	  with	  SR-­‐B1	  promotes	  E2	  binding	  to	  the	  tetraspanin	  protein	  CD81,	  and	  virion	  entry	  requires	   SR-­‐B1’s	   ability	   to	   transfer	   lipids	   from	   the	   lipoprotein	   to	   the	   cellular	  membrane,	   not	   its	   interaction	  with	  E2,	   since	   a	  mutation	   in	   SR-­‐B1	   that	   inhibits	   its	  ability	   to	   transfer	   lipids	  does	  not	   inhibit	  HCV	  attachment,	  but	  prevents	  viral	  entry	  (41,	  42).	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Figure	  1.3	  HCV	  entry	  into	  hepatocytes.	  Step	  1:	  The	  LVP	  attached	  to	  HSPG	  and/or	  LDR.	  Step	  2:	  SR-­‐B1	  interacts	  with	  VLP	  and	  E2.	  Step	  3:	  CD81	  binds	  E2.	  Step	  4:	  CD81	  and	   the	   LVP	   translocation	   to	   the	   tight	   junction	   between	   hepatocytes	   were	   CD81	  interacts	  with	   claudin-­‐1.	   Step	   5:	   Clathrin-­‐mediated	   endocytosis	   of	   LVP	   along	  with	  CD81	  and	  probably	  claudin-­‐1	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CD81	  binding	  is	  important	  for	  two	  reasons:	  	  it	  prepares	  HCV	  for	  fusion	  with	  the	   endosome,	   (43)	   and	   stimulates	   its	   translocation	   to	   hepatocyte	   tight	   junctions	  (44).	   	   Within	   the	   tight	   junctions	   CD81	   interacts	   with	   the	   tight	   junction	   proteins	  claudin-­‐1	   and	   occludin	   (45,	   46).	   	   Claudin-­‐1	   and	   occludin	   have	   no	   known	   physical	  interaction	   with	   the	   LVP	   and	   are	   thus	   considered	   co-­‐receptor	   proteins.	   	   How	  occludin	  aids	  in	  HCV	  entry	  is	  not	  known	  but	  it	  does	  not	  involve	  attachment	  (47).	  	  At	  some	  point	  after	  HCV	  interacts	  with	  CD81,	  the	  transferrin	  receptor	  1	  (TfR1)	  assists	  in	  HCV	  entry	  by	  an	  as	  yet	  unknown	  mechanism	  (48).	  	  Recently	   the	   Niemann-­‐Pick	   C1-­‐like	   1	   (NPC1L1)	   has	   been	   identified	   as	   a	  receptor	   required	   for	   HCV	   entry.	   	   There	   is	   no	   evidence	   that	   NPC1L1	   interacts	  directly	   with	   HCV,	   but	   it	   appears	   to	   interact	   with	   cholesterol	   on	   the	   LVP	   (49).	  	  	  Lindenbach	  and	  Rice	  in	  a	  recent	  review	  speculated	  that	  NPC1L1	  might	  help	  modify	  the	  LVP	  to	  further	  induce	  the	  interaction	  between	  CD81	  and	  E2	  (18)	  as	  it	  prepares	  HCV	  for	  fusion	  with	  the	  endosome.	  Claudin-­‐1’s	   role	   in	  HCV	   entry	   is	   also	   uncharacterized	   but	   data	   suggest	   that	  the	  HCV	  virion-­‐CD81	  complex,	  and	  claudin-­‐1	  induce	  clathrin-­‐mediated	  endocytosis	  (50,	   51).	   	   After	   clathrin-­‐mediate	   endocytosis,	   HCV	   fusion	   with	   the	   endosome	   is	  triggered	  by	  endosome	  acidification	  and	  the	  genome	  is	  released	  into	  the	  cytoplasm	  were	  it	  can	  begin	  to	  translate	  proteins	  from	  its	  genome	  (43,	  52)	  	  
1.1.3.2 	  Translation	  	  Once	  access	  to	  the	  cytosol	  is	  gained	  the	  HCV	  genome	  serves	  as	  a	  template	  for	  translation.	  Mentioned	  briefly	  in	  1.1.2,	  HCV	  utilizes	  an	  IRES	  located	  in	  the	  5’UTR	  for	  cap-­‐independent	   translation.	   RNA	   in	   the	   5’UTR	   forms	   a	   structured	   IRES	   RNA	  element,	   which	   is	   able	   to	   recruit	   translation	   initiation	   proteins	   and	   ribosomes	  independent	  from	  the	  cap	  binding	  proteins	  to	  initiate	  translation.	  	  	  The	   HCV	   5’UTR	   contains	   four	   domains,	   domains	   I	   to	   IV,	   which	   are	   highly	  conserved	  among	  genotypes.	  Domains	  II,	  III,	  IV,	  and	  sequences	  past	  the	  UTR	  into	  the	  core	   coding	   sequence	   comprise	   the	   IRES.	   	  Domain	   III	   is	   responsible	   for	   recruiting	  the	  40S	  ribosome	  and	  all	  three	  domains	  act	  to	  retain	  the	  40S	  ribosome	  and	  place	  it	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in	  the	  proper	  orientation	  with	  respect	  to	  the	  AUG	  start	  codon.	  	  Once	  the	  ribosome	  is	  recruited	  and	  retained,	  the	  cellular	  initiation	  factors	  are	  recruited.	  	  eIF3	  is	  recruited	  by	   domain	   III	   and	   associates	   with	   the	   40S	   ribosome.	   This	   association	   allows	   the	  recruitment	  of	  the	  ternary	  complex	  eIF2-­‐GTP-­‐tRNAmet,	  which	  upon	  phosphorylation	  by	   eIF5	   leads	   to	   the	   addition	   of	   the	   60S	   ribosome	   and	   the	   formation	   of	   the	  translational	  competent	  80s	  ribosome	  complex	  (53-­‐55).	  	  HCV	  translation	  is	  also	  influenced	  by	  cis-­‐acting	  elements	  outside	  of	  the	  IRES.	  Immediately	   down	   stream	   of	   the	   IRES	   in	   the	   core	   coding	   sequence	   there	   are	  numerous	  secondary	  structures,	  which	  have	  been	  demonstrated	  to	  up-­‐regulate	  and	  down-­‐regulate	  HCV	  translation.	  	  As	  summarized	  in	  a	  recent	  review	  by	  Hoffman	  and	  Liu,	  the	  influence	  of	  the	  core	  region	  on	  HCV	  translation	  is	  suggested	  to	  be	  mediated	  by	  viral	  and/or	  host	  protein	  binding	  or	   long-­‐range	  RNA-­‐RNA	  interactions	  between	  the	  core	  region	  and	  other	  parts	  of	  the	  HCV	  genomic	  RNA	  (54).	  	  Additionally,	  a	  stem-­‐loop	  present	  in	  the	  NS5B	  coding	  region	  of	  HCV	  has	  been	  demonstrated	  to	  enhance	  HCV	  translation	  by	  interacting	  with	  the	  IRES	  through	  domain	  III	  (56).	  	  	  Similar	   to	   the	   5’UTR,	   the	   3’UTR	   is	   also	   divided	   into	   distinct	   domains.	   	   The	  three	  domains	  of	  the	  3’UTR	  are	  the	  variable	  domain,	  the	  poly	  (U/C)	  domain,	  and	  X-­‐tail	   domain.	   	   All	   three	   domains	   up-­‐regulate	   HCV	   translation,	   presumably	   through	  direct	  RNA-­‐RNA	  interaction	  with	  the	  5’UTR,	  or	  possibly	  by	  proteins	  attached	  to	  the	  3’UTR	   stimulating	   HCV	   translation	   (57).	   	   The	   interaction	   of	   the	   5’UTR	   with	   the	  3’UTR	   also	   indicates	   that	   HCV	   translation	   probably	   occurs	   in	   a	   closed-­‐loop	  orientation,	  like	  that	  of	  cap-­‐dependent	  translation.	  	  	  	  HCV	  IRES	  function	  is	  also	  influenced	  by	  trans-­‐acting	  host	  proteins,	  known	  as	  ITAFs	   (IRES	   trans-­‐acting	   factors).	   These	   proteins	   include	   the	   La	   autoantigen,	   also	  called	  the	  La	  protein,	  mice	  minute	  virus	  NS1	  associated	  protein	  1	  (NSAP1),	  insulin-­‐like	   growth	   factor	   2	   mRNA	   binding	   protein	   1	   (IMP-­‐1),	   LSm1-­‐7,	   heterogeneous	  ribonuclear	   protein	   D	   and	   L	   (hnRNP	  D	   and	   hnRNP	   L),	   that	   bind	   directly	   to,	   or	   in	  close	  proximity,	  with	   the	   IRES,	  and	  promote	  HCV	  translation	  (58-­‐61).	   	  Conversely,	  Gemin5	  down	  regulates	  translation	  by	  interacting	  with	  domain	  III	  of	  the	  IRES	  (62).	  	  Interestingly,	  many	  of	  the	  ITAFs	  demonstrate	  the	  ability	  to	  interact	  with	  each	  other	  suggesting	  a	  complex	  role	  in	  coordinating	  HCV	  translation	  (55,	  60,	  63,	  64).	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HCV	   proteins	   represent	   another	   set	   of	   ITAFs,	   however	   the	   roles	   of	   the	  individual	   HCV	   proteins	   are	   controversial.	   Many	   reports	   have	   indicated	   that	   the	  same	  proteins	  can	  increase,	  decrease	  or	  have	  no	  effect	  on	  HCV	  translation	  (54,	  65).	  	  	  The	   development	   of	   better	   culture	   systems	   should	   provide	   a	   more	   definitive	  understanding	  of	  the	  effects	  the	  individual	  HCV	  proteins	  have	  on	  HCV	  translation	  in	  the	  near	  future.	  Lastly,	  certain	  miRNAs	  have	  been	  identified	  that	  affect	  HCV	  translation.	  The	  miRNA	   miR-­‐199a*,	   miR-­‐196	   and	   miR-­‐122	   have	   all	   been	   identified	   to	   affect	   HCV	  translation	  and	  their	  role	  in	  HCV	  life	  cycle	  will	  be	  discussed	  in	  depth	  elsewhere.	  	  
1.1.3.3 	  Replication	  	  As	  HCV	  is	  a	  positive	  sense	  RNA	  virus,	  its	  genome	  acts	  as	  a	  template	  for	  both	  protein	   translation	   (which	   occurs	   in	   the	   5’	   to	   3’	   direction)	   and	   RNA	   replication	  (which	  proceeds	  in	  the	  3’	  to	  5’	  direction).	  Thus,	  at	  some	  point	  the	  HCV	  genome	  must	  cease	   translating,	   and	   initiate	   replication.	   How	   HCV	   regulates	   the	   switch	   from	  translation	  to	  replication	  is	  not	  yet	  known,	  and	  the	  process	  by	  which	  HCV	  replicates	  is	   still	   poorly	   understood.	   Limiting	   our	   understanding	   of	   HCV	   replication	   is	   the	  difficulty	  in	  separating	  translation	  from	  replication	  without	  abolishing	  the	  virus	  life	  cycle.	  Replication	  appears	  to	  function	  in	  cis,	  by	  proteins	  derived	  from	  the	  genome,	  so	  thus	   far	   methods	   to	   study	   replication	   in	   isolation	   of	   translation	   have	   not	   been	  developed.	   Another	   limiting	   factor	   is	   the	   inability	   to	   trans-­‐complement	   viral	  components	   involved	   in	  HCV	  genome	   replication.	  Thus,	   it	   is	   difficult	   to	   determine	  what	  individual	  viral	  proteins	  are	  doing.	  Most	  studies	  must	  thus	  rely	  on	  microscopic	  techniques	   to	   observe	   protein	   location	   and	   replication	   induced	   structures	   in	   HCV	  infected	  cells.	  	  During	  the	  HCV	  life	  cycle,	  HCV	  protein	  expression	  causes	  the	  appearance	  of	  a	  MW	   in	   the	   cytosol.	   	   The	   MW	   is	   derived	   from	   the	   endoplasmic	   reticulum	   (ER)	  membrane	  and	  is	  thought	  to	  be	  the	  site	  of	  HCV	  replication	  (66,	  67).	  	  The	  topology	  of	  the	   MW	   that	   HCV	   utilizes	   for	   replication	   is	   still	   under	   debate.	   	   Recent	   evidence	  suggests	  that	  replication	  occurs	   inside	  or	  on	  the	  outer	  surface	  of	   infection	  induced	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double	   membrane	   and/or	   multiple	   membrane	   vesicles	   (66).	   	   The	   inability	   to	  demonstrate	   actively	   replicating	   HCV	   RNA	   due	   to	   the	   limitations	   of	   the	   current	  methods	  prevents	  definitive	  answers	  on	  where	  HCV	  replicates	  in	  the	  MW.	  RNA	  replication	  occurs	  through	  a	  RNA	  negative	  strand	  intermediate.	  Progeny	  RNA	   synthesis	   is	   carried	   out	   by	   the	   viral	   RNA	  dependent	  RNA	  polymerase,	  NS5B.	  NS5B	  can	  generate	  both	  the	  positive	  and	  the	  negative	  strand	  HCV	  RNA	  in-­‐vitro	  (68)	  but	   this	   synthesis	   requires	   self-­‐priming	   in	   the	   presence	   of	   large	   amount	   of	  nucleotides.	  	  In-­‐vivo,	  it	  is	  likely	  that	  NS5B	  relies	  on	  viral	  and	  host	  proteins	  to	  assist	  in	  priming	   and	   initiation	   of	   RNA	   synthesis,	   however	   this	   mechanism	   has	   not	   been	  elucidated.	  The	  ability	  to	  construct	  viable	  sub-­‐genomic	  replicons	  indicates	  that	  the	  non-­‐structural	   proteins	   NS3,	   NS4A,	   NS4B,	   NS5A	   and	  NS5B	   are	   sufficient	   for	   HCV	   RNA	  amplification.	   	   Using	   HCV	   replicons	   and	   genetic	   screens,	   several	   host	   proteins	  associated	  with	   HCV	   replication	   have	   been	   identified	   and	   have	   been	   described	   in	  detail	   elsewhere	   (69).	   	  However,	   I	  will	  describe	  a	   few	  key	  examples	  of	  HCV	  virus-­‐host	  interaction.	  	  Human	  vesicle-­‐associated	  membrane	  protein-­‐associated	  protein	  A	  (hVAP-­‐A),	   a	   protein	   involved	   in	   intracellular	   vesicle	   trafficking,	   interacts	  with	   the	  hypophosphorylated	  form	  of	  NS5A	  and	  promotes	  RNA	  replication	  (70).	  In	  addition,	  the	  hVAP-­‐A	  interaction	  and	  phosphorylation	  of	  NS5A	  has	  been	  suggested	  to	  regulate	  the	  switch	  between	  HCV	  translation	  and	  replication	  (71,	  72).	   	   In	  a	  second	  example	  Cyclophilin	  A	  (CypA),	  a	  cellular	  chaperone	  protein,	  interacts	  with	  NS5A	  to	  promote	  HCV	   replication.	   CypA	   is	   thought	   to	   promote	   HCV	   replication	   by	   altering	   the	  conformation	   of	   NS5A	   (73),	   but	   its	   precise	   role	   in	   HCV	   replication	   remains	   to	   be	  determined	  (69,	  74).	  	  Interestingly,	  CypA	  inhibitors	  such	  as	  alisporivir,	  are	  emerging	  as	  promising	  anti-­‐HCV	  therapeutics	  (9,	  75).	  Similar	  to	  HCV	  translation,	  cis-­‐acting	  elements	  in	  the	  HCV	  genome	  have	  been	  demonstrated	   to	   influence	  HCV	  replication.	   	  As	  discussed	  previously,	   the	  3’UTR	  of	  HCV	  is	  divided	  into	  three	  regions	  (the	  variable	  domain,	  the	  poly	  (U/C)	  domain,	  and	  X-­‐tail	   domaim),	   and	   not	   surprisingly	   given	   that	   negative	   strand	   RNA	   replication	  begins	   at	   the	   3’	   end,	   each	   region	   has	   been	   shown	   to	   be	   important	   for	   HCV	  replication.	   The	   X-­‐tail	   domain	   contains	   3	   highly	   conserved	   stem-­‐loops	   and	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mutational	   analysis	   of	   the	   stem-­‐loops	   indicated	   that	   both	   the	   sequences	   and	  structures	  of	  the	  stem-­‐loops	  are	  required	  for	  HCV	  replication	  (69,	  76).	  	  The	  second	  stem-­‐loop	  has	  been	  demonstrated	  to	  interact	  with	  a	  stem-­‐loop	  located	  in	  the	  NS5B	  coding	  region	  (77).	   	  This	   interaction	   is	  essential	   for	  HCV	  replication,	  and	  although	  the	   stem-­‐loop	   in	   the	   X-­‐tail	   domain	   cannot	   be	   moved,	   the	   stem-­‐loop	   in	   the	   NS5B	  coding	   region	   can	   be	   relocated	   to	   the	   3’UTR	   and	   replication	   can	   still	   occur.	  Interestingly,	  the	  last	  base	  in	  the	  3’	  end	  of	  HCV	  participates	  in	  stem-­‐loop	  base	  paring	  thus	  limiting	  its	  access	  by	  NS5B.	  	  This	  stem-­‐loop	  is	  thought	  to	  protect	  the	  RNA	  from	  degradation,	  but	   also	   indicates	  a	   level	  of	   complexity	   required	   for	  HCV	   to	   replicate	  the	  negative	  strand.	  	  	  The	   poly	   (U/C)	   domain	   is	   required	   for	   HCV	   replication,	   and	   must	   contain	  over	  26	  consecutive	  uracils	  for	  replication	  to	  occur	  (78).	  	  The	  poly	  U	  track	  is	  thought	  to	   bind	   viral	   and	   host	   proteins,	   but	   its	   exact	   roll	   in	   replication	   is	   not	   fully	  understood.	  The	  variable	  region	  of	  the	  3’UTR	  is	  not	  essential	  for	  HCV	  replication	  but	  alterations	   to	   it	   leads	   to	   a	   decrease	   in	   HCV	   replication,	   indicating	   it	   provides	   a	  function	  for	  replication	  (79).	  The	  3’UTR	  of	  the	  negative	  strand	  is	  the	  complement	  of	  the	  5’UTR	  and	  is	  thus	  also	  important	  for	  positive	  strand	  genome	  synthesis.	  Not	  much	  is	  known	  regarding	  how	  the	  3’end	  of	  the	  negative	  strand	  induces	  RNA	  synthesis,	  but	  it	  is	  proposed	  to	  be	  simpler	  because	  unlike	  the	  3’end	  of	  the	  positive	  strand,	  the	  last	  base	  is	  not	  involved	  in	  a	  stem-­‐loop	  structure	  and	  therefore	  theoretically	  is	  easier	  to	  prime	  for	  initiation	  and	   elongation	   (80).	   The	   secondary	   structure	   of	   the	  minus	   strand	  3’	   end	  has	   also	  been	   predicted	   to	   form	   5	   stem-­‐loops	   within	   the	   initial	   250	   base-­‐pairs	   (81-­‐84).	  	  Utilizing	  bi-­‐cistronic	  constructs,	  the	  first	  three	  stem-­‐loops	  were	  demonstrated	  to	  be	  required	   for	  positive	  strand	  synthesis,	   and	   the	  other	   loops,	  although	  not	   required,	  also	  contribute	  (84,	  85).	  	  	  	  
1.1.3.4 	  Assembly	  and	  release	  	  Following	  HCV	  genome	  replication	  in	  the	  MW,	  some	  of	  its	  replicated	  genomes	  are	  assembled	  into	  new	  virions.	  	  The	  assembly	  and	  release	  of	  the	  virus	  is	  thought	  to	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occur	  in	  parallel	  with	  the	  formation	  and	  release	  of	  lipoproteins	  and	  is	  not	  cytolytic.	  	  Again,	  the	  definitive	  mechanism	  by	  which	  HCV	  virions	  are	  assembled	  and	  released	  is	  poorly	   understood	   but	   experimental	   evidence	   sheds	   some	   light	   on	   assembly	   and	  release.	  Virion	  assembly	  appears	  to	  be	  initiated	  by	  an	  interaction	  between	  NS5A	  and	  core	   on	   lipid	   droplets	   (86).	   	   The	   HCV	   nucleocapsid	   protein,	   core,	   associates	   with	  cytosolic	  lipid	  droplets	  after	  it	  is	  synthesized	  (14).	  	  HCV	  virion	  assembly	  is	  initiated	  concurrently	  with	  the	  disassociation	  of	  core	  from	  the	  lipid	  droplets.	  	  An	  interaction	  between	   NS5A	   and	   core	   may	   facilitate	   the	   disassociation	   between	   core	   and	   lipid	  droplets	   (32,	   87).	   This	   step	   is	   thought	   to	   bridge	   the	   replication	   complexes	   and	  assembly	   since	   NS5A	   is	   associated	   with	   replication	   complexes,	   and	   thus	   HCV	  genomes,	  and	  perhaps	  acts	  as	  a	  signal	  to	  initiate	  assembly.	  	  In	  the	  next	  step	  of	  virion	  assembly,	  HCV	  leaves	  the	  MW	  and	  buds	  into	  the	  ER.	  	  NS2	  is	  thought	  to	  orchestrate	  this	  process	  by	  recruiting	  the	  ER	  anchored	  HCV	  envelope	  proteins	  E1	  and	  E2,	  along	  with	  NS3-­‐4,	  and	  p7	  to	  the	  core-­‐lipid-­‐HCV	  RNA-­‐NS5A	  complex	  (88-­‐90).	  	  	  Although	  the	  non-­‐structural	  proteins	  are	  not	  associated	  with	  the	  virion	  particle	  after	  release,	  they	  are	   required	   for	   assembly	   and	   possibly	   egress.	   These	   interactions	   are	   thought	   to	  result	  in	  viral	  RNA	  being	  transported	  in	  association	  with	  core	  to	  bud	  into	  the	  ER	  (18,	  34).	  	   Once	  in	  the	  ER,	  HCV	  virions	  enter	  a	  secretory	  pathway	  similar	  to	  that	  used	  by	  VLDLs.	   	   During	   this	   process	   HCV	   likely	   interacts	   with	   lipoproteins,	   however	   HCV	  does	   not	   appear	   to	   be	   assimilated	   into	   VLDLs	   because	   VLDLs	   require	   ApoB,	   a	  protein	  that	  can	  be	  present	  on,	  but	  is	  not	  required	  for	  HCV	  particles;	  thus,	  how	  and	  when	  HCV	  requires	  its	  lipoproteins	  is	  not	  fully	  understood	  (91,	  92).	  However,	  when	  HCV	  acquires	  its	  lipoproteins	  it	  requires	  ApoE,	  as	  it	  is	  essential	  to	  generate	  mature	  infectious	  particles	   (92).	  HCV	   is	   then	   released	   into	   the	   cytoplasm,	   or	   alternatively	  can	  directly	  infect	  neighbouring	  cells	  using	  a	  process	  that	  does	  not	  require	  release	  of	  the	  particle	  (93).	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 Hepatitis	  C	  virus	  life	  cycle	  and	  miRNAs	  1.2 	  	  Cellular	   miRNAs	   are	   endogenously	   expressed	   short	   double	   stranded	   RNAs	  that	   associate	   with	   mRNAs	   and	   modulate	   their	   translation	   and	   stability.	   	   Human	  cells	   express	   over	   1000	  miRNAs,	   and	   they	   are	   estimated	   to	   regulate	   at	   least	   one	  third	  of	   the	   total	  mRNAs	  expressed	   (94).	   	  The	  HCV	   life	   cycle	   is	   influenced	  directly	  and	   indirectly	   by	   cellular	   miRNAs.	   Several	   miRNAs	   that	   affect	   HCV	   infection	   and	  pathogenesis	   have	   been	   reviewed	   by	   Thibault	   et	   al.	   (95).	   This	   thesis	   will	   focus	  extensively	  on	  the	  interaction	  between	  HCV	  and	  the	  microRNA-­‐122	  (miR-­‐122)	  with	  consideration	   to	   potential	   host	   accessory	   proteins	   that	   are	   involved	   in	   their	  relationship.	  	  	  
1.2.1 miR-­‐122	  	  	  
1.2.1.1 Cellular	  function	  	  The	  miRNA	  miR-­‐122	  is	  abundantly	  expressed	  in	  the	  liver	  and	  is	  estimated	  to	  constitute	   70%	   of	   all	   the	   total	   miRNAs	   expressed	   in	   the	   mammalian	   liver,	   with	  roughly	  135	  000	  copies	  per	  cell	  (96).	  	  miR-­‐122	  is	  22	  nucleotides	  long	  and	  is	  derived	  from	  the	  5’	  end	  of	  the	  hcr	  mRNA,	  a	  non-­‐coding	  gene.	  Interestingly,	  miR-­‐122	  has	  been	  demonstrated	  to	  regulate	  the	  expression	  of	  cationic	  amino	  acid	  transporter	  1	  (CAT-­‐1).	  	  Under	  normal	  cell	  conditions	  miR-­‐122	  sequesters	  CAT-­‐1	  in	  p-­‐bodies,	  but	  during	  times	   of	   stress,	   such	   as	   hepatocyte	   re-­‐generation,	  miR-­‐122	   repression	   is	   released,	  and	  CAT-­‐1	  is	  actively	  translated	  (97).	  	  In	  the	  context	  of	  the	  liver,	  miR-­‐122	  regulates	  lipid	   and	   cholesterol	   metabolism,	   hepatocyte	   differentiation,	   circadian	   regulation,	  and	  iron	  homeostasis	  (98,	  99).	  	  Recently,	  several	  targets	  within	  these	  pathways	  have	  been	  demonstrated	  to	  directly	  interact	  with	  miR-­‐122	  (100-­‐102).	  	  However,	  miR-­‐122	  regulation	   cannot	   explain	   the	   outcome	   of	   the	   effects	   on	   all	   these	   pathways	  suggesting	   that	  many	  miR-­‐122	   targeted	   genes	   are	   yet	   to	   be	   identified.	   Short-­‐term	  inactivation	   of	   miR-­‐122	   does	   not	   appear	   to	   be	   detrimental,	   and	   may	   in	   fact	   be	  beneficial,	  as	  it	  has	  been	  demonstrated	  to	  lower	  serum	  cholesterol	  (103).	  However,	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miR-­‐122	   knockout	   mice	   exhibit	   persistent	   hepatosteatosis,	   fibrosis	   and	   develope	  HCC,	  suggesting	  that	  miR-­‐122	  has	  important	  roles	  in	  the	  liver	  including	  as	  a	  tumour	  suppressor	  (98,	  102).	  	  
1.2.1.2 Direct	  interaction	  with	  the	  HCV	  genome	  	  miR-­‐122	   has	   an	   unconventional	   relationship	   with	   HCV.	   The	   conventional	  interaction	   between	   a	   miRNA	   and	   its	   target	   mRNA	   leads	   to	   suppressed	   protein	  expression.	   	   In	  the	  case	  of	  miR-­‐122	  and	  HCV,	  the	   interaction	  promotes	  expression,	  and	  virus	  replication	  rather	  than	  acting	  as	  a	  suppressor.	  	  The	  relationship	  between	  HCV	  and	  miR-­‐122	  is	  also	  unconventional	  in	  that	  miR-­‐122	  interacts	  with	  the	  5’	  end	  of	  the	  HCV	  genome	  instead	  of	  the	  customary	  3’	  end	  (Fig.	  1.4).	   	   Jopling	  et	  al.	  observed	  that	  in	  order	  for	  HCV	  to	  replicate,	  it	  requires	  direct	  association	  of	  miR-­‐122	  with	  two	  binding	   sites	   in	   the	  HCV	  5’UTR.	   	  This	  was	  demonstrated	  by	   the	   fact	  HCV	   contains	  two	   sites	   that	   are	   separated	   by	   a	   highly	   conserved	   8-­‐9	   nucleotides,	   which	   are	  complementary	  to	  miR-­‐122	  seed	  sequence	  (a	  7-­‐8	  nucleotide	  span	  in	  the	  5’	  end	  of	  the	  miR-­‐122	  required	  for	  miRNA	  suppression	  activity)	  in	  its	  5’UTR.	  Mutations	  to	  these	  sites	   rendered	   the	   virus	   incapable	   of	   replicating	   unless	   a	   synthetic	   miR-­‐122	   that	  contained	   complimentary	   mutations	   that	   reinstate	   binding	   was	   added	   to	   the	  experiment	   (104,	   105).	   These	   experiments	   demonstrated	   that	   miR-­‐122	   was	  required	   for	   HCV	   replication,	   and	   its	   requirement	   is	   through	   a	   direct	   nucleotide	  interaction	  between	  HCV	  genomic	  RNA	  and	  miR-­‐122.	   	   In	  addition	  to	  miR-­‐122	  seed	  sequence,	   binding	   of	   miR-­‐122	   to	   the	   HCV	   genome	   also	   required	   annealing	   of	  nucleotides	   outside	   of	   the	   seed	   sequence	   (106).	   The	   amount	   of	   annealing	   of	   the	  extra	  nucleotides	  varies	  between	  HCV	  genotypes	  (107),	  however	  when	  the	  miR-­‐122	  seed	   sequence	   is	   bound	   at	   binding	   site	   1,	   nucleotides	   15	   and	   16	   of	  miR-­‐122	   also	  interact	  with	  the	  HCV	  5’	  terminus	  at	  conserved	  nucleotides	  at	  position	  2	  and	  3	  (106,	  107)	   (Fig	   1.4).	   This	   interaction	   is	   thought	   to	   give	   HCV	   5’end	   the	   appearance	   of	  dsRNA	  and	  potentially	  protects	  it	  from	  degradation.	  Analysis	  of	  HCV	  genome	  has	   revealed	   two	  other	  potential	  miR-­‐122	  binding	  sites.	   The	   third	   site	   was	   identified	   at	   the	   same	   time	   as	   the	   first	   two	   sites	   and	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Figure	   1.4	   miR-­‐122	   bound	   to	   the	   5'UTR	   of	   HCV	   genotype	   2a.	   	   A	   schematic	  diagram	  of	  how	  two	  molecules	  of	  miR-­‐122	  bind	  and	  interact	  with	  the	  5’UTR	  of	  HCV	  genotype	  2a.	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evidence	  suggests	  it	  does	  not	  play	  a	  role	  in	  HCV	  life	  cycle	  (105,	  108).	  	  The	  fourth	  site	  is	   present	   in	   genotypes	   1,	   3,	   4,	   and	   6	   and	   displays	   the	   ability	   to	   inhibit	   HCV	  replication	   and	   translation	   (109).	   Since	   the	   fourth	   site	   is	   not	   present	   on	   all	  genotypes,	   its	   purpose	   in	   HCV	   replication	   is	   unknown	   but	   may	   be	   important	   for	  suppressing	  HCV	  during	  the	  establishment	  of	  a	  chronic	  infection	  in	  genotypes	  which	  encode	  this	  fourth	  miR-­‐122	  bindings	  site.	  	  
1.2.1.3 Effects	  on	  HCV	  	  	  Early	  reports	  indicated	  that	  miR-­‐122	  promoted	  HCV	  RNA	  replication	  but	  did	  not	   influence	   viral	   translation	   (105).	   Subsequent	   reports	   confirmed	   that	   HCV	   can	  translate	  without	  miR-­‐122	  binding	   to	  HCV	  5’UTR,	  but	   that	  miR-­‐122	  binding	   to	   the	  5’UTR	  promotes	  viral	  translation	  by	  about	  2	  fold	  (108,	  110-­‐112).	  However,	  in	  spite	  of	  the	  influence	  of	  miR-­‐122	  on	  HCV	  translation,	  the	  increase	  in	  translation	  does	  not	  account	  for	  HCV	  dependency	  on	  miR-­‐122	  for	  replication.	  This	  was	  demonstrated	  by	  comparing	  replication	  levels	  of	  an	  HCV	  mutant,	  which	  could	  not	  bind	  miR-­‐122	  with	  an	   HCV	   mutant	   having	   a	   modified	   IRES	   that	   attenuated	   translation	   to	   a	   similar	  extent	   as	   the	  miR-­‐122	   binding-­‐mutant.	  While	   replication	   of	   the	   IRES	  mutant	  was	  attenuated,	   the	  mutant	   that	  could	  not	  bind	  miR-­‐122	  exhibited	  no	  replication	  at	  all	  (110).	   	   This	   suggests	   that	   while	  miR-­‐122’s	   influence	   on	   translation	  may	   enhance	  replication,	  other	  roles	  that	  promote	  HCV	  replication	  likely	  exist.	  	  One	   other	   role	   for	   miR-­‐122-­‐binding	   is	   to	   stabilize	   the	   HCV	   genomic	   RNA	  (113-­‐115).	   	  miR-­‐122	   increases	  HCV	   stability	   by	   protecting	   the	   5’end	   of	  HCV	   from	  degradation	  by	  the	  5’	   to	  3’	  exonuclease	  Xrn1	  (113,	  115).	   	  Following	  knockdown	  of	  Xrn1,	  HCV	  RNA	  to	  which	  miR-­‐122	  cannot	  bind,	  displayed	  the	  same	  decay	  rate	  and	  protein	   expression	   as	   HCV	   RNA	   in	   the	   presence	   of	   miR-­‐122	   (without	   Xrn1	  knockdown)	   (113).	   This	   observation	   suggests	   that	   miR-­‐122	   augments	   HCV	  translation	   solely	   through	   protecting	   the	   genome	   from	   degradation	   by	   Xrn-­‐1.	  	  However,	  an	  HCV	  mutant	  that	  could	  not	  bind	  miR-­‐122	  was	  still	  unable	  to	  replicate	  even	   when	   Xrn1	   was	   knocked	   down,	   indicating	   a	   secondary	   role	   for	   miR-­‐122	   in	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promoting	  HCV	  replication	  (113).	  	  	  How	  miR-­‐122	  promotes	  replication	  independent	  from	  genome	  stabilization	  is	  still	  unknown.	  Although	  many	  reports	  suggest	  that	  miR-­‐122	  is	  required	  for	  HCV	  replication,	  there	   is	   evidence	   that	   HCV	   can	   replicate	   independently	   of	   miR-­‐122.	   	   HCV	   sub-­‐genomic	   replicons	   replicate	   in	   Hep3B	   cells	   which	   to	   do	   not	   produce	   detectable	  levels	  of	  miR-­‐122	  (116).	  The	  observed	  replication	  was	  approximately	  100	  fold	  less	  efficient	  than	  miR-­‐122-­‐dependent	  replication.	  	  Similarly,	  Li	  et	  al.	  demonstrated	  that	  RNAs	  having	  point	  mutations	  to	  the	  first	  miR-­‐122	  binding	  site	  were	  able	  to	  replicate	  in	   the	   presence	   of	   a	   miR-­‐122	   antagonist,	   which	   rendered	   wild-­‐type	   (WT)	   virus	  incapable	   of	   replicating,	   suggesting	   that	   these	  RNAs	  had	   escaped	   the	   requirement	  for	  miR-­‐122	  (117).	  	  Although	  the	  replication	  of	  these	  viruses	  in	  the	  presence	  of	  miR-­‐122	  was	  a	  fraction	  of	  WT	  virus,	  the	  data	  suggest	  that	  miR-­‐122	  greatly	  enhances	  HCV	  replication,	  but	  may	  not	  be	  absolutely	  required	  for	  it.	  Another	   possibility	   is	   that	  miR-­‐122	  may	   regulate	   HCV	   stability,	   translation	  and/or	   replication	   by	   modifying	   the	   secondary	   structure	   of	   HCV	   genomic	   RNA.	  Several	   in-­‐vitro	   studies	   have	   been	   conducted	   to	   analyze	   RNA	   conformational	  changes	  miR-­‐122	  can	  cause	  in	  the	  5’UTR.	  One	  study	  indicated	  that	  miR-­‐122	  binding	  affected	  a	   long	  range	  RNA-­‐RNA	   interaction	   that	  may	   function	  as	  a	  switch	  between	  HCV	  replication	  and	  translation.	  The	  interaction	  was	  predicted	  to	  occur	  between	  the	  5’UTR	   and	   a	   region	  within	   core	   protein’s	   coding	   sequence	   (118).	   	  However,	   since	  this	   region	  of	  core	   is	  not	  present	   in	  HCV	  sub-­‐genomic	  replicons	  whose	   translation	  and	   replication	   are	   also	   stimulated	   by	   miR-­‐122,	   the	   biological	   relevance	   of	   this	  potential	  interaction	  is	  unknown	  (116).	  Two	  other	  studies	  analyzed	  changes	  to	  the	  conformation	  of	  the	  HCV	  5’	  UTR	  by	  using	  selective	  2’	  hydroxyl	  acylation	  analyzed	  by	  primer	  extension	  (SHAPE)	  analysis.	  	  SHAPE	  analysis	  works	  by	  adding	  bulky	  adducts	  to	   the	   ribose	   2’	   hydroxyl	   group	   of	   RNA,	   which	   blocks	   elongation	   by	   reverse	  transcriptase	   at	   the	   nucleotide.	   	   The	   availability	   of	   the	   2’	   hydroxyl	   group	   varies	  depending	   on	   whether	   the	   nucleotide	   is	   involved	   in	   RNA	   secondary	   interaction.	  Thus,	  after	  primer	  extension	  by	  reverse	  transcriptase,	  the	  product	  can	  be	  run	  on	  a	  gel	  to	  determine	  the	  availability	  of	  the	  nucleotide	  based	  on	  the	  size	  and	  intensity	  of	  fragments	  visualized	   (119).	   In	   these	   studies,	  miR-­‐122’s	  affinity	   for	   the	   second	  site	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was	  greater	   than	   for	   the	   first,	  and	  binding	   to	   the	  second	  site	  was	  not	  required	   for	  interactions	   with	   the	   nucleotides	   outside	   of	   the	   seed	   sequence	   (115,	   120).	   In	  addition,	   the	   interaction	  of	  miR-­‐122	  with	   the	   second	  miR-­‐122	  binding	   site	   caused	  structural	   modification	   to	   the	   5’UTR,	   outside	   of	   the	   miR-­‐122	   binding	   site	   region,	  	  and	  within	  the	  HCV	  IRES	  (115).	  While	  these	  modifications	  could	  promote	  or	  inhibit	  translation	   and/or	   replication,	   the	   biological	   relevance	   of	   the	   findings	   in-­‐vivo	   are	  unknown	  and	  require	   further	  analysis,	  since	  these	  studies	  were	  conducted	   in-­‐vitro	  with	  single	  stranded	  miR-­‐122	  in	  the	  absent	  of	  cellular	  proteins.	  	  	  
 HCV	  replication	  and	  miRNA	  proteins	  1.3 	  Given	   the	   requirement	   for	   miR-­‐122	   to	   bind	   to	   the	   HCV	   genome,	   it	   is	   not	  surprising	   that	   many	   of	   the	   proteins	   involved	   in	   miRNA	   suppression	   have	   been	  linked	  to	  HCV	  replication,	  since	  a	  cascade	  of	  host	  proteins	  are	  required	  for	  miRNA	  biogenesis,	   processing,	   and	   suppression	   activity.	   Further	   evidence	   for	   the	  involvement	  of	  host	  proteins	  to	  process	  miR-­‐122	  before	  it	  can	  be	  used	  to	  augment	  HCV	  replication	  comes	  from	  the	  observation	  that	  single	  stranded	  synthetic	  miR-­‐122	  can	   not	   promote	   HCV	   replication	   suggesting	   that	   more	   than	   simple	   RNA-­‐RNA	  annealing	  is	  required	  (112).	  	  	  
1.3.1 miRNA	  biogenesis	  proteins	  required	  for	  miR-­‐122	  augmentation	  of	  HCV	  
replication	  	  
1.3.1.1 miRNA	  biogensis	  	  Biogenesis	   of	   miRNA	   commences	   in	   the	   nucleus	   as	   primary	   miRNA	   (pri-­‐miRNA),	  naturally	  occurring	  hairpins	  within	  noncoding	  RNA	  transcripts	  (121).	  	  The	  microprocessor	  complex	  	  (MPC)	  cleaves	  the	  individual	  pri-­‐miRNA	  hairpin	  from	  the	  transcript	   to	   form	   precursor-­‐miRNAs	   (pre-­‐miRNA)	   but	   pre-­‐miRNAs	   can	   also	   be	  derived	  from	  exon	  and	  introns	  of	  coding	  RNA.	  	  The	  MPC	  is	  composed	  of	  the	  RNase	  III	  enzyme	   Drosha	   in	   a	   complex	   with	   DiGeorge	   syndrome	   critical	   region	   gene	   8	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(DGCR8)	  (122).	  	  The	  cleavage	  of	  the	  pri-­‐miRNA	  occurs	  when	  DGCR8	  recognizes	  the	  hairpin	   and	   the	   single	   stranded	   RNA	   next	   to	   the	   hairpin,	   which	   leads	   to	   the	  recognition	   and	   Drosha	   cleavage	   to	   generate	   the	   pre-­‐miRNA	   hairpin	   with	   a	   two-­‐nucleotide	  overhang	  (123).	  	  	  Once	   processed,	   the	   pre-­‐miRNA	   is	   exported	   from	   the	   nucleus	   into	   the	  cytoplasm.	   Translocation	   from	   the	   nucleus	   occurs	   via	   the	   Exportin	   5-­‐RanGTP	  process	  (124).	  	  	  Exportin	  5	  recognizes	  and	  binds	  the	  hairpin	  structure,	  and	  not	  only	  facilitates	  transport	  of	  the	  pre-­‐miRNA	  but	  also	  stabilizes	  the	  hairpin	  structure	  (125).	  	  The	  pre-­‐miRNA	   is	   released	   into	   the	  cytoplasm	  by	   the	  hydrolysis	  of	  RanGTP	  (125).	  	  Once	  in	  the	  cytoplasm,	  Dicer	  further	  processes	  the	  pre-­‐miRNA	  to	  a	  mature	  miRNA.	  	  Dicer	  binds	  to	  the	  pre-­‐miRNA	  and	  its	  RNase	  III	  activity	  removes	  the	  loop	  portion	  of	  the	   hairpin	   to	   leave	   a	   22	   nucleotide	   double	   stranded	   RNA	   having	   a	   2	   nucleotide	  overhang	  at	  each	  3’	  end	  (126,	  127).	  	  	  	  Following	   cleavage,	   Dicer	   retains	   the	   mature	   miRNA	   and	   with	   the	   help	   of	  HIV-­‐1	  transactivating	  response	  RNA-­‐binding	  protein	  (TRBP)	  and/or	  PACT	  is	  able	  to	  interact	  with,	  and	  transfer	  the	  miRNA	  to	  an	  argonaute	  protein.	  Argonaute	  proteins	  are	  key	  proteins	  in	  the	  complex	  that	  mediates	  miRNA	  gene	  silencing	  and	  is	  the	  core	  of	  a	  miRNA-­‐protein	  complex	  called	  the	  RNA-­‐induced	  silencing	  complex	  (RISC)	  (128-­‐130).	  	  	  	  
1.3.1.2 HCV	  and	  the	  biogenesis	  of	  miR-­‐122	  	  During	  the	  HCV	   life	  cycle,	  Dicer	  appears	   to	  be	  required	  to	  process	  pre-­‐miR-­‐122	  to	  miR-­‐122.	  	  Knocking	  down	  Dicer	  inhibits	  HCV	  replication,	  but	  its	  effect	  can	  be	  reversed	  by	  supplying	  the	  cells	  with	  synthetic	  mature	  miR-­‐122,	  indicating	  that	  HCV	  requires	   Dicer	   to	   process	   miR-­‐122	   for	   its	   use	   (112),	   but	   suggests	   that	   Dicer	   is	  dispensable	  for	  miR-­‐122	  loading	  into	  RISC.	  	  Similarly,	  TRBP	  has	  also	  been	  implicated	  in	   miRNA	   biogenesis,	   and	   its	   knockdown	   leads	   to	   decreased	   HCV	   replication.	  	  Contrary	   to	   Dicer,	   the	   supplementation	   of	   miR-­‐122	   does	   not	   fully	   restore	   HCV	  replication	  in	  TRBP	  depleted	  cells	  suggesting	  a	  secondary	  role	  of	  TRBP	  in	  the	  HCV	  life	  cycle	  (112),	  possibly	  in	  loading	  miR-­‐122	  into	  RISC.	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1.3.2 miRNA	  gene	  suppression	  proteins	  required	  for	  miR-­‐122	  augmentation	  
of	  the	  HCV	  life	  cycle	  	  
1.3.2.1 miRNA	   gene	   suppression:	   strand	   selection,	   incorporation	   into	   RISC,	  
and	  mRNA	  suppression	  	  Human	  cells	  have	  four	  argonaute	  (Ago)	  proteins	  (Ago1,	  2,	  3	  and	  4).	  The	  Ago	  proteins	   play	   a	   pivotal	   role	   in	   miRNA	   gene	   suppression	   and	   are	   responsible	   for	  selecting	   the	   strand	   of	   the	   double	   stranded	   miRNA	   that	   will	   be	   retained,	   and	  therefore	   which	   mRNA	   sequence	   will	   be	   targeted.	   Once	   a	   miRNA	   has	   been	  transferred	   to	   an	   Ago	   protein	   it	   undergoes	   strand	   selection.	   Strand	   selection	   is	  based	   on	   base-­‐pairing	   thermodynamic	   stability	   along	   the	  miRNA	  duplex,	  with	   the	  strand	  having	   less	  stable	  base	  pairing	  at	   the	  5’	  end	  being	  retained	  and	  denoted	  as	  the	  guide	  strand,	  while	   the	  other	  strand,	   the	  passenger	  strand,	   is	  discarded	   (131).	  	  The	  single	  stranded	  RNA	  loaded	  Ago	  combines	  with	  GW-­‐182	  to	  form	  a	  mature	  RISC	  capable	  of	  suppressing	  gene	  expression	  (132).	  	  	  Mature	  RISC	  utilizes	  the	  sequence	  of	  the	  guide	  strand	  to	  bind	  to	  the	  3’UTR	  of	  mRNA.	  	  If	  the	  binding	  is	  100%	  complementary	  between	  the	  mRNA	  and	  guide	  strand	  and	   the	   Ago	   protein	   participating	   in	   the	   RISC	   is	   Ago2,	   then	   the	   transcript	   can	   be	  cleaved	   at	   the	  middle	   of	   the	   guide	   strand,	   resulting	   in	   the	   silencing	  of	   that	  mRNA	  (133).	  	  If	  the	  binding	  is	  not	  100%	  complementary,	  or	  the	  RISC	  is	  composed	  of	  one	  of	  the	  other	  three	  Ago	  isoforms,	  then	  translation	  can	  be	  temporarily	  stalled,	  leading	  to	  the	  degradation	  of	  the	  transcript	  or	  halting	  translation	  for	  subsequent	  re-­‐activation.	  	  Silencing	  requires	  the	  host	  protein	  GW-­‐182.	  	  Ago	  proteins	  interact	  with	  GW-­‐182	  and	  GW-­‐182	   is	   predicted	   to	   interact	   with	   the	   poly-­‐A	   binding	   protein	   and	   impede	  translation	   by	   preventing	   the	   circularization	   of	   the	   transcript	   (132).	   GW-­‐182	   also	  recruits	  de-­‐adenylating	  and	  de-­‐capping	  enzymes,	  which	  leads	  to	  de-­‐adenylation	  and	  de-­‐capping	   of	   the	   transcript	   resulting	   in	   5’	   to	   3’	   degradation	   of	   the	   transcript	   by	  Xrn1	  (94,	  134,	  135).	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1.3.2.2 miRNA	  suppression	  proteins,	  miR-­‐122,	  and	  HCV	  	  miR-­‐122	  recognizes	  and	  binds	  HCV	  as	  part	  of	  RISC,	  or	  a	  RISC	   like	   complex.	  	  This	  was	  supported	  by	  the	  fact	  that	  the	  Ago	  proteins	  are	  required	  for	  efficient	  HCV	  replication,	   and	   for	   miR-­‐122	   to	   promote	   HCV	   replication	   (136).	   	   Early	   evidence	  suggested	   that	   all	   four	   Ago	   proteins	   influence	   HCV	   replication,	   but	   recent	  observations	   suggest	   that	   only	   Ago2	   has	   a	   significant	   effect	   on	   HCV	   (114).	  	  Knockdown	  of	  Ago2	  leads	  to	  a	  decrease	  in	  HCV	  replication	  and	  translation,	  which	  is	  directly	  related	  to	  the	  dependency	  of	  HCV	  on	  miR-­‐122	  (111).	  	  Ago2	  in	  combination	  with	   miR-­‐122	   has	   been	   demonstrated	   to	   bind	   to	   the	   5’UTR	   of	   HCV,	   and	   this	  association	  stabilizes	  the	  genome	  and	  promotes	  viral	  translation	  (114,	  137).	  	  In	  the	  absence	   of	   Ago2,	   miR-­‐122	   cannot	   enhance	   HCV	   stability,	   indicating	   that	   Ago2	   is	  required	   for	   the	   interaction	   between	   miR-­‐122	   and	   HCV	   (114).	   	   At	   this	   time	   it	   is	  unknown	   whether	   Ago2	   is	   simply	   required	   for	   delivery	   of	   miR-­‐122	   to	   the	   HCV	  genome	  or	  if	  Ago2	  and/or	  GW-­‐182	  participates	  in	  the	  mechanism	  of	  action	  of	  miR-­‐122.	  A	  role	  GW-­‐182	  in	  HCV	  replication	  has	  been	  observed,	  but	  conflicting	  activities	  have	   been	   reported	   (138-­‐141).	   GW-­‐182	   is	   transcribed	   as	   three	   different	   isoform,	  two	  of	  which	  have	  been	  demonstrated	  to	  affect	  HCV	  translation	  (140).	  How	  GW-­‐182	  affects	   HCV	   translation	   is	   unknown,	   but	   given	   its	   association	  with	   Ago2,	   it	   seems	  plausible	  that	  GW-­‐182	  assists	  in	  miR-­‐122	  binding	  to	  the	  5’UTR,	  but	  this	  remains	  to	  be	   confirmed.	   	  However,	   others	  have	   reported	   that	  GW-­‐182	  had	  no	  effect	   on	  HCV	  replication	  or	  translation	  (139,	  141)	  thus,	  the	  effect	  of	  GW-­‐182	  on	  HCV	  replication	  requires	   further	   research	   in	   order	   to	   determine	  what	   effects,	   if	   any,	   GW-­‐182	  may	  have	  on	  HCV	  and	  miR-­‐122	  augmentation.	  	  	  	  
 The	  role	  of	  p-­‐bodies	  in	  miRNA	  suppression	  and	  miR-­‐122	  augmentation	  of	  1.4
HCV	  	  Many	  of	  the	  proteins	  associated	  with	  miRNA	  directed	  mRNA	  degradation	  are	  found	  within	  special	  cellular	  compartments	  called	  processing	  bodies	  (p-­‐bodies)	  and	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thus	   miRNA	   suppressed	   transcripts	   are	   thought	   to	   be	   stored	   and	   degraded	   in	   p-­‐bodies	  (97).	  	  
1.4.1 Processing	  bodies	  (p-­‐bodies)	  	  
1.4.1.1 Composition	  and	  function	  of	  p-­‐bodies	  	  P-­‐bodies	  are	  sites	  of	  mRNA	  degradation	  and	  storage	  (Fig.	  1.5).	  	  How	  p-­‐bodies	  are	   formed	   is	  not	  well	  understood	  but	  many	  of	   the	  proteins	   found	   in	  p-­‐bodies	  are	  able	  to	  associate	  with	  one	  another,	  and	  potentially	  explains	  how	  p-­‐bodies	  assemble	  (142,	  143).	   	  They	  are	  transient	  compartments,	  whose	  size	  and	  abundance	  depends	  on	  cellular	  translation	  conditions.	  For	  example,	  when	  cells	  are	  actively	  proliferating	  and	   therefore	   actively	   generating	   mRNAs,	   p-­‐bodies	   are	   more	   abundant	   than	   in	  quiescent	  cells.	  In	  addition,	  when	  cellular	  translation	  is	  inhibited	  by	  drugs	  or	  cellular	  stress,	   p-­‐body	   abundance	   increases	   to	   accommodate	   storage	   and	   degradation	   of	  untranslated	  mRNAs	  (97,	  143-­‐147).	  	  	  There	  are	  many	  proteins	  that	  have	  been	  demonstrated	  to	  be	  associated	  with	  p-­‐bodies,	   and	   the	   majority	   have	   also	   been	   linked	   to	   miRNA	   silencing	   and	   mRNA	  degradation.	   These	   include	   the	   RISC	   associated	   Ago	   (148)	   and	   GW-­‐182	   proteins	  (132),	   as	  well	   as	   the	  de-­‐capping	   enzymes	  DCP1	   and	  DCP2,	   de-­‐capping	   associating	  proteins	  LSm1-­‐7,	  5’	  to	  3’	  exonuclease	  Xrn1	  (149),	  and	  the	  RNA	  helicase	  DDX6	  (150).	  	  Thus,	  miRNAs	  may	  target	  mRNAs	  to	  p-­‐bodies	  for	  storage	  or	  degradation	  and	  may	  be	  a	   key	   mechanism	   by	   which	   miRNAs	   silence	   protein	   expression.	   Knocking	   down	  many	  of	  the	  resident	  p-­‐body	  proteins	  results	   in	  the	  disappearance	  of	  p-­‐bodies,	  but	  the	   disappearance	   of	   p-­‐bodies	   does	   not	   necessarily	   abolish	   translation	   repression	  (151-­‐153).	   Thus,	   while	   some	   of	   the	   p-­‐body	   proteins	   are	   required	   for	   miRNA	  silencing,	   the	   presence	   of	   microscopically	   visible	   p-­‐bodies	   is	   not	   essential.	  	  Therefore	  it	  is	  believed	  that	  the	  major	  role	  of	  p-­‐bodies	  is	  to	  degrade	  transcripts	  but	  they	  may	  not	  physically	  repress	  translation.	  	  This	  view	  is	  supported	  by	  the	  fact	  that	  p-­‐bodies	  do	  not	   form	  unless	   there	  are	  stalled	  mRNAs	   in	   the	  cytoplasm	  (154,	  155).	  	  However,	   there	   is	   evidence	   that	  mRNAs	   can	   leave	   p-­‐body	   structures	   and	   re-­‐enter	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Figure	   1.5	   P-­‐bodies	   in	   Huh7.5	   cells.	   P-­‐bodies	   were	   detected	   in	   Huh7.5	   cells	  utilizing	   a	   polyclonal	   antibody	   for	   the	   resident	   p-­‐body	   protein	   Ge-­‐1.	   	   The	   white	  arrows	  indicate	  a	  few	  of	  the	  numerous	  p-­‐bodies	  present	  within	  the	  cells.	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active	  translation	  (97)	  suggesting	  that	  p-­‐body	  structures,	   in	  addition	  to	  being	  sites	  of	  degradation	  may	  represent	  storage	  areas	  of	  untranslated	  mRNAs.	   	  How	  mRNAs	  are	   selected	   for	  degradation	  or	   to	   re-­‐enter	   active	   translation	   is	  unknown,	  but	  one	  could	  imagine	  it	  might	  depend	  on	  the	  proteins	  associated	  with	  the	  mRNAs.	  	  
1.4.2 P-­‐body	  proteins	  and	  their	  association	  with	  HCV	  and	  miR-­‐122	  	  The	  p-­‐body	  associated	  protein	  LSm-­‐1,	  which	  has	  a	  role	  in	  mRNA	  de-­‐capping	  promotes	  HCV	  replication	  and	  translation	  (139,	  141,	  156).	  	  Interestingly,	  Lsm-­‐1	  has	  been	  demonstrated	  to	  promote	  HCV	  translation	  by	  increasing	  miR-­‐122’s	  effects	  on	  translation.	   	   Since	   LSm-­‐1	   is	   not	   present	   in	  miR-­‐122	  RISC	  pull	   downs,	   the	   effect	   is	  thought	  to	  be	  independent	  of	  Ago2/RISC	  (156).	  	  	  As	  discussed	  in	  detail	  in	  section	  1.2.1.3,	  the	  p-­‐body	  protein	  Xrn1	  inhibits	  HCV	  if	  the	  genome	  is	  not	  protected	  by	  miR-­‐122.	  	  However,	  whether	  Xrn1	  acts	  on	  HCV	  in	  a	  p-­‐body	  is	  unknown.	  	  	  
 Relationship	  of	  p-­‐bodies	  and	  p-­‐body	  proteins	  with	  other	  viruses	  1.5 	  Since	   p-­‐bodies	   are	   sites	   for	   RNA	   degradation,	   it	   seems	   rational	   that	   RNA	  viruses	  would	  require	  a	  mechanism	  to	  avoid	  being	  targeted	  to,	  and	  degraded	  in	  p-­‐bodies.	   	  This	  is	  particularly	  important	  for	  viruses	  whose	  genomes	  do	  not	  resemble	  mRNA	  because	  they	  have	  elements	  such	  as	  uncapped	  5’	  ends,	  or	  lacking	  poly	  A	  tails,	  which	   would	   normally	   signal	   RNA	   for	   transport	   to	   p-­‐bodies	   for	   degradation.	  	  Interestingly,	  some	  viruses	  avoid	  p-­‐body	  targeting	  by	  abolishing	  their	  structures	  in	  infected	   cells,	  while	   others	   circumvent	   normal	   p-­‐body	   functions	   by	   using	   them	   to	  enhance	  viral	  replicative	  success.	  	  	  
1.5.1 Viruses	  that	  disrupt	  p-­‐body	  formation	  	  Flaviviruses,	  West	  Nile	  virus	  (WNV)	  and	  Dengue	  virus	  infections	  decrease	  the	  presence	  of	  visible	  intracellular	  p-­‐bodies	  (2,	  157).	  	  Inhibition	  of	  p-­‐body	  formation	  by	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these	  viruses	  is	  thought	  to	  be	  advantageous	  for	  a	  few	  reasons.	  Firstly,	  the	  disruption	  of	  p-­‐bodies	  prevents	  the	  virus	  genome	  from	  being	  degraded	  by	  pathways	  that	  utilize	  p-­‐bodies.	   	  Secondly,	   interfering	  with	  p-­‐bodies	  may	  also	  promote	  continuous	  active	  cellular	  translation	  in	  the	  cell,	  a	  condition	  that	  would	  be	  advantageous	  to	  WNV	  and	  Dengue	   virus	   because	   they	   require	   the	   cell	   to	   be	   actively	   translating	   in	   order	   to	  generate	  viral	  proteins.	  	  Thirdly,	  disruption	  of	  p-­‐bodies	  could	  potentially	  allow	  WNV	  and	  Dengue	  virus	  access	  to	  p-­‐body	  proteins	  (normally	  sequestered	  in	  p-­‐bodies)	  that	  the	  viruses	  require	  for	  efficient	  replication	  (158,	  159).	  	  The	  mechanism	  by	  which	  p-­‐bodies	  are	  inhibited	  by	  WNV	  and	  Dengue	  virus	  is	  unknown.	  The	  disappearance	  of	  p-­‐bodies	   could	   be	   the	   result	   of	   the	   virus	   directly	   targeting	   their	   assembly,	   or	   a	  consequence	   of	   the	   virus	   competition	   for	   p-­‐body	   proteins,	   thus	   limiting	   their	  availability	  to	  form	  visible	  p-­‐bodies	  in	  the	  cell.	  	  Poliovirus	  (PV)	  actively	   inhibits	  cellular	  translation	  (160).	   	  Recently,	  PV	  has	  also	   been	   observed	   to	   inhibit	   p-­‐body	   formation	   during	   the	   mid-­‐phase	   of	   its	  replication	   cycle	   (161).	   PV	   infections	   decreased	   the	   presence	   of	   certain	   p-­‐body	  resident	   proteins,	   but	   did	   not	   affect	   the	   level	   of	   any	   of	   proteins	   known	   to	   be	  required	   for	   p-­‐body	   assembly,	   thus	   the	   mechanism	   by	   which	   PV	   inhibits	   p-­‐body	  formation	  is	  unclear.	  	  P-­‐body	  disappearance	  could	  be	  the	  result	  of	  PV	  inhibiting	  the	  production	   of	   an	   unknown	   protein	   required	   for	   p-­‐body	   assembly,	   or	   due	   to	  inhibiting	  expression	  of	  a	  combination	  of	  proteins	  that	  result	  in	  an	  inability	  to	  form	  p-­‐bodies.	  	  The	  inhibition	  of	  p-­‐bodies	  by	  PV	  is	  speculated	  to	  aid	  PV	  by	  preventing	  its	  genomic	  RNAs	  from	  being	  degraded	  (161).	  	  Influenza-­‐A	  virus	  (IAV)	  nucleoprotein	  (NP)	  also	   interacts	  with	  p-­‐bodies	  and	  the	   p-­‐body	   protein	   RNA-­‐associated	   protein	   55	   (Rap55).	   	   Rap55	   is	   required	   for	   p-­‐body	  formation	  and	  impedes	  IAV	  replication.	  In	  addition,	  as	  IAV	  genomic	  RNA	  levels	  increase	   during	   infection,	   p-­‐body	   abundance	   decreases.	   The	   inverse	   correlation	  suggests	   that	   p-­‐bodies	   negatively	   influence	   IAV	   replication,	   probably	   by	  sequestering	   NP	   and	   viral	   RNA	   bound	   by	   NP	  within	   p-­‐bodies.	   IAV	   non-­‐structural	  protein	  1	  (NS-­‐1)	  has	  also	  been	  demonstrated	  to	  interact	  with	  Rap55	  later	  on	  in	  IAV	  infection	   suggesting	   that	   NS-­‐1	   prevents	   p-­‐body	   assembly	   and	   inhibits	   the	  recruitment	  of	  NP	  and	  viral	  RNA	  bound	  by	  NP	  to	  p-­‐bodies	  (162).	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1.5.2 Viruses	  that	  utilize	  p-­‐bodies	  to	  augment	  their	  replication	  	  Hantavirus	   transcripts	   require	   cellular	  5’	   caps	   for	   translation	   initiation	  and	  uses	  cap	  snatching	  to	  obtain	  caps	  from	  host	  mRNAs.	  	  Interestingly,	  researchers	  have	  demonstrated	   that	   hantaviruses	   obtain	   5’	   caps	   from	   host	  mRNAs	   inside	   p-­‐bodies.	  	  Hantavirus	  nucleocapsid	  (N)	  protein	  binds	  to	  the	  5’	  cap	  of	  cellular	  mRNA	  destined	  for	   p-­‐bodies.	   Once	   in	   the	   p-­‐body	   the	   mRNA	   is	   degraded,	   but	   N	   protein	   remains	  bound	  to	  the	  5’	  cap	  preserving	  it	  for	  its	  own	  use	  (163).	  	  How	  N	  protein	  facilitates	  the	  export	  of	  5’	   caps	   from	   the	  p-­‐body	  and,	   interacts	  with	   the	  Hantavirus	  proteins	  and	  mRNA	  is	  unknown.	  The	  Brome	  Mosaic	  virus	   (BMV)	  has	  a	  segmented	  RNA	  genome.	   	  Two	  of	   the	  RNA	  segments	  enter	  p-­‐bodies	  and	  this	  is	  thought	  to	  be	  an	  important	  step	  for	  virus	  replication	   (164).	   BMV	   has	   also	   been	   demonstrated	   to	   require	   known	   p-­‐body	  resident	  proteins	  for	  translation,	  replication	  and	  particle	  assembly	  (164,	  165).	  	  
 The	   influence	   of	   the	   p-­‐body	   associated	   DEAD-­‐box	   helicase	   DDX6	   on	  1.6
viruses	  	  DDX6,	  a	  DEAD-­‐box	  helicase	  (Fig.	  1.6)	  is	  required	  for	  p-­‐body	  formation	  and	  is	  generally	   considered	   a	   translation	   suppressor	   (166).	   	   Interestingly,	   this	   RNA	  helicase,	  along	  with	  other	  DEAD-­‐box	  helicases	  have	  also	  been	  identified	  to	  affect	  the	  life	  cycle	  of	  numerous	  viruses	  	  
1.6.1 DEAD-­‐box	  helicases	  	  DEAD-­‐box	   helicases	   are	   members	   of	   the	   RNA	   helicase	   superfamily	   2.	  	  Superfamily	   2	   helicases	   are	   composed	   of	   two	   RecA-­‐like	   domains,	   which	   contain	  seven	   conserved	  motifs	  within	   the	   helicase	   core.	   	   The	   name	  DEAD-­‐box	   is	   derived	  from	   the	  conserved	  amino	  acid	   sequence	  of	  Asp	   (D),	  Glu	   (E),	  Ala	   (A),	   and	  Asp	   (D)	  found	   in	  motif	   II	  of	   the	   first	  domain	   (Fig.	  1.6).	   	  The	  N-­‐	  and	  C-­‐terminal	  ends	  of	   the	  protein	   are	   thought	   to	   define	   the	   functionality	   of	   different	   DEAD-­‐box	   proteins	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within	  the	  cell.	  DEAD-­‐box	  proteins	  participate	  in	  a	  variety	  of	  RNA	  processing	  events	  and	  can	  unwind	  RNA,	  function	  as	  a	  RNA	  clamp	  for	  recruiting	  other	  factors,	  remove	  proteins	  from	  RNA,	  act	  as	  a	  chaperone,	  participate	  in	  strand	  annealing	  and	  regulate	  cellular	  translation.	  As	   the	   name	   suggests	   DEAD-­‐box	   helicases	   can	   function	   as	   helicases.	  	  However,	   they	  are	  unique	  helicases	  as	   they	  do	  not	  work	  processively	   in	  a	  5’	   or	  3’	  direction.	   DEAD-­‐box	   helicases	   bind	   short	   RNA	   hairpins	   and	   induce	   strand	  separation.	  The	  helicase	  domains	  bind	  to	  the	  backbone	  of	  the	  RNA	  and	  thus	  do	  not	  have	   sequence	   specificity.	   The	   limiting	   factor	   of	   strand	   separation	   activity	  performed	  by	  DEAD-­‐box	  helicases	  is	  the	  length	  and	  stability	  of	  the	  hairpin	  (167),	  as	  DEAD-­‐box	   helicases	   are	   ineffective	   at	   separating	   hairpins	   that	   are	   longer	   than	   22	  bases	  (168).	  	  Strand	  separation,	  regardless	  of	  the	  size	  of	  the	  hairpin,	  by	  a	  DEAD-­‐box	  helicase	  requires	  one	  bound	  ATP	  (169).	  However	  ATP	  hydrolysis	  is	  not	  required	  to	  induce	  a	  strand	  separation	  event,	  but	  is	  required	  for	  the	  disassociation	  of	  the	  DEAD-­‐box	  helicase	  from	  the	  RNA	  (170).	  Determinants	  in	  the	  N-­‐	  and	  C-­‐	  terminal	  domains	  of	  DEAD-­‐box	  helicases	  enhance	  their	  function.	  In	  some	  DEAD-­‐box	  helicases,	  the	  N-­‐	  and	  C-­‐terminal	  associate	  with	  other	  components,	  such	  as	  proteins	  and	  RNA	  structures,	  which	  increase	  the	  likelihood	  of	  them	  being	  loaded	  onto	  RNA	  and	  initiating	  a	  strand	  separation	  event	  (171,	  172).	  	  Since	  DEAD-­‐box	  proteins	  bind	  RNA	  without	  sequence	  specificity,	  the	  N-­‐	  and	  C-­‐	  terminal	  ends	  of	  DEAD-­‐box	  proteins	  can	  regulate	  the	  action	  of	  these	  proteins.	  As	   described	   above,	   DEAD-­‐box	   helicases	   bind	   to	   RNA	   and	   after	   ATP	  hydrolysis	  are	  released	  from	  the	  RNA.	  However,	  DEAD-­‐box	  proteins	  can	  also	  remain	  clamped	   on	   RNA	   and	   facilitate	   the	   recruitment	   of	   other	   proteins.	   	   For	   example,	  eIF4AIII	   is	   a	   DEAD-­‐box	   protein	   required	   for	   the	   assembly	   of	   the	   exon	   junction	  complex	   (EJC).	   The	   EJC	   is	   composed	   of	   three	   core	   proteins,	   eIF4AIII,	  MAGOH	   and	  Y14.	   The	   EJC	   formation	   is	   facilitated	   by	   eIF4AIII	   binding	   to	   a	   hairpin	   within	   an	  mRNA	  prior	  to	  exon	  ligation.	  	  MAGOH/Y14	  heterodimers	  then	  interact	  with	  the	  RNA	  bound	   eIF4AIII,	   preventing	   the	   release	   of	   the	   hydrolysed	   ATP,	   thus	   clamping	  eIF4AIII	  to	  the	  mRNA,	  and	  forming	  the	  EJC	  on	  the	  mRNA	  (173,	  174).	  Removal	  of	  the	  EJC	  from	  the	  mRNA	  in	  the	  cytoplasm	  could	  theoretically	  be	  mediated	  by	  the	  release	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of	  ADP	  +	  Pi	  from	  eIF4AIII,	  which	  should	  facilitate	  the	  disassociation	  of	  eIF4AIII,	  and	  the	  EJC	  from	  the	  RNA,	  but	  this	  has	  not	  been	  demonstrated	  experimentally.	  DEAD-­‐box	  helicases	  have	  also	  been	  demonstrated	  to	  alter	  ribonucleoproteins	  (RNP).	   Interestingly	   the	   Saccharomyces	   cerevisiae	   DEAD-­‐box	   helicase	   Dpb5p	   has	  been	  implicated	  in	  mRNA	  transport	  from	  the	  nucleus	  to	  the	  cytoplasm	  and	  is	  located	  near	   nuclear	   pores.	   Dpb5p	   mutants	   incapable	   of	   hydrolysing	   ATP	   cause	  accumulation	   of	   mRNA	   at	   nuclear	   pores.	   The	   nucleus-­‐restricted	   mRNAs	   were	  further	   evaluated	   and	   observed	   to	   contain	   the	   nuclear	   export	   protein	   Mex67p.	  These	   findings	   indicate	   that	   DpB5p	   interacts	   with	   mRNA	   and	   results	   in	   the	  dissociation	  of	  Mex67p	  from	  the	  mRNA,	  allowing	  the	  mRNA	  to	  enter	  the	  cytoplasm	  (175).	  	  There	  are	  still	  no	  known	  mechanisms	  by	  which	  DEAD-­‐box	  proteins	  displace	  proteins	   from	   the	   RNA,	   but	   evidence	   suggests	   that	   DEAD-­‐box	   proteins	   may	   not	  require	  their	  strand	  separation	  ability	  to	  accomplish	  the	  feat	  (176).	  Although	  there	  is	   no	   suggested	   mechanism,	   one	   can	   imagine	   that	   the	   process	   of	   breaking	   down	  RNPs	  would	  be	  regulated	  tightly,	  since	  RNP	  assembly	  is	  probably	  energy	  intensive,	  compared	  to	  a	  small	  hairpin	  strand	  separation	  event,	  which	  only	  cost	  the	  cell	  1	  ATP	  molecule.	  Similarly	  to	  protein	  function,	  which	  requires	  proper	  protein	  folding,	  RNA	  also	  requires	   proper	   secondary	   and	   tertiary	   folding	   for	   their	   function.	   The	   HCV	   IRES	  structured	   RNA	   discussed	   previously	   exemplifies	   this.	   	   To	   prevent	   proteins	   from	  taking	   unfavourable	   conformations,	   cells	   utilize	   chaperones.	   For	   example,	   as	  proteins	   are	   being	   translated,	   the	   newly	   added	   amino	   acids	   (aa)	   can	   come	   into	  contact	   and	   make	   an	   undesirable	   interaction	   that	   renders	   the	   protein	   inactive.	  	  Normally	   these	   aas	   are	   required	   for	   an	   interaction	   at	   a	   different	   place	  within	   the	  protein	  which	  would	  allow	  for	  the	  proper	  folding,	  however	  the	  aa	  required	  for	  the	  proper	   interaction	   has	   not	   been	   added	   onto	   the	   aa	   chain	   yet,	   this	   allows	   for	   an	  undesired	  interaction	  between	  aas.	  Chaperones	  are	  proteins	  that	  temporary	  interact	  with	  a	   translating	  protein	   to	  either	  block	  an	  undesirable	   interaction	  or	  promote	  a	  desirable	  one.	  	  RNAs	  also	  require	  proper	  secondary	  and	  tertiary	  structure	  and	  thus	  also	   need	   to	   prevent	   undesirable	   base	   pairing	   and	   promote	   correct	   base	   pairing.	  	  DEAD-­‐box	   helicases	   provide	   a	  mechanism	   for	   the	   cell	   to	   accomplish	   this	   task.	   As	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discussed	  previously,	  DEAD-­‐box	  helicases	  do	  not	  recognize	  a	  specific	  sequence	  and	  are	   able	   to	   induce	   strand	   separation	   of	   short	   RNA	   duplexes	  with	  minimal	   energy	  input.	   These	   characteristics	   make	   DEAD-­‐box	   proteins	   ideal	   candidates	   as	   RNA	  chaperones.	   The	   DEAD-­‐box	   protein	   CYT-­‐19	   has	   been	   extensively	   studied	   and	  functions	   as	   a	   RNA	   chaperone.	   	   CYT-­‐19	   promotes	   the	   correct	   folding	   of	   group	   I	  introns	  of	  mitochondrial	  RNA	  in-­‐vivo.	  	  Interestingly,	  there	  is	  also	  evidence	  that	  after	  the	  correct	  folding	  of	  the	  intron	  is	  achieved,	  CYT-­‐19	  is	  inhibited	  from	  acting	  on	  the	  RNA	  again.	  	  This	  model	  of	  self-­‐regulation	  exemplifies	  CYT-­‐19	  as	  an	  RNA	  chaperone	  since	   a	   DEAD-­‐box	   helicase	   would	   not	   be	   expected	   to	   recognize	   the	   difference	  between	   correctly	   folded	   and	   mis-­‐folded	   RNA,	   and	   would	   be	   expected	   to	   act	  randomly	  on	  short	  hairpins	  (177-­‐179).	  In	   contrast	   to	   their	   helicase	   activity,	   DEAD-­‐box	   proteins	   also	   function	   in	  strand	  annealing,	  and	  promote	  the	  formation	  of	  duplex	  RNA	  structures.	  	  The	  DEAD-­‐box	   helicases	   CrhR	   and	   DED1,	   from	   cyanobacteria	   and	   Saccharomyces	   cerevisiae	  respectively,	   are	   capable	   of	   directing	   strand	   exchange	   between	   two	   different	  segments	   of	   RNA	   (180-­‐182).	   	   However,	   to	   date	   this	   phenomenon	   has	   only	   been	  observed	  in-­‐vitro	  and	  has	  yet	  to	  be	  confirmed	  in	  an	  in-­‐vivo	  system.	  	   DEAD-­‐box	   helicases	   are	   also	   thought	   to	   have	   the	   potential	   to	   sense	  metabolites	   and	   therefore	   respond	   to	   cellular	   stress	   such	   as	   glucose	   shortage.	  	  Certain	  DEAD-­‐box	  proteins	  bind	  AMP.	  So,	  when	  levels	  are	  increased	  during	  times	  of	  cellular	   stress,	   binding	   of	   AMP	   by	   the	   DEAD-­‐box	   helicase	   could	   act	   as	   a	   form	   of	  general	   cellular	   regulation	   leading	   to	   up	   regulation	   or	   down	   regulation	   of	   gene	  expression.	   	   The	   up	   or	   down	   regulation	   would	   be	   the	   result	   of	   AMP-­‐DEAD-­‐box	  protein	  increased	  or	  decreased	  affinity	  for	  RNA	  (182,	  183).	  	  
1.6.2 DDX6	  known	  cellular	  functions	  
	   DDX6	   is	   present	   at	   a	   high	   concentration	   in	   cells	   and	   is	   estimated	   to	   out-­‐number	   the	   amount	  of	  mRNA	  by	   seven	   fold,	  with	   the	   vast	  majority	   of	   the	  protein	  associated	  with	  p-­‐bodies	   (184).	   	  DDX6	  knockdown	  completely	  abolishes	  visible	  p-­‐body	   structures	   and	   has	   the	   most	   dramatic	   effect	   on	   p-­‐bodies	   compared	   to	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knockdown	  of	  other	  p-­‐body	  resident	  proteins.	  	  This	  is	  demonstrated	  by	  the	  inability	  of	   DDX6	   knockdown	   cells	   to	   form	   p-­‐bodies	   in	   the	   presence	   of	   the	   potent	   p-­‐body	  inducer,	  arsenic,	  unlike	  the	  knockdown	  of	  all	  other	  p-­‐body	  resident	  proteins	  which	  still	   allow	  p-­‐body	   formation	   in	   the	  presence	  of	  arsenic	   (166).	  The	  core	  of	  DDX6	   is	  the	  DEAD-­‐box	  helicase,	   but	   the	  protein	  also	   contains	   an	  N’	   terminal	  domain	  of	  61	  amino	  acids	  which	  contains	  glutamine	  and	  asparagine	   that	   is	  predicted	   to	   interact	  with	  other	  proteins	  and	  itself.	  	  How	  DDX6	  is	  able	  to	  assemble	  p-­‐bodies	  is	  unknown,	  but	  the	  helicase	  activity	  is	  required	  (185)	  and	  the	  N’	  terminal	  domain	  is	  predicted	  to	  be	  required	  (184).	  DDX6	   also	   has	   a	   key	   role	   in	   regulating	   gene	   expression	   and	  maturation	   of	  reticulocytes.	   The	   final	   step	   in	   the	   production	   of	   mature	   reticulocytes	   is	   the	  degradation	  of	  the	  mitochondria	  by	  the	  enzyme	  human	  reticulocyte	  15-­‐lipoxygenase	  (hr15-­‐LOX)	   (186).	   	   Since	   reticulocytes	   do	   not	   have	   a	   nucleus	   they	   are	   unable	   to	  make	  more	  mRNA,	   therefore	   the	  mRNA	   for	   hr15-­‐LOX	  must	   be	   present	   in	   the	   cell	  prior	   to	   the	   loss	   of	   the	   nucleus,	   but	   not	   expressed	   until	   the	   proper	   time	   in	  maturation.	   Regulation	   of	   hr15-­‐LOX	   is	   mediated	   by	   p-­‐body	   localization.	   The	  translation	   of	   hr15-­‐LOX	   mRNA	   is	   inhibited	   by	   being	   bound	   by	   heterogeneous	  ribonucleoprotein	   (hnRNP)	  K	   and	   E1	   (187),	   and	  DDX6	   has	   been	   demonstrated	   to	  interact	  with	  hnRNP	  K	  and	  E1	  to	  localize	  the	  proteins	  and	  bound	  hr15-­‐LOX	  mRNA	  to	  p-­‐bodies.	  Later,	  and	  by	  an	  unknown	  mechanism,	  hr15-­‐LOX	  is	  released	  from	  p-­‐bodies	  to	  induce	  expression	  and	  maturation	  of	  reticulocytes	  (188).	  	  Ernoult-­‐Lange	  et	  al.	  have	  put	  forth	  a	  model	  to	  explain	  how	  DDX6	  suppresses	  translation	  based	  on	  the	  observation	  that	  DDX6	  is	  present	  in	  high	  concentration	  in	  the	  cell.	  They	  suggest	  that	  upon	  suppression,	  multiple	  DDX6	  proteins	  are	  recruited	  to	  the	  mRNA.	  	  DDX6	  coats	  the	  mRNA	  and	  causes	  it	  to	  relax	  its	  secondary	  structure.	  Stalled	  mRNAs	  then	  associate	  with	  other	  stalled	  mRNAs	  and	  assemble	  a	  p-­‐body,	  or	  alternatively	  are	  recruited	  to	  a	  p-­‐body.	  	  This	  model	  is	  based	  on	  the	  observations	  that	  DDX6	  forms	  multimers	  in	  the	  presence	  of	  mRNA	  (184).	   	  DDX6	  could	  then	  facilitate	  the	  degradation	  of	   the	  mRNA,	  or	   retain	   it	   in	   storage	   for	   re-­‐activation	   later.	   	  DDX6	  has	   also	   been	   demonstrated	   to	   interact	   with	   eIF4E	   in	   p-­‐bodies.	   Although	   the	  purpose	   of	   this	   interaction	   is	   unknown,	   it	   could	   modulate	   translation	   (150).	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Figure	  1.6	  The	  DEAD-­‐box	  RNA	  helicase	  DDX6.	   	  A	  diagram	  of	  the	  DEAD-­‐box	  RNA	  helicase	   DDX6,	  which	   is	   composed	   of	   2	   RecA-­‐like	   domains	   consisting	   of	   9	  motifs.	  	  Motif	  II	  contains	  the	  DEAD	  amino	  acid	  sequence.	  Motifs	  Ia,	  Ib,	  IV	  and	  V	  are	  involved	  in	  RNA	  binding	  while	  motifs	  Q,	  I,	   II,	  V	  and	  VI	  contribute	  to	  ATP	  binding.	  The	  61	  N-­‐terminal	   amino	   acids	   are	   predicted	   to	   participate	   in	   RNA	   and	   protein-­‐protein	  interactions.	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DDX6	  has	   also	  been	   linked	   to	   IRES	  mediated	   translation.	   	   In	   neuronal	   cells	  under	  normal	  cellular	  conditions,	  DDX6	  interacts	  with	  and	  inhibits	  translation	  from	  the	   IRES	   responsible	   for	   translating	   hypoxia	   inducible	   factor	   1α	   (HIF-­‐1α).	   	  When	  oxygen	  is	  scarce,	  miR-­‐130a	  binds	  to	  DDX6	  mRNA	  and	  inhibits	   its	  translation.	   	  This	  interaction	   leads	   to	   a	   decrease	   in	   DDX6	   proteins,	   but	   not	   DDX6	   mRNA	   and	   an	  increase	   in	   HIF-­‐1α	   protein,	   but	   not	   HIF-­‐1α	  mRNA.	   These	   data	   suggest	   that	   DDX6	  physically	  interacts	  with	  the	  HIF-­‐1α	  IRES	  to	  impede	  HIF-­‐1α	  mRNA	  translation	  (189).	  	  A	   similar	   observation	   was	   made	   with	   respect	   to	   the	   vascular	   endothelial	   growth	  factor	  (VEGF).	  VEGF	  promotes	  blood	  vessel	   formation.	   Its	  mRNA	  contains	  an	  IRES,	  and	  is	  present	  at	  all	  times	  in	  the	  cell,	  but	  is	  only	  expressed	  during	  times	  of	  hypoxia	  (190).	  DDX6	  has	  been	  demonstrated	  to	  interact	  with	  VEGF	  IRES	  and	  decrease	  VEGF	  expression.	   Conversely,	   DDX6	   knockdown	   promotes	   expression	   of	   VEGF	   during	  times	   of	   normoxia	   suggesting	   that	   DDX6	   has	   a	   role	   in	   regulating	   the	   VEGF	   IRES	  (191).	  In	  contrast,	  DDX6	  has	  been	  observed	  to	  stimulate	  translation	  from	  the	  c-­‐Myc	  IRES	   (192).	   It	   is	   thought	   that	   DDX6	   up	   regulates	   c-­‐Myc	   by	   interacting	   with	   and	  unwinding	  the	  c-­‐Myc	  IRES	  (193,	  194).	  Interestingly,	   DDX6	   has	   also	   been	   observed	   to	   contribute	   to	   miRNA	   gene	  suppression.	  	  siRNA	  and	  miRNA	  silencing	  in	  HeLa	  cells	  was	  attenuated	  when	  DDX6	  	  expression	  was	   blocked.	   DDX6	   also	   interacts	  with	   Ago1	   and	   Ago2,	   and	   its	   role	   in	  miRNA	  and	  siRNA	  gene	  suppression	  is	  thought	  to	  occur	  through	  these	  interactions.	  While	  the	  contribution	  of	  DDX6	  to	  miRNA	  and	  siRNA	  silencing	  was	  less	  than	  that	  of	  Ago2	   or	   GW-­‐182,	   these	   observations	   suggest	   DDX6	   is	   an	   active	   participant	   in	   the	  mechanism	  of	  miRNA	  suppression	  (153).	  	  
1.6.3 The	  relationship	  between	  DDX6	  and	  viruses	  	  There	   is	   evidence	   in	   the	   literature	   that	   the	   human	   immunodeficiency	   virus	  (HIV)	   requires	   DDX6	   for	   efficient	   assembly	   of	   virus	   particles.	   DDX6	   knockdown	  leads	   to	   a	   decrease	   in	   HIV	   particle	   assembly,	   and	   DDX6	   is	   thought	   to	   promote	  assembly	  through	  an	  interaction	  with	  HIV	  gag	  protein,	  and	  potentially	  HIV	  genomic	  RNA	   (195,	  196).	  However	   there	  are	  also	   reports	   suggesting	   that	  DDX6	   is	   antiviral	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towards	  HIV,	  where	  knockdown	  of	  DDX6	  led	  to	  an	  increase	  in	  HIV	  replication.	  	  The	  antiviral	  effects	  of	  DDX6	  were	  attributed	  to	  DDX6’s	  role	  in	  the	  miRNA	  suppression	  pathway,	  which	  has	  been	  observed	   to	   inhibit	  HIV	  replication	  (197-­‐199).	  Given	   the	  conflicting	  observations	  reported,	  the	  role	  DDX6	  plays	  in	  HIV’s	  life	  cycle	  is	  not	  fully	  explained	   and	   may	   be	   quite	   complex.	   Similarly,	   the	   retrovirus	   prototype	   Foamy	  virus	  (PFV)	  utilizes	  DDX6	  for	  encapsidation	  of	   its	  genome.	  During	  virion	  assembly,	  DDX6	  accumulates	  at	  assembly	  sites	  and	  co-­‐localizes	  with	  gag,	  capsid	  protein,	  and	  PFV	  RNA.	  The	  DDX6	  helicase	  domain	  is	  required	  for	  PFV	  assembly,	  and	  knockdown	  of	   DDX6	   leads	   to	   a	   decrease	   in	   particle	   release,	   and	   the	   percentage	   of	   particles	  containing	  genomic	  RNA	  (200).	  The	  data	  suggest	  DDX6	  plays	  an	   important	   role	   in	  the	  incorporation	  of	  PFV	  RNA	  into	  the	  capsid.	  	  The	   adenovirus	  protein	  E4	  11K	   interacts	  with	  DDX6.	   E4	  11K	  promotes	   the	  accumulation	   of	   DDX6	   in	   aggresomes	   (201),	   but	   the	   implication,	   purpose	   and	  consequence	  of	  this	   interaction,	  and	  sequestration	  of	  DDX6	  into	  aggresomes	  is	  not	  understood	  at	  this	  time.	  As	   mentioned	   previously,	   WNV	   and	   Dengue	   virus	   affect	   p-­‐bodies	   during	  infection.	   In	   the	   case	  of	  WNV	  many	  of	   the	  p-­‐body	  proteins	   including	  DDX6,	  LSm1,	  GW-­‐182	  and	  Xrn1	   are	   recruited	   to	  WNV	  RNA	   replication	   sites,	   and	  knockdown	  of	  several	   of	   the	   recruited	   p-­‐body	   proteins	   leads	   to	   a	   decrease	   in	  WNV	   replication.	  However	  DDX6	  knockdown	  was	  not	  tested	  in	  these	  experiments	  and	  its	  role	  in	  being	  recruited	  to	  WNV	  replication	  sites	  remains	  unknown	  (159).	  	  Dengue	  virus	  2	  (DENV-­‐2)	   has	   also	   been	   demonstrated	   to	   recruit	   DDX6	   to	   sites	   of	   viral	   replication.	  	  Inhibition	  of	  DDX6	  through	  siRNA	  knockdown	  led	  to	  a	  decrease	  in	  DENV-­‐2	  assembly	  and	  release	   indicating	  DDX6	  promotes	  DENV-­‐2	  virion	  production.	   	  DDX6	   interacts	  with	   DENV-­‐2	   RNA	   and	   can	   bind	   two	   stem-­‐loop	   structures	   in	   the	   DENV-­‐2’s	   3’UTR	  suggesting	  DDX6	  is	  directly	  involved	  in	  DENV-­‐2	  replication	  (158).	  Given	  the	  ability	  of	  DDX6	  to	  interact	  with	  DENV-­‐2	  RNA,	  it	  is	  probable	  that	  DDX6	  promotes	  the	  DENV-­‐2	   life	   cycle	   at	   the	   RNA	   replication,	   translation	   and/or	   assembly	   stage,	   perhaps	   to	  promote	  translation,	  or	  as	  an	  RNA	  chaperone.	  	  DDX6	  has	  also	  been	  implicated	  in	  the	  life	  cycle	  of	  HCV.	  	  An	  increase	  in	  DDX6	  expression	   was	   observed	   in	   liver	   biopsies	   of	   patients	   suffering	   HCV-­‐associated	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hepatocellular	  carcinoma	  and	  HCV-­‐related	  chronic	  hepatitis	  (202).	  Although	  a	  direct	  association	  of	  HCV	  between	  DDX6	  had	  not	  been	  demonstrated,	   it	  will	  be	  discussed	  in-­‐length	  later	  on.	  	  
1.6.3.1 Related	  DEAD-­‐box	  helicases	  and	  viruses	  	  
1.6.3.1.1 DDX1	  	  	  The	   cellular	   function	   of	   DDX1	   is	   not	  well	   defined,	   but	   it	   localizes	   to	   stress	  granules,	  sites	  of	  mRNA	  storage,	  and	  binds	  K	  homology	  splicing	  regulatory	  protein	  (KSRP)	  and	  increases	  AU-­‐rich	  element	  (ARE)-­‐mediated	  mRNA	  decay,	  a	  degradation	  pathway	   based	   on	   the	   recognition	   of	   AU	   elements	   in	   the	   3’UTR	   of	   mRNA	   (203).	  DDX1	  (and	  DDX3	  as	  discussed	  below)	  also	  facilitates	  export	  of	  HIV	  transcripts	  from	  the	  nucleus	  (204)	  by	  promoting	  oligomerization	  of	  Rev	  protein,	  a	  step	  required	  for	  efficient	  HIV	  transcript	  export	  (205).	  	  	  	  DDX1	  promotes	  translation	  of	  the	  double	  stranded	  DNA	  virus	  JC	  virus	  (JCV)	  (206).	  	  It	  is	  thought	  to	  promote	  JCV	  translation	  by	  forming	  a	  complex	  with	  cleavage	  stimulation	   factor	   (CstF),	   which	   has	   been	   observed	   to	   interact	   with	   the	   JCV	  transcriptional	  control	  region	  (207).	   	  Inhibition	  of	  DDX1	  leads	  to	  a	  decrease	  in	  JCV	  protein	  expression,	  supporting	  DDX1’s	  role	  in	  augmenting	  JCV	  translation	  (206).	  Utilizing	  a	  yeast	  two-­‐hybrid	  system,	  coronavirus	  exonuclease	  protein	  nsp14	  was	  identified	  to	  interact	  with	  DDX1.	  Subsequent	  experiments	  indicated	  that	  DDX1	  slightly	   promoted	   replication	   of	   a	   coronavirus	   (208),	   but	   the	   mechanism	   of	  replication	  promotion	  is	  unknown.	  Interestingly,	  the	  3’UTR	  of	  the	  positive	  genomic	  strand	  and	  the	  5’UTR	  of	  the	  negative	  strand	  of	  HCV	  have	  also	  been	  demonstrated	  to	  interact	  with	  DDX1	  (209).	  	  While	  the	  purpose	  of	  this	  interaction	  is	  unknown,	  the	  fact	  that	  DDX1	  can	  interact	  with	  both	  the	  positive	  and	  negative	  strand	  suggests	  a	  role	  in	  HCV	  replication.	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1.6.3.1.2 DDX3	  	  DDX3	   is	   a	   DEAD-­‐box	   helicase	   implicated	   in	   many	   aspects	   of	   cellular	   RNA	  metabolism	   such	   as	   splicing,	   export,	   translation	   regulation	   (210),	   and	   innate	  immune	   signalling	   (211).	   Not	   surprisingly	   due	   to	   its	   ability	   to	   stimulate	   innate	  immunity,	  DDX3	  affects	  several	  viruses	  including	  Hepatitis	  B	  virus	  (HBV),	  HIV,	  WNV,	  Japanese	  Encephalitis	  virus	  (JEV)	  and	  HCV.	  	  DDX3	  appears	  to	  have	  an	  antiviral	  effect	  on	   HBV	   through	   interacting	   with	   HBV	   polymerase	   within	   the	   nucleocapsid	   (212)	  and	   by	   potentially	   increasing	   the	   interferon	   response	   in	   HBV	   infected	   cells	   (213,	  214).	   In	   the	   case	   of	   HIV,	  WNV,	   JEV	   and	   HCV,	   DDX3	   is	   required	   for	   efficient	   viral	  replication	  (215).	  	  HIV’s	  dependency	  on	  DDX3	  for	  replication	  has	  been	  associated	  with	  its	  role	  in	   aiding	   the	   transport	   of	   HIV	   transcripts.	   Unspliced	   and	   partially	   spliced	   HIV	  transcripts	   encode	   a	   Rev-­‐response	   element	   (RRE),	   which	   is	   bound	   by	   HIV	   Rev	  protein.	   Rev	   is	   responsible	   for	   enhancing	   the	   export	   of	   HIV	   transcripts	   from	   the	  nucleus	   to	   the	   cytoplasm.	   When	   DDX3	   is	   knocked	   down,	   unspliced	   and	   partially	  spliced	  HIV	  transcripts	  bound	  by	  Rev,	  remain	  in	  the	  nucleus.	  This	  evidence	  strongly	  supports	   that	  DDX3	   is	   instrumental	   in	   facilitating	   the	   transport	   of	  Rev	  bound	  HIV	  transcripts	   (216).	  The	  mechanism	  by	  which	  DDX3	   facilitates	   transport	   of	  HIV	  Rev	  bound	   transcripts	   may	   be	   similar	   to	   the	   support	   of	   mRNA	   translocation	   by	   the	  DEAD-­‐box	   helicase	   Dbp5p	   of	   Saccharomyces	   cerevisiae,	   as	   discussed	   previously	  (216).	   	  The	  HIV	  Tat	  protein,	  which	  regulates	  HIV	  gene	  transcription,	  also	   interacts	  with	   DDX3.	   This	   interaction	   leads	   to	   an	   increase	   in	   HIV	   translation	   and	   thus	  promotes	  HIV	  success	  (217,	  218).	  	  DDX3	   is	  also	   required	   for	   the	  HCV	   life	   cycle,	  but	   its	  mechanism	  of	  action	   is	  unclear.	  Some	  studies	  have	  suggested	  that	  the	  HCV	  core	  protein	  interacts	  with	  DDX3	  while	   others	   suggest	   a	   direct	   role	   for	   DDX3	   in	   promoting	   HCV	   replication	  independent	   from	   core	   (219,	   220).	   The	   role	   DDX3	   plays	   in	   WNV	   has	   yet	   to	   be	  determined,	  but	  similarly	  to	  HCV,	  knocking	  down	  DDX3	  leads	  to	  a	  decrease	  in	  viral	  replication	   (159)	   and	   DDX3	   co-­‐localizes	   with	   viral	   RNA	   at	   sites	   of	   replication.	  	  Similarly,	   JEV	   replication	   is	   impeded	   by	   DDX3	   knockdown	   and	   is	   thought	   to	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influence	  its	  replication	  and	  translation	  by	  interacting	  with	  the	  5’	  and	  3’	  UTR	  as	  well	  as	  some	  of	  JEV	  viral	  proteins	  (221).	  	  	  
1.6.3.1.3 DDX5	  	  	  DDX5	   (p68)	   is	   a	   co-­‐activator	   for	   the	   expression	   of	   several	   genes	   and	  participates	  in	  various	  cell	  processes.	  For	  example,	  DDX5	  enhances	  Drosha’s	  ability	  to	  process	   certain	  miRNAs	   (222,	  223)	  and	  promotes	   the	   splicing	  of	  mRNAs	   (224).	  	  Similarly	  to	  DDX1,	  DDX5	  was	  identified	  using	  a	  yeast	  two-­‐hybrid	  screen	  to	  interact	  with	  coronavirus	  helicase	  protein	  nsp13.	  	  Knockdown	  of	  DDX5	  led	  to	  a	  decrease	  in	  coronavirus	   replication	   demonstrating	   that	   DDX5	   is	   proviral,	   (225)	   but	   the	  mechanism	   of	   action	   is	   unknown	   at	   this	   time	   and	   requires	   further	   investigation.	  	  Like	   many	   of	   the	   DEAD-­‐box	   proteins	   discussed	   thus	   far,	   DDX5	   has	   also	   been	  demonstrated	  to	  induce	  Rev-­‐associated	  transport	  of	  HIV	  transcripts	  (226).	  	  	  	  During	   JEV	   infection,	  DDX5	   is	  mobilized	   from	   the	  nucleus	   to	   the	   cytoplasm	  where	  it	   interacts	  with	  viral	  proteins	  NS3	  and	  NS5,	  and	  co-­‐localizes	  with	  JEV	  RNA.	  DDX5	  interacts	  with	  JEV	  RNA	  3’UTR.	   	  Knockdown	  of	  DDX5	  inhibits	  JEV	  replication,	  but	   not	   translation.	   Therefore,	   DDX5	   interaction	   with	   JEV	   RNA	   and	   proteins	  facilitates	  JEV	  RNA	  replication	  (227).	  	  A	  role	  for	  DDX5	  in	  virion	  assembly	  and	  release	  is	   also	   possible	   but	   has	   not	   been	   examined.	   Similarly	   to	   JEV,	   HCV	   has	   also	   been	  observed	   to	   redistribute	   DDX5	   from	   the	   cytoplasm	   to	   the	   nucleus.	   The	  redistribution	  is	  attributed	  to	  an	  interaction	  between	  DDX5	  and	  the	  C-­‐terminal	  end	  of	  HCV	  NS5B,	  and	  inhibition	  of	  DDX5	  resulted	  in	  a	  decrease	  in	  HCV	  negative	  strand	  synthesis	  in	  the	  context	  of	  a	  full-­‐length	  replicating	  construct.	  	  However,	  there	  was	  no	  decrease	   in	   negative	   strand	   synthesis	   observed	   when	   utilizing	   a	   sub-­‐genomic	  replicon,	  an	  RNA	  in	  which	  the	  structural	  proteins	  have	  been	  deleted.	  This	  suggests	  that	  DDX5	  may	  play	   a	   role	   in	   the	   switch	   from	  RNA	   replication	   to	   virion	   assembly	  (228).	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1.6.3.1.4 DDX17	  and	  DDX21	  	  Both	   DDX17	   and	   DDX21	   are	   DEAD-­‐box	   helicases	   that	   promote	   HIV	   RNA	  packaging.	  DDX17	  is	  required	  for	  the	  alternative	  splicing	  of	  some	  proteins	  such	  as,	  those	   involved	   in	   the	  estrogen	  and	  androgen	   signalling	  pathways	   (229),	  while	   the	  cellular	   role	   of	   DDX21	   is	   unknown.	   After	   siRNA	   knockdown	   of	   both	   helicases,	  released	  HIV	  particles	  were	  less	  infectious	  due	  to	  a	  decrease	  in	  HIV	  RNA	  present	  in	  the	  released	  particles,	  indicating	  that	  DDX17	  and	  DDX21	  aid	  in	  the	  packaging	  of	  HIV	  RNA.	  There	  is	  evidence	  that	  both	  DDX17	  and	  DDX21	  interact	  with	  HIV	  Gag	  protein	  and	  this	  interaction	  is	  speculated	  to	  be	  the	  mechanism	  by	  which	  DDX17	  and	  DDX21	  promote	  viral	  RNA	  packaging	  (230,	  231).	  Since	  DDX17	  and	  DDX21	  perform	  a	  similar	  function	  it	  is	  possible	  they	  perform	  a	  redundant	  function	  or	  work	  cooperatively,	  but	  this	  has	  yet	  to	  be	  examined.	  DDX21	  has	   recently	   been	  demonstrated	   to	   impede	   IAV	  RNA	   replication,	   by	  binding	  to	  IAV	  PB1	  protein,	  one	  of	  the	  three	  viral	  proteins	  required	  to	  form	  the	  IAV	  RNA	   polymerase	   (232,	   233).	   The	   inhibition	   of	   IAV	   RNA	   replication	   by	   DDX21	   is	  alleviated	   by	   IAV	   NS-­‐1	   protein	   binding	   to	   DDX21,	   which	   prevents	   DDX21	   from	  interacting	  with	  PB1.	  DDX21	  only	  effects	  IAV	  replication	  early	  after	  infection	  as	  NS-­‐1	  is	   produced	   in	   higher	   quantity	   then	   PB1,	   therefore	   NS-­‐1	   outcompetes	   PB1	   for	  DDX21	  binding	  (232).	  	  	  
1.6.3.1.5 DDX56	  	  DDX56	  (NOH61)	  is	  a	  nuclear	  protein	  and	  is	  suspected	  to	  aid	  in	  the	  assembly	  of	  the	  60S	  ribosomal	  subunit	  (234).	  It	  is	  not	  required	  for	  WNV	  RNA	  replication	  but	  associates	   with	   WNV	   capsid	   protein	   and	   influences	   the	   production	   of	   infectious	  particles	   (235).	   Through	   mutational	   analysis,	   the	   C-­‐terminal	   end	   of	   DDX56	   was	  found	   to	  be	  responsible	   for	   the	   interaction	  with	   the	  capsid	  protein.	  Knockdown	  of	  DDX56	  leads	  to	  a	  decrease	  in	  infectious	  particles	  generated	  within	  the	  cell,	  but	  not	  in	   the	   efficiency	   by	   which	   particles	   are	   released,	   indicating	   that	   DDX56-­‐capsid	  interaction	  positively	  influences	  the	  incorporation	  of	  viral	  genomes	  into	  particles.	  In	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order	   for	   successful	   incorporation	   of	   WNV	   genomes,	   DDX56	   helicase	   activity	   is	  required,	  thus	  suggesting	  that	  DDX56	  helps	  to	  remodel	  the	  WNV	  genome	  into	  a	  form	  capable	  of	  being	  incorporated	  into	  a	  particle	  (236).	  	  
1.6.3.1.6 Modulators	  of	  intracellular	  immunity	  	  As	  there	  are	  numerous	  DEAD-­‐box	  proteins	  in	  the	  cell,	  which	  do	  not	  generally	  bind	  with	   specificity,	  many	  have	   been	   linked	   to	   cellular	   signalling.	   	   As	   such	  many	  DEAD-­‐box	  proteins	  interact	  with	  antiviral	  pathways	  within	  the	  cell.	  Therefore,	  many	  DEAD-­‐box	  proteins	  have	  the	  potential	  to	  be	  antiviral	  or	  proviral,	  depending	  on	  how	  the	  protein	  influences	  their	  activity.	  	  Many	  of	  these	  scenarios	  have	  been	  discussed	  in	  depth	  and	  reviewed	  by	  Fullam	  et	  al.	  and	  will	  not	  be	  discussed	  in	  length	  here,	  but	  is	  an	   important	   concept	   to	   retain	  when	   considering	   DEAD-­‐box	   proteins	   and	   viruses	  (211).	   	  	  	  
 HCV	  treatment	  strategies	  1.7 	  
1.7.1 Current	  therapy	  	  As	  mentioned	  briefly	  at	  the	  beginning	  of	  this	  chapter,	  the	  classical	  treatment	  for	  HCV	   is	   a	   combination	   therapy	   composed	  of	   ribavirin	  and	  pegylated-­‐IFNα.	  This	  treatment	  was	  administered	   for	  48	  weeks	   in	  patients	  with	  genotype	  1,	  4,	  5	  and	  6,	  and	   for	   24	   weeks	   in	   patients	   with	   genotype	   2	   and	   3	   (237).	   	   Unfortunately,	   this	  treatment	   was	   accompanied	   by	   severe	   side	   effects	   such	   nausea,	   malaise,	   anemia,	  and	  depression,	  which	   led	  many	  people	   to	  quit	   the	   therapy	  early.	   	   In	  addition,	   the	  treatment	   was	   not	   always	   effective,	   in	   particular,	   the	   treatment	   only	   cleared	   the	  virus	   in	  40-­‐50%	  of	  the	  patients	  with	  genotype	  1	  and	  upwards	  of	  80%	  in	  the	  other	  genotypes	  (238).	  Clearance	  of	  the	  virus	  is	  determined	  as	  less	  than	  50	  UI/ml	  of	  HCV	  in	   the	   patients’	   blood	   24	   weeks	   post	   treatment	   and	   is	   deemed	   as	   a	   sustained	  virological	  response	  (SVR).	   	   If	  after	  24	  weeks	  of	   treatment,	   the	  HCV	  RNA	  is	  higher	  the	  50	  UI/ml,	  the	  patient	  is	  deemed	  a	  non-­‐responder	  (238).	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Given	   the	   lack	   of	   effectiveness	   of	   pegylated-­‐IFNα	   and	   ribavirin	   against	  genotype	   1,	   viral	   protease	   inhibitors	   were	   recently	   added	   to	   the	   combination	  therapy,	   known	   as	   triple	   therapy.	   	   Boceprevir	   or	   telaprevir	   were	   both	   recently	  approved	   for	   HCV	   treatment	   and	   act	   to	   inhibit	   genotype	   1	   NS3/4A	   protease	   (9).	  	  Regardless	   of	   the	   protease	   inhibitor	   used,	   the	   triple	   therapy	   has	   a	   duration	   of	   48	  weeks.	  However,	  the	  timing	  and	  inclusion	  of	  the	  protease	  inhibitor	  varies	  depending	  on	  the	  inhibitor	  selected,	  the	  patients	  previous	  treatment,	  and	  ongoing	  response	  to	  the	   treatment	   (239).	   Through	   triple	   therapy,	   viral	   clearance	   for	   genotype	   1	   has	  increased	  to	  70-­‐80%.	  Unfortunately,	  boceprevir	  and	  telaprevir	  only	  inhibit	  genotype	  1.	   Similar	   to	   the	   pegylated-­‐IFNα	   and	   ribavirin	   treatment,	   triple	   therapy	   also	   has	  severe	  side	  effects	  for	  the	  patient	  (9,	  239).	  	  	  Very	   recently,	   two	   new	   DAAs	   have	   been	   approved	   for	   use	   in	   Canada.	  	  Sofosbuvir	  is	  a	  nucleoside	  analogue	  and	  can	  be	  used	  in	  combination	  with	  pegylated-­‐IFNα	   and	   ribavirin	   to	   treat	   genotype	   1	   and	   4,	   or	   with	   ribavirin	   alone	   to	   treat	  genotype	   2	   and	   3	   (240).	   	   Simeprevir	   is	   another	  NS3/4A	  protease	   inhibitor	   and	   is	  approved	  for	  use	  in	  combination	  with	  pegylated-­‐IFNα	  and	  ribavirin	  (241).	  	  	  
1.7.2 Potential	  future	  treatments	  	  The	   current	   treatments,	   which	   include	   DAA	   have	   provided	   an	   increase	   in	  efficacy,	  but	  still	  are	  not	  100%	  effective	  at	  clearing	  HCV,	  and	  are	  accompanied	  with	  adverse	   side	   effects	   for	   the	   patients	   due	   to	   the	   inclusion	   of	   pegylated-­‐IFNα.	  Therefore,	  there	  is	  still	  much	  room	  for	  improvement	  to	  the	  standard	  of	  care,	  and	  the	  future	   goal	   is	   the	   development	   of	   an	   effective	   combination	   therapy	   that	   excludes	  pegylated-­‐IFNα.	  	  
1.7.2.1 Future	  DAA	  and	  host	  manipulation	  treatment	  	  The	   recent	   introduction	   of	   new	   effective	  DAAs	   against	  HCV	   is	   just	   the	   first	  wave	  of	  new	  DAAs.	  	  Many	  other	  DAAs	  in	  phase	  II	  and	  III	  clinical	  trials	  display	  fewer	  side	   effects	   and	   can	   achieve	   SVR	   without	   the	   inclusion	   of	   pegylated-­‐IFNα	   and	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ribavirin.	   The	   exclusion	   of	   pegylated-­‐IFNα	   and	   ribavirin	   has	   led	   to	   a	   dramatic	  decrease	  in	  the	  side	  effects.	  These	  DAA	  include	  nucleoside	  analogs,	  non-­‐nucleoside	  inhibitors,	  and	  inhibitors	  against	  NS3/NS4A,	  and	  NS5A.	  It	  appears	  that	  the	  future	  of	  HCV	   therapy	  will	   remain	  a	   combination	   therapy,	  but	   the	   combination	  will	   only	  be	  DAAs	  targeting	  various	  aspects	  of	  HCV	  (242).	  	  	  
1.7.2.2 Targeting	  host	  factors	  to	  inhibit	  HCV	  	  There	  are	  two	  treatments	  that	  have	  entered	  phase	  II	  clinical	  trials	  that	  inhibit	  host	   factors	   that	   result	   in	   a	   decrease	   in	  HCV	   replication.	   One	   of	   the	   treatments	   is	  based	  on	   the	  observation	   that	   compounds	   that	   interfere	  with	  cyclophilin	  A	   inhibit	  HCV	  (9).	  Cycolphilin	  A	  is	  a	  cellular	  chaperone	  protein	  that	  is	  thought	  to	  interact	  with	  NS5A	  and	  modify	  its	  confirmation	  in	  a	  pro-­‐viral	  fashion	  (73).	  The	  second	  treatment	  is	  based	  on	  HCV’s	  dependency	  for	  miR-­‐122.	  Utilizing	  a	  15-­‐nucleotide	  locked	  nucleic-­‐acid	  modified	  antisense	  oligonucleotide	  that	  binds	  with	  high	  affinity	  to	  the	  5’end	  of	  miR-­‐122	  (LNA-­‐122),	  miR-­‐122	  can	  be	  sequestered.	  The	  sequestration	  removes	  miR-­‐122	   and	   potently	   inhibits	   HCV	   replication.	   In	   clinical	   trails,	   LNA-­‐122	   is	   highly	  effective	   at	   reducing	   HCV	   levels	   in	   humans	   and	   Chimpanzee	   while	   not	   inducing	  escape	  mutants	  or	  causing	  adverse	  side	  effects	  (103,	  243).	  	  
1.7.2.3 siRNA	  targeted	  degradation	  	  Interestingly,	   small	  double	   stranded	   silencing	  RNA	   (siRNA)	  potently	   inhibit	  HCV	  replication	  in	  cell	  culture	  (244-­‐246).	  This	  type	  of	  treatment	  takes	  advantage	  of	  the	   fact	  HCV	   is	   a	   positive	   sense	  RNA	  virus,	   and	   thus	   is	   readily	   targeted	   for	   siRNA	  mediated	  degradation.	  	  siRNAs	  have	  been	  designed	  that	  target	  conserved	  sequences	  within	   the	  HCV	  genome.	  The	   theory	   is	   that	   the	  siRNA	  will	   recognize	   the	  virus	  and	  cleave	   the	  genome,	  and	   if	   the	  siRNA	  targets	  a	  conserved	  (and	  essential)	   sequence,	  the	  virus	  will	  be	  unable	  to	  escape	  the	  siRNA	  by	  incorporation	  of	  point	  mutations	  to	  the	   target	   sequence.	   	   Although	   preliminary	   data	   has	   indicated	   that	   HCV	   specific	  siRNAs	   are	  highly	   effective,	   none	  have	  progressed	   to	   clinical	   trials.	   	   This	   could	  be	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due	   to	   the	   fact,	   even	   though	   the	   siRNA	   target	   conserved	   regions,	   HCV	   still	   has	  demonstrated	   enough	   flexibility	   in	   those	   regions	   to	  mutate	   and	   escape	   the	   siRNA	  (247,	  248).	  	  	  	  
 Summary	  1.8 	  This	   literature	   review	  has	   discussed	   the	   current	   knowledge	   regarding	  HCV	  and	   its	   life	   cycle,	  with	  an	  emphasis	  on	  HCV’s	  unique	  relationship	  with	   the	  miRNA,	  miR-­‐122.	  Much	  has	  been	  discovered	  regarding	  the	  association	  of	  HCV,	  miR-­‐122	  and	  components	  of	  the	  miRNA	  suppression	  pathway.	  However	  the	  role	  of	  p-­‐bodies,	  and	  the	  proteins	  that	  comprise	  p-­‐bodies	  have	  yet	  to	  be	  fully	  elucidated.	  Thus,	  a	  portion	  of	  this	  literature	  review	  not	  only	  discussed	  what	  is	  known	  about	  p-­‐bodies	  and	  HCV,	  but	  what	  p-­‐bodies	  are,	  and	  their	  known	  role	   in	   the	   life	  cycle	  of	  other	  viruses.	  This	  literature	  review	  also	  focused	  on	  the	  core	  p-­‐body	  protein	  DDX6	  and	  other	  DEAD-­‐box	  RNA	  helicases.	  The	   focus	  on	  DDX6	   is	  based	  on	   its	  elevation	   in	   the	   liver	  of	  patients	  with	   HCV	   associated	   HCC,	   with	   no	   known	   function	   in	   supporting	   HCV	   life	   cycle.	  	  Given	   that	   DDX6	   is	   a	   DEAD-­‐box	   helicase,	   its	   reason	   for	   being	   elevated	   in	   HCV	  associated	   HCC	   could	   be	   associated	   with	   an	   unknown	   cellular	   function	   of	   DDX6	  and/or	   other	   observed	   and	   predicted	   functions	   of	   DEAD-­‐box	   helicases	  within	   the	  cell	   and	  with	   other	   viruses.	   Lastly,	   this	   literature	   review	   focuses	   on	   the	   past	   and	  current	  therapy	  for	  patients	  infected	  with	  HCV	  and	  the	  great	  strides	  made	  towards	  very	  effective	   treatment	  with	  an	  emphasis	  on	   the	  encouraging	   results	  of	   targeting	  miR-­‐122-­‐HCV	  relationship	  as	  a	  possible	  treatment.	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2.0 HYPOTHESES	  AND	  OBJECTIVES	  	  
 Rationale	  2.1 	  HCV	   has	   an	   intricate	   and	   complicated	   dependency	   on	   miR-­‐122.	   This	  dependency	   includes	   many	   components	   of	   the	   miRNA	   suppression	   pathway	  including	  the	  Ago	  proteins.	  DDX6	  has	  been	  demonstrated	  to	  interact	  with	  Ago1	  and	  Ago2	  and	   is	   required	   for	  miRNA	   suppression	  of	  mRNA	  and	  p-­‐body	   formation	   and	  maintenance.	   DDX6	   is	   also	   up	   regulated	   in	   HCV	   associated	   HCC	   and	   HCV-­‐related	  chronic	  hepatitis	  suggesting	  that	  the	  helicase	  may	  be	  involved	  directly	  or	  indirectly	  in	   the	   HCV	   life	   cycle	   and	   pathogenesis.	   These	   observations	   suggested	   to	   us	   that	  DDX6	  might	  affect	   the	  HCV	   life	  cycle	   through	  a	   role	   in	   the	  mechanism	  of	  action	  of	  miR-­‐122.	   However,	   the	   fact	   that	   other	   flaviviruses	   such	   as	  WNV	   and	  Dengue	   also	  disrupt	  p-­‐bodies	  and	  recruit	  DDX6	  to	  sites	  of	  viral	  replication,	  suggest	  it	  is	  possible	  that	  HCV	  might	  also	  utilize	  DDX6	  in	  a	  non-­‐miR-­‐122	  dependent	  manner	  as	  well.	  	  	  To	   enhance	   HCV	   replication,	   miR-­‐122	   binds	   through	   Watson-­‐Crick	   base	  pairing	  to	  two	  miR-­‐122	  binding	  sites	  within	  the	  HCV	  5’UTR.	  	  Because	  HCV	  requires	  miR-­‐122	   binding	   for	   efficient	   replication,	   the	   miR-­‐122	   binding	   region	   is	   highly	  conserved	   in	   all	   HCV	   genotypes.	   The	   conservation	   of	   nucleotides	   and	   the	  requirement	  of	  miR-­‐122	  to	  bind	  in	  conjunction	  with	  RISC	  components	  suggests	  that	  this	  area	  should	  also	  be	  accessible	  to	  siRNA/RISC	  complexes,	  and	  should	  be	  a	  prime	  target	  for	  antiviral	  inhibition	  by	  inducing	  siRNA	  mediated	  degradation.	  	  In	  addition,	  although	  the	  miR-­‐122	  binding	  region	  is	  highly	  conserved,	  constant	  pressure	  placed	  on	  the	  virus	  by	  repeated	  siRNA	  treatment	  will	  reveal	  the	  tolerance	  for	  mutations	  in	  the	  miR-­‐122	  binding	  region.	  	   	  
	  44	  
 Hypotheses	  2.2 	  i. HCV	  requires	  the	  DEAD-­‐box	  helicase	  DDX6	  for	  effective	  replication.	  	  ii. DDX6	   affects	  HCV	   replication	   by	   supporting	  miR-­‐122	   augmentation	   of	  HCV	  replication.	  	   iii. Binding	   of	   the	   miR-­‐122/Ago2	   complex	   to	   the	   conserved	   miR-­‐122	   binding	  region	  in	  HCV	  5’UTR	  is	  required	  for	  efficient	  HCV	  replication,	  which	  makes	  it	  a	  target	  for	  siRNA	  cleavage	  as	  a	  therapeutic	  strategy.	  	  iv. If	   the	  sequences	   targeted	  by	  miR-­‐122	  binding	  site	   targeting	  siRNAs	  are	  not	  essential	   for	   HCV	   replication,	   then	   after	   several	   rounds	   of	   treatment	   with	  siRNA	  targeting	  the	  miR-­‐122	  binding	  region,	  viruses	  having	  mutations	  within	  the	  miR-­‐122	  binding	  sites	  will	  be	  selected	  and	  their	  analysis	  will	  reveal	   the	  tolerance	  for	  point	  mutations	  in	  this	  region.	  	  	  
 Objectives	  2.3 	  i. Determine	   the	   effect	   of	   DDX6	   depletion	   on	   HCV	   translation	   and	   RNA	  amplification.	  	  	  ii. Determine	  if	  the	  effects	  of	  DDX6	  depletion	  on	  HCV	  translation	  and	  replication	  are	  dependent	  or	   independent	  of	   the	  effects	  of	  miR-­‐122	  on	  HCV	  translation	  and	  replication.	  	  iii. Design	  siRNA	  that	  target	  the	  miR-­‐122	  binding	  region	  and	  assess	  their	  ability	  to	  inhibit	  HCV	  replication.	  	   iv. Assess	  the	  ability	  of	  miR-­‐122	  binding	  site	  targeting	  siRNAs	  to	  inhibit	  an	  HCV	  genome	  containing	  a	  point	  mutation	  within	  the	  target	  region.	  	   v. Treat	   Huh7.5	   cells	   repeatedly	   with	   siRNAs	   targeting	   the	   miR-­‐122	   binding	  region	  to	  assess	  the	  evolution	  of	  virus	  resistance	  to	  the	  siRNAs.	  	  	  vi. Sequence	  the	  5’UTR	  of	  the	  viral	  RNAs	  selected	  in	  objective	  v.	  to	  identify	  the	  specific	  escape	  mutants	  that	  have	  evolved.	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3.0 MODULATION	  OF	  HEPATITIS	  C	  VIRUS	  RNA	  ACCUMULATION	  AND	  
TRANSLATION	  BY	  DDX6	  AND	  miR-­‐122	  ARE	  MEDIATED	  BY	  SEPARATE	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 Permission	  to	  use	  3.1
	  	   In	  accordance	  with	  PLOS	  ONE	  no	  permission	  is	  required	  from	  the	  authors	  or	  the	   publisher	   to	   reuse,	   reprint,	   modify,	   distribute,	   and/or	   copy	   of	   articles.	   The	  details	   of	   the	   permission	   to	   use	   can	   be	   found	   at	  http://www.plosone.org/static/license;jsessionid=143CACBB004B7D2C222B1CA785EAA375	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  3.2	  	   Adam	   Huys	   performed	   all	   the	   experiments	   described	   and	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   in	   the	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  7.	   	  Patricia	  A.	  Thibault	  performed	  some	  of	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   the	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  by	  Patricia	  A.	  Thibault	  and	  Joyce	  A.	  Wilson.	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 Abstract	  3.3 	  DDX6	   and	   other	   p-­‐body	   proteins	   are	   required	   for	   efficient	   replication	   of	  Hepatitis	  C	  virus	  (HCV)	  through	  unknown	  mechanisms.	  	  DDX6	  has	  been	  implicated	  in	  miRNA	  induced	  gene	  silencing,	  and	  since	  efficient	  HCV	  replication	  and	  translation	  relies	  on	  the	  cellular	  microRNA,	  miR-­‐122,	  we	  hypothesized	  that	  DDX6	  had	  a	  role	  in	  the	  mechanism	  of	   action	   of	  miR-­‐122.	  However,	   by	   using	  multiple	  HCV	   translation	  and	  replication	  assays,	  we	  have	  found	  this	  is	  not	  the	  case.	  DDX6	  silencing	  decreased	  HCV	  replication	  and	  translation,	  but	  did	  not	  affect	  the	  ability	  of	  miR-­‐122	  to	  stimulate	  HCV	  translation	  or	  promote	  HCV	  RNA	  accumulation.	  In	  addition,	  the	  negative	  effect	  of	  DDX6	   silencing	  on	  HCV	   replication	   and	   translation	  was	  not	   dependent	   on	  miR-­‐122	   association	   with	   the	   HCV	   genome.	   Thus,	   DDX6	   does	   not	   have	   a	   role	   in	   the	  activity	  of	  miR-­‐122,	  and	  it	  appears	  that	  DDX6	  and	  miR-­‐122	  modulate	  HCV	  through	  distinct	   pathways.	   This	   effect	   was	   seen	   in	   both	   Huh7.5	   cells	   and	   in	   Hep3B	   cells,	  indicating	  that	  the	  effects	  are	  not	  cell	  type	  specific.	  Since	  infections	  by	  other	  viruses	  in	   the	   Flaviviridae	   family,	   including	   Dengue	   and	   West	   Nile	   virus,	   also	   disrupt	   p-­‐bodies	   and	   are	   regulated	   by	   DDX6,	  we	   speculate	   that	   DDX6	  may	   have	   a	   common	  function	  that	  support	  the	  replication	  of	  several	  Flaviviruses.	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 Introduction	  3.4 	  Processing	   bodies	   (p-­‐bodies)	   are	   transient	   cellular	   compartments	   where	  mRNAs	  are	  degraded	  and	  sometimes	  stored	  (97,	  146,	  249).	  P-­‐bodies	  are	  composed	  of	   an	   array	   of	   proteins	   such	   as	   mRNA	   de-­‐capping,	   de-­‐adenylating,	   and	   RNA	  exoribonuclease	   enzymes,	   many	   of	   which	   have	   been	   implicated	   in	   miRNA	  suppression	   and	   mRNA	   turn-­‐over.	   The	   composition,	   location,	   and	   number	   of	   p-­‐bodies	   in	   a	   cell	   is	   dynamic	   and	   based	   on	  mRNA	   degradation	   requirements	   (146).	  Fewer	  p-­‐bodies	  are	  found	  in	  cells	  under	  conditions	  of	  increased	  mRNA	  translation,	  due	   to	   a	   reduced	   need	   for	   mRNA	   degradation,	   and	   conversely,	   when	   mRNA	  degradation	   is	   promoted	   by	   impeded	   cellular	   translation,	   p-­‐bodies	   are	   found	   in	  greater	  numbers	  and	  increased	  size.	  	  microRNA-­‐mediated	   mRNA	   silencing	   involves	   both	   the	   suppression	   of	  translation,	   and	   induction	   of	   mRNA	   degradation	   (250).	   The	   process	   of	   miRNA	  silencing	  involves	  binding	  of	  miRNA	  and	  associating	  proteins	  Argonaute	  (Ago)	  and	  GW-­‐182.	  GW-­‐182	  then	  associates	  with	  Poly(A)-­‐binding	  protein	  (PABP)	  and	  several	  host	  protein	  components	  of	  the	  deadenylation	  complexes,	  which	  is	  believed	  to	  be	  at	  least	   part	   of	   the	  mechanism	   by	  which	  miRNAs	   suppress	   translation	   and	   promote	  mRNA	   degradation	   (251,	   252).	   P-­‐bodies	   are	   the	   likely	   sites	   of	   miRNA-­‐induced	  mRNA	  degradation	  since	  they	  contain	  high	  concentrations	  of	  miRNAs,	  Ago	  and	  GW-­‐182	   (143).	   The	   resident	   p-­‐body	   protein	   DDX6	   (RCK,	   p54)	   is	   essential	   for	   the	  assembly	   and	   maintenance	   of	   p-­‐bodies,	   and	   depletion	   of	   DDX6	   inhibits	   p-­‐body	  formation,	  even	  when	  stimulated	  by	  arsenite,	  a	  robust	   translation	   inhibitor	  and	  p-­‐body	   inducer	   (166).	   DDX6	   and	   its	   homologues	   from	   different	   species	   such	   as	  
Saccharomyces	  cerevisiae	  (Dhh1),	  Xenopus	  laevis	  (Xp54)	  and	  Caenorhabditis	  elegans	  (CGH-­‐1)	  are	  members	  of	   the	  DEAD-­‐box	  RNA	  helicase	   family	  and	  bind	  to	  RNA	  with	  high	  affinity.	  Once	  bound,	  DDX6	  has	  the	  ability	  to	  modify	  the	  secondary	  structure	  of	  the	   RNA	   in	   an	   energy	   independent	   and	   dependent	   manner	   (184,	   185,	   188).	   In	  addition,	   the	  S.	  cerevisiae	  DDX6	  homologue,	  Dhh1,	  stimulates	  decapping	  of	  mRNAs	  by	  decreasing	  the	  rate	  of	  translation,	  presumably	  by	  exposing	  the	  cap	  to	  decapping	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enzymes	  (253,	  254).	  DDX6	  is	  also	  believed	  to	  enhance	  miRNA	  gene	  suppression,	  as	  its	  knockdown	  leads	  to	  an	  alleviation	  of	  miRNA	  suppression	  in	  HeLa	  cells	  (153).	  Some	   RNA	   viruses	   have	   been	   shown	   to	   disrupt	   p-­‐bodies	   during	   infection,	  while	  others	  appear	  to	  use	  them	  as	  sites	  for	  replication,	  assembly,	  and	  release;	  thus,	  the	  relationship	  between	  p-­‐bodies	  and	  RNA	  viruses	  has	  been	  the	  focus	  of	  extensive	  study	  (157,	  164,	  200,	  255,	  256).	  Of	  particular	  interest	  is	  the	  Hepatitis	  C	  virus	  (HCV)	  a	   human	   pathogen	   that	   causes	   liver	   cirrhosis,	   liver	   failure	   and	   hepatocellular	  carcinoma.	  HCV,	  a	  9.6kb	  positive	  strand	  RNA	  virus	  and	  member	  of	  the	  Flaviviradae	  family,	  has	  been	  demonstrated	  to	  alter	  p-­‐body	  distribution	  during	  infections	  (257).	  The	  role	  of	   the	  redistribution	  of	  p-­‐bodies	  during	  HCV	  infection	   is	  unknown,	  but	  p-­‐bodies	   themselves	   do	   not	   appear	   to	   be	   required	   for	   HCV	   replication	   (257,	   258).	  However,	  knocking	  down	  p-­‐body	  proteins	  Lsm-­‐1,	  PatL-­‐1,	  Ge-­‐1,	  GW-­‐182,	  Ago2,	  and	  DDX6	   results	   in	   reduced	   HCV	   replication,	   indicating	   a	   direct	   or	   indirect	   role	   for	  these	  proteins	  in	  supporting	  the	  HCV	  life	  cycle	  (111,	  139,	  141,	  259).	  DDX6	  protein	  levels	  are	  also	  frequently	  elevated	  in	  HCV-­‐associated	  carcinomas,	  while	  being	  down-­‐regulated	  in	  other	  liver	  carcinomas,	  suggesting	  a	  possible	  role	  in	  HCV-­‐induced	  liver	  pathology	  (202).	  Knocking	  down	  DDX6	  in	  cell	  culture	  reduces	  HCV	  RNA	  replication,	  but	   there	   is	  conflicting	  evidence	  regarding	  whether	  DDX6	  silencing	  decreases	  HCV	  translation	   (141,	   259).	   Scheller	   et	  al.	   (141)	   found	   that	   DDX6	   knockdown	   reduced	  HCV	   translation	   levels	  while	   Jangra	   et	  al.	   (259)	   observed	   no	   effect	   on	   translation.	  DDX6	  has	  been	  demonstrated	  to	  co-­‐precipitate	  with	  HCV	  core	  protein,	  and	  through	  binding	   to	   core,	   associate	   with	   HCV	   RNA	   (259).	   DDX6	   also	   localizes	   near	   HCV	  replication	   centers,	   suggesting	   it	  may	   play	   a	   role	   in	   trafficking	   or	   regulating	   HCV	  RNA	   (139,	  257,	  259).	  Thus	   the	   function	  of	  DDX6	   in	  HCV	   replication	  needs	   further	  study	   in	   order	   to	   better	   understand	   the	   relationship	   and	   its	   possible	   link	   to	  hepatocellular	  carcinoma.	  	  HCV	   requires	   miR-­‐122,	   an	   abundantly	   expressed	   liver-­‐specific	   miRNA,	   to	  efficiently	  establish	  an	  infection	  (105),	  however	  the	  mechanism	  of	  action	  of	  miR-­‐122	  is	  unknown.	  The	   relationship	  between	  miR-­‐122	  and	  HCV	   is	  unusual	   in	   that	  unlike	  conventional	   miRNA-­‐mRNA	   interactions,	   which	   normally	   take	   place	   between	   the	  miRNA	  seed	  region	  (the	  5’	  nucleotides	  2-­‐8)	  and	  sequences	  in	  the	  3’	  UTR	  of	  mRNA,	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miR-­‐122	  binds	  to	  two	  tandem	  seed	  binding	  sequences	  within	  the	  HCV	  5’	  UTR	  (104,	  105).	  In	  addition,	  instead	  of	  down-­‐regulating	  translation	  and	  RNA	  stability,	  miR-­‐122	  promotes	  viral	  RNA	  accumulation,	  mostly	  by	  stabilizing	  the	  HCV	  genome,	  although	  it	  can	  also	  stimulate	  translation	  (108,	  110,	  114,	  260);	  and	  a	  direct	  role	  for	  miR-­‐122	  in	  promoting	   viral	   genome	   replication	   has	   not	   been	   ruled	   out	   (113).	   Like	   in	  miRNA	  suppression,	  annealing	  between	  the	  seed	  sequences	  of	  miR-­‐122	  to	  the	  HCV	  genome	  is	  required	  for	  activity,	  but	  unusually,	  so	  too	  are	  some	  of	  the	  nucleotides	  outside	  of	  the	  seed	  sequence;	  in	  particular,	  nucleotides	  15	  and	  16	  at	  the	  miR-­‐122	  3’	  end	  anneal	  to	   sequences	   at	   the	   5’	   end	   of	   the	   HCV	   genome,	   creating	   an	   RNA	   overhang	  which	  likely	   protects	   the	   uncapped	   HCV	   5’	   terminus	   from	   access	   by	   RNA	   degradation	  enzymes	  (106).	  Lastly,	  the	  space	  between	  the	  two	  miR-­‐122	  binding	  sites,	  and	  Ago2	  are	   also	   crucial	   for	   miR-­‐122	   augmentation	   of	   HCV	   RNA	   accumulation	   (104,	   111,	  140).	   Importantly,	   using	  miR-­‐122	   antagonists	   to	   block	   the	   activity	   of	   miR-­‐122	   in	  both	   chimpanzees	   and	   humans	   dramatically	   decreased	   serum	   HCV	   titres,	   making	  miR-­‐122	  a	  promising	  target	  for	  antiviral	  treatment	  and	  highlights	  the	  importance	  of	  miR-­‐122	   and	   the	   miRNA	   pathway	   in	   HCV	   life	   cycle	   (103).	   As	   a	   result,	   efforts	   to	  understand	  the	  mechanism	  of	  action	  of	  miR-­‐122	  are	  ongoing.	  	  Because	   DDX6	   knockdown	   attenuates	   miRNA	   suppression	   activity,	   we	  hypothesized	   that	   DDX6	   may	   modulate	   HCV	   replication	   and	   translation	   by	  mediating	   the	   activity	   of	   miR-­‐122,	   or	   vice	   versa.	   Jangra	   et	   al.	   showed	   that	   DDX6	  knockdown	  did	  not	  affect	  the	  ability	  of	  miR-­‐122	  to	  augment	  HCV	  replication	  (259),	  and	  our	  goal	  was	  to	  expand	  on	  these	  studies	  by	  using	  several	  model	  HCV	  replication	  and	   translation	  assay	   systems	   to	   confirm	  whether	   there	   is,	   or	   is	  not,	   a	   connection	  between	   the	   influence	   of	   DDX6	   and	   miR-­‐122	   on	   the	   HCV	   life	   cycle.	   First,	   our	  observations	   confirm	   that	   DDX6	   knockdown	  modulates	   both	  HCV	   translation	   and	  replication.	   Next	   we	   show	   that	   the	   DDX6	   is	   not	   required	   for	   miR-­‐122	   to	   affect	  translation,	  nor	  is	  miR-­‐122	  annealing	  required	  for	  DDX6	  to	  affect	  HCV	  translation.	  In	  addition,	   by	   using	   various	   assays	   to	   analyze	   HCV	   RNA	   accumulation,	   including	   a	  novel	   assay	   in	  which	  HCV	   replicates	   independently	   from	  miR-­‐122	   (116),	  we	   have	  confirmed	  both	  that	  DDX6	  is	  not	  required	  for	  the	  activity	  of	  miR-­‐122	  on	  HCV	  RNA	  accumulation,	  and	   that	  miR-­‐122	   is	  not	   required	   for	   the	   influence	  of	  DDX6	  on	  HCV	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replication.	  These	  data	  are	  strong	  indicators	  that,	  although	  both	  DDX6	  and	  miRNAs	  are	  located	  within	  p-­‐bodies	  and	  are	  implicated	  in	  miRNA	  suppression	  activity,	  they	  do	   not	   affect	   HCV	   replication	   and	   translation	   through	   a	   common	   mechanistic	  pathway.	  	  	  
	  
 Materials	  and	  methods	  3.5 	  
3.5.1 Cell	  culture	  	  	  	  Huh7.5	   cells	   (261)	   were	   used	   for	   all	   experiments	   unless	   otherwise	   stated,	  and	  were	  grown	  in	  D-­‐MEM	  supplemented	  with	  10%	  fetal	  bovine	  serum,	  0.1ηM	  non-­‐essential	  amino	  acids	  (Wisent,	  Montreal,	  Canada),	  and	  100	  units/ml	  Pen/Strep	  (Life	  Technologies,	  Burlington	  ON,	  Canada).	   	  Hep3B	  cells	  (ATCC	  number	  HB-­‐8064)	  are	  a	  human	   hepatoma	   cell	   line	   and	  were	   grown	   under	   the	   same	   conditions	   as	   Huh7.5	  cells.	   	  
3.5.2 Plasmids	  and	  DNA	  probes	  	  The	   pSGR	   JFH-­‐1	   Fluc	   WT	   sub-­‐genomic	   replicon	   was	   provided	   by	   Dr.	   T.	  Wakita	   (262)	   and	   the	   full-­‐length	   genome	   constructs	   pJ6/JFH-­‐1	   (p7-­‐Rluc2A),	  pJ6/JFH-­‐1	   (p7-­‐Rluc2A)	  GNN,	   (herein	  called	   J6/JFH-­‐1	  Rluc	  and	   J6/JFH-­‐1	  Rluc	  GNN)	  were	   provided	   by	  Dr.	   Charles	  M.	   Rice	   (263).	   	   pJ6/JFH-­‐1	  Rluc	   p34,	   pJ6/JFH-­‐1	  Rluc	  p34	  GNN,	  and	  pSGR	  JFH-­‐1	  p3	  were	  described	  previously	  (111,	  116).	   	  The	  plasmids	  pT7Luc	  and	  pRL-­‐TK	  were	  obtained	   from	  Promega	  Co.	   (Madison,	  WI).	   	  pLuc-­‐122x2	  and	  pLuc-­‐122x2	  S1+S2:p3-­‐4	  were	  kindly	  provided	  by	  Dr.	  Peter	  Sarnow	  (104),	  and	  the	  plasmid	  pRL-­‐TK	  CXCR4	  4x	  was	  provided	  by	  Dr.	  Tariq	  M.	  Rana	  (153).	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3.5.3 Small	   interfering	   RNAs	   (siRNA),	   duplex	  microRNA	   (miRNA),	   and	  miR-­‐
122	  antagonist	  sequences	  	  	  All	   small	   RNAs	   were	   synthesized	   by	   Thermo-­‐scientific	   Dharmacon	   Inc	  (Lafayette,	   CO).	   	   The	   target	   sequence	   for	   the	   siRNA	   used	   for	   siControl	   was	  GAGAGUCAGUCAGCUAAUCA	   and	   siDDX6	   was	   ACCCGAGGUAUUGAUAUACAA.	   	   The	  sequence	   for	   the	   duplex	   miRNA	   were	   as	   follows:	   miControl,	  GAGAGUCAGUCAGCUAAUCA;	   miCXCR4	   antisense,	   UGUUAGCUGGAGUGAAAACUU;	  miCXCR4	   sense,	   GUUUUCACUCCAGCUAACACA;	   miR-­‐122,	  UGGAGUGUGACAAUGGUGUUUGU;	   miR-­‐122p3	   UGCAGUGUGACAAUGGUGUUUGU;	  miR-­‐122p3-­‐4	   UGCUGUGUGACAAUGGUGUUUGU;	   miR-­‐122*,	  AAACGCCAUUAUCACACUAAAUA.	   miR-­‐122,	   miR-­‐122p3,	   and	   miR-­‐122p34	   duplex	  were	   formed	  by	  annealing	   the	   indicated	  miRNA	  guide	  strand	  with	  miR-­‐122*.	   	  The	  miR-­‐122	  antagonist,	  hsa-­‐miR-­‐122a	  miRIDIAN	  microRNA	  Hairpin	   Inhibitor,	  bears	  a	  proprietary	  sequence.	  	  
3.5.4 In-­‐vitro	  RNA	  transcription	  	  	  	  HCV	   RNA	   transcripts	   were	   prepared	   from	   XbaI-­‐linearized	   plasmids	   as	  described	   previously	   (111)	   by	   using	   the	  MEGAScript	   T7	   High	   Yield	   Transcription	  Kit,	   while	   pRL-­‐TK	   was	   linearized	   with	   BglII	   to	   generate	   Rluc	   mRNA	   and	   pT7	  luciferase	   was	   linearized	   with	   XmnI	   to	   generate	   Fluc	   mRNA	   using	   mMessage	  mMachine	  T7	  Transcription	  Kit	  (Life	  Technologies,	  Burlington,	  ON,	  Canada)	  (116).	  	  
3.5.5 Electroporation	  of	  Huh7.5	  and	  Hep3B	  cells	  	  	  Huh7.5	  and	  Hep3B	  cells	  were	  electroporated	  as	  previously	  described	  (116).	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3.5.6 Transient	  HCV	  replication	  assays	  	  	  Huh7.5	   cells	  were	   initially	   electroporated	  with	  60pmol	  of	   siRNA	   to	   achieve	  knockdown	   of	   the	   desired	   protein.	   Three	   days	   post-­‐electroporation,	   cells	   were	  electroporated	  again	  with	  1µg	  of	  HCV	  RNA,	  1ug	  of	  control	  mRNA,	  60pmol	  of	  siRNA,	  and	   60	   pmol	   of	   miRNA,	   if	   applicable.	   	   Electroporated	   cells	   were	   re-­‐suspended	   in	  8mL	  of	  media	  and	  plated	   for	   luciferase	  assays,	  protein	  analysis,	  RNA	  analysis,	  and	  cell	   number	   assays.	   Cells	   where	   harvested	   3	   days	   post-­‐electropoartion	   unless	  otherwise	  specified.	  An	  additional	  luciferase	  assay	  sample	  was	  harvested	  at	  1-­‐hour	  post-­‐electroporation	   to	   confirm	   electroporation	   efficiency.	   	   Experiments	   with	  Hep3B	  cells	  were	   conducted	  using	   the	   same	  method,	   except	   that	  5μg	  of	  HCV	  RNA	  was	  used	  instead	  of	  1μg.	  	  
3.5.7 Transient	  HCV	  translation	  assays	  	  	  	  Huh7.5	  cells	  were	  electroporated	  on	  day	  0	  with	  60pmol	  of	  siRNA	  in	  order	  to	  silence	  the	  gene	  of	  interest.	  	  The	  cells	  were	  electroporated	  again	  on	  day	  3	  with	  5ug	  of	   J6/JFH-­‐1	   RLuc	   GNN	   or	   J6/JFH-­‐1	   RLuc	   p34	   GNN	   RNA	   and	   1ug	   of	   Fluc	   capped	  mRNA.	   Immediately	  prior	   to	   the	   second	  electroporation	   a	   sample	  of	   the	   cells	  was	  harvested	   for	   analysis	   of	   protein	   knockdown	   by	   western	   blot.	   	   After	   the	   second	  electroporation,	   cells	   were	   plated	   for	   luciferase	   assays,	   RNA	   analysis	   and	   cell	  number	  assays	  and	  were	  harvested	  3.5	  hours	  post-­‐second-­‐electroporation.	  	  	  
3.5.8 Translation	  suppression	  assays	  	  	  	  Huh7.5	   cells	   were	   electroporated	   with	   60pmol	   of	   siRNA	   on	   day	   0,	  resuspended	  in	  8ml	  of	  media	  and	  then	  300μl	  was	  seeded	  into	  each	  well	  of	  a	  24-­‐well	  plate.	   	   Two	   days	   post-­‐electroporation	   the	   cells	   were	   transfected	   with	   100ng	   of	  plasmids	  pLuc-­‐122x2	  or	  pLuc-­‐122x2	  S1+S2:p3-­‐4,	  and	  pRL-­‐TK;	  or	  pRL-­‐TK	  CXCR4	  4x	  and	   pLuc-­‐122x2	   S1+S2:p3-­‐4	   (104)	   and	   0.05	   –	   5pmol	   of	   miRNA	   per	   well	   using	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Lipofectamine	  2000	  (Life	  Technologies,	  Burlington,	  ON,	  Canada)	  and	  the	  suggested	  protocol.	  	  Cells	  were	  harvested	  24	  hours	  post-­‐transfection	  for	  luciferase	  assays.	  	  	  	  	  	  	  	  
3.5.9 Luciferase	  assays	  	  Luciferase	  assays	  were	  performed	  as	  previously	  described	  (111).	  Briefly,	  the	  cells	  where	  washed	  with	  phosphate-­‐buffered	  saline	   (PBS),	   and	   lysed	   into	  100μl	  of	  the	   appropriate	   lysis	   buffer.	   Luciferase	   levels	   were	   assayed	   by	   using	   Renilla	  Luciferase,	  Firefly	  Luciferase,	  or	  Dual	  Luciferase	  assay	  kits	  (Promega	  Co.,	  Madison.	  WI,	   USA)	   and	   light	   emission	   was	   measured	   by	   the	   Glomax	   20/20	   Luminometer	  (Promega	  Co.,	  Madison,	  WI,	  USA).	  	  	  
3.5.10 Cell	  number	  assay	  	  	  	  Cell	   numbers	  were	   calculated	   three	   days	   post-­‐electroporation	   or	   24	   hours	  post-­‐transfection	  using	  WST-­‐1	  reagent.	  	  The	  WST-­‐1	  assay	  was	  performed	  according	  to	   the	   protocol	   provided	   by	   Roche	   (Roche	   Canada,	  Mississauga,	   ON,	   Canada).	   Cell	  numbers	  were	  determined	  by	  comparing	  them	  to	  a	  standard	  curve.	  	  
3.5.11 RNA	  purification	  	  	  Cells	  were	  harvested	   into	  1mL	  of	  Trizol	   (Life	  Technologies,	  Burlington,	  ON,	  Canada)	  and	  RNA	  purified	  using	  the	  manufacturer’s	  recommended	  protocol.	  	  
3.5.12 Northern	  blot	  analysis	  	  	  	  Northern	  blots	  were	  conducted	  as	  previously	  described	  (111).	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3.5.13 Real-­‐time	  PCR	  analysis	  of	  RNA	  	  	  	  RNA	  was	  reverse-­‐transcribed	  using	  the	  iScript	  reverse	  transcription	  kit	  (Bio-­‐Rad	  Inc.,	  Missassauga,	  ON,	  Canada).	  	  DDX6	  mRNA	  (Life	  Technologies,	  Hs00898913)	  and	  GAPDH	  mRNA	   (used	   as	   internal	   control	   [#4352934E])	   levels	  were	   quantified	  using	  TaqMan	  (Life	  Technologies)	  probes,	  primers,	  and	  protocol.	  HCV	  and	  Fluc	  RNA	  levels	  where	  determined	  using	  primers	  directed	  towards	  the	  Renilla	  (RLuc)	  gene	  in	  the	   reporter	   HCV	   genomic	   RNA,	   and	   Fluc	   in	   the	   control	   mRNA	   as	   described	  previously	  (112)	  	  
3.5.14 SDS-­‐Page	  and	  western	  blot	  analysis	  	  	  Protein	  samples	  were	  collected	  by	  lysing	  equal	  number	  of	  cells	  in	  SDS-­‐PAGE	  protein	   lysis	  buffer	  (10%	  SDS,	  5%	  beta-­‐mercaptoethanol,	  20%	  glycerol,	  0.2M	  Tris-­‐HCl,	   pH	   6.8,	   0.05%	   bromophenol	   blue).	   	   Samples	   were	   electrophoresed	   through	  10%	  SDS-­‐polyacrylamide	  gels	  and	  transferred	  onto	  a	  Hybond-­‐C	  Extra	  nitrocellulose	  membrane	   (GE	   Healthcare,	   Mississauga,	   ON,	   Canada).	   	   Blots	   were	   probed	   with	  primary	   antibodies	   (1:5000)	   mouse	   monoclonal	   anti-­‐actin	   (AC-­‐15;	   Abcam,	  Cambridge,	   MA,	   USA)	   and	   (1:5000)	   rabbit	   anti-­‐RCK	   (DDX6	   antibody;	   Bethyl	   labs,	  Montgomery,	  TX,	  USA).	  	  Blots	  were	  then	  probed	  with	  (1:1000)	  anti-­‐mouse	  (800nm)	  and	   anti-­‐rabbit	   (680nm)	   infrared	   dye-­‐linked	   secondary	   antibody	   (Li-­‐Cor	  Biosciences,	  Lincoln,	  NE)	  and	  visualized	  using	  a	  Li-­‐Cor	  Odyssey	  infrared	  imager	  and	  knockdown	   was	   determined	   using	   Odyssey	   Infrared	   Imaging	   System	   Application	  Software	  Version	  3.0.	  	  	  
3.5.15 Fluorescence	  microscopy	  	  	  	  Huh7.5	  cells	  were	  plated	  onto	  an	  8-­‐chamber	  slide.	  	  The	  cells	  were	  fixed	  using	  paraformaldehyde	  and	  permeabilized	  with	  0.5%	  Triton	  X-­‐100.	  	  The	  cells	  were	  then	  exposed	   to	   primary	   antibody,	   human	   IC6	   polyclonal	   antibody	   (264)	   (a	   gift	   from	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Marvin	  Fritzler),	  followed	  by	  secondary	  antibody,	  Alexa	  fluor®594	  Goat	  anti-­‐human	  IgG	   (H+L)	   (Life	   Technologies,	   Burlington,	   ON,	   Canada).	   Fluorescence	   images	  were	  obtained	  using	  a	  Zeiss	  axiovert	  200M	  inverted	  microscope	  at	  a	  magnification	  of	  63	  x	  10	  and	  the	  Axiovision	  4.6	  software.	  	  	  	  
3.5.16 Statistical	  analyses	  	  	  Data	   are	   presented	   as	   the	   average	   of	   least	   three	   independent	   experiments,	  unless	   otherwise	   indicated,	   and	   error	   bars	   represent	   the	   standard	  deviation	   (SD).	  	  Data	   analysis	   was	   carried	   out	   with	   Prism	   5	   software.	   P	   values,	   unless	   otherwise	  indicated	   were	   calculated	   by	   using	   Student	   t-­‐test	   *P<0.05,	   **p<0.01,	   ***p<0.001,	  ****p<0.0001.	  	  
 Results	  3.6 	  
3.6.1 Depletion	  of	  DDX6	  reduces	  p-­‐body	  abundance	  	  	  Following	  DDX6-­‐specific	  or	  control	  siRNA	  treatment,	  levels	  of	  DDX6	  protein,	  mRNA	   and	   p-­‐bodies	   were	   evaluated	   by	   western	   blot,	   qRT-­‐PCR,	   and	   microscopic	  analysis.	   Huh7.5	   cells	   treated	   with	   DDX6	   siRNA	   expressed	   79%	   ±	   9%	   less	   DDX6	  protein	  and	  81%	  less	  mRNA,	  compared	  to	  cells	  treated	  with	  control	  siRNA	  (Fig.	  3.1A	  and	   B).	   DDX6	   knockdown	   also	   significantly	   reduced	   the	   abundance	   of	   visible	   p-­‐bodies	  (Fig.	  3.1D).	  P-­‐body	  disruption	  was	  enumerated	  by	  assessing	  the	  number	  of	  p-­‐bodies	  per	   cell	   in	   random	   fields	  of	  100	  cells.	   	  Only	  9%	  of	   the	  Huh7.5	  cells	   treated	  with	   siDDX6	   contained	   two	  or	  more	  p-­‐bodies	   in	   contrast	   to	  96%	   in	   cells	   that	  had	  been	  treated	  with	  control	  siRNA	  (Fig.	  3.1C).	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Figure	  3.1	  DDX6	  specific	  siRNA,	  siDDX6,	  depletes	  cells	  of	  DDX6	  and	  disrupts	  p-­‐
body	  formation.	  (A)	  Western	  blot	  analysis	  shows	  siDDX6	  protein	  levels	  in	  siControl	  and	   siDDX6	   treated	   cells.	   The	   values	   represent	   the	   average	   relative	  DDX6	  protein	  levels	   and	   standard	   deviation	   from	   western	   blot	   analyses	   of	   12	   independent	  experiments	  (B)	  qRT-­‐PCR	  analysis	  show	  that	  siDDX6	  depletes	  cells	  of	  DDX6	  mRNA	  	  (C)	   Enumeration	   of	   cells	   containing	   two	  or	   fewer	  p-­‐bodies	   after	   siRNA	   treatment.	  	  (D)	  Immunoflorescence	  staining	  of	  p-­‐bodies	  by	  staining	  for	  the	  p-­‐body	  protein	  (Ge-­‐1)	  in	  DDX6	  depleted	  cells	  and	  control	  cells.	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3.6.2 Silencing	   of	   DDX6	   attenuates	   replication	   of	   both	   full-­‐length	   and	   sub-­‐
genomic	  HCV	  replicon	  RNA	  	  	  Three	  days	  following	  DDX6	  knockdown,	  replication	  of	  both	  bi-­‐cistronic	  JFH-­‐1	  replicon	   RNA	   (SGR	   JFH-­‐1	   FLuc)	   and	   full-­‐length	   J6/JFH-­‐1	   RLuc	   HCV	   RNA	   was	  evaluated.	   Both	   RNAs	   contain	   luciferase	   reporter	   genes	   so	   that	   HCV	   replication	  could	  be	   evaluated	  based	  on	   luciferase	   expression.	  At	   3	  days	  post-­‐electroporation	  luciferase	   expression	   from	   sub-­‐genomic	   and	   full-­‐length	   HCV	   replicons	   was	  decreased	  by	  30%	  and	  45%	  respectively	   in	  DDX6	   silenced	   cells	   (Fig.	   3.2A	  and	  B).	  Reduced	  HCV	   replication	  was	  not	   attributed	   to	   a	   defect	   in	   cell	   proliferation,	   since	  WST-­‐1	  assays	  indicated	  that	  DDX6	  silencing	  did	  not	  significantly	  affect	  cell	  numbers	  present	   at	   the	   time	   of	   harvest	   (Fig.	   3.2C	   and	   D),	   and	   DDX6	   knockdown	   was	  confirmed	   by	   western	   blot	   (data	   not	   shown).	   These	   results	   are	   similar	   to,	   and	  confirm,	   those	   reported	   by	   Scheller	   et	  al.,	   Jangra	  et	  al.,	   and	  Pager	   et	  al.	  (139,	   141,	  259).	   	  
3.6.3 DDX6	  knockdown	  suppresses	  HCV	  translation	  	  	  The	  effect	  of	  DDX6	  on	  HCV	  translation	  was	  examined	  by	  co-­‐electroporating	  DDX6-­‐depleted	  and	  control	  cells	  with	  non-­‐replicating	  full-­‐length	  HCV	  RNA	  carrying	  a	  Renilla	  luciferase	  reporter	  gene	  (J6/JFH-­‐1	  Rluc	  GNN)	  and	  capped	  firefly	  luciferase	  mRNA	   (FLuc).	   Relative	  HCV	   translation	   levels	  were	  determined	  by	   calculating	   the	  ratio	   of	   Renilla	   luciferase	   vs.	   firefly	   luciferase	   expression.	   Knockdown	   of	   DDX6	  reduced	  HCV	  translation	  of	  full-­‐length	  J6/JFH-­‐1	  Rluc	  GNN	  by	  46%	  compared	  to	  cells	  treated	  with	  control	  siRNA	  (Fig.	  3.3A,	  miControl).	  The	  phenotype	  attributed	  to	  DDX6	  silencing	   is	   consistent	   with	   that	   previously	   reported	   by	   Scheller	   et	   al.	   (141).	  	  However,	  we	   saw	   inconsistent	   data	   regarding	  whether	  DDX6	   knockdown	   affected	  HCV	  translation.	  Results	  obtained	  using	  the	  identical	  method	  in	  an	  earlier	  passage	  of	  Huh7.5	  cells	  indicated	  that	  DDX6	  silencing	  did	  not	  affect	  HCV	  translation	  (Fig.	  3.4).	  This	  data	  is	  consistent	  with	  those	  reported	  by	  Jangra	  et	  al.	  (259).	   	  Quantitative	  RT-­‐	  
	  59	  
	   	  
	  
	  
Figure	   3.2	   DDX6	   depletion	   attenuates	   sub-­‐genomic	   and	   full-­‐length	   HCV	  







Figure	   3.3	   siDDX6	   depletion	   decreases	   HCV	   translation,	   but	   does	   not	   affect	  




Figure	  3.4	   In	  a	   subset	  of	  experiments	  we	  observed	   that	  HCV	   translation	  was	  
not	  inhibited	  by	  DDX6	  knockdown.	  (A)	  Relative	  luciferase	  expression	  of	  J6/JFH-­‐1	  Rluc	   after	   electroporation	   with	   siDDX6	   or	   siControl.	   (B)	   Relative	   RNA	   ratios	   of	  J6/JFH-­‐1	  Rluc	  GNN	  to	  capped	  firefly	  mRNA	  measured	  by	  qRT-­‐PCR.	  (C)	  Western	  blot	  analysis	   of	   cell	   lysates	   confirming	   knockdown	   of	   DDX6.	   (D)	   Relative	   luciferase	  expression	   of	   J6/JFH-­‐1	   Rluc	   m34	   in	   presence	   and	   absence	   of	   miR-­‐122	   p34.	   The	  graph	  on	   the	   right	   shows	   the	   relative	   fold	   translation	   stimulation	  by	  miR-­‐122p34.	  (E)	  Relative	  RNA	  ratios	  of	  J6/JFH-­‐1	  Rluc	  GNN	  p34	  to	  capped	  firefly	  mRNA	  measured	  by	  qRT-­‐PCR.	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PCR	  quantification	  of	  HCV	  and	  control	  Fluc	  RNA	  support	  that	  the	  influence	  of	  DDX6	  and	  miR-­‐122	  on	  HCV	  were	  on	   translation	   rather	   than	  RNA	   stabilization	   (Fig.	   3.3B	  and	   Fig.	   3.4B).	   A	   western	   blot	   confirmed	   efficient	   DDX6	   knockdown	   in	   the	   cells	  treated	  with	  siDDX6	  (Fig.	  3.3C,	  Fig.	  3.4C).	  	  
3.6.4 DDX6	  knockdown	  does	  not	  affect	  the	  efficiency	  of	  miR-­‐122	  stimulation	  
of	  HCV	  translation	  	  	  Since	  we	  hypothesized	  that	  DDX6	  was	  involved	  in	  the	  activity	  of	  miR-­‐122,	  we	  expected	   DDX6	   knockdown	   to	   attenuate	   the	   ability	   of	   miR-­‐122	   to	   stimulate	   HCV	  translation.	   To	   test	   this	   we	   analyzed	   HCV	   translation	   stimulation	   by	   miR-­‐122	  following	   knockdown	   of	   DDX6.	   Co-­‐electroporation	   of	  miR-­‐122	  with	   J6/JFH-­‐1	  Rluc	  GNN	  stimulated	  HCV	  translation	  1.6	  fold,	  and	  siRNA	  depletion	  of	  DDX6	  did	  not	  affect	  the	   efficiency	   by	   which	   miR-­‐122	   stimulated	   translation	   (Figure.	   3.3A,	   miR-­‐122).	  Thus,	   DDX6	   silencing	   had	   no	   affect	   on	   the	   ability	   of	   miR-­‐122	   to	   stimulate	   HCV	  translation.	   To	   further	   confirm	   our	   observations,	   we	   assayed	   the	   effect	   of	   DDX6	  knockdown	   on	  HCV	   translation	   stimulation	   by	   an	   exogenously	   provided	   synthetic	  miR-­‐122	   (miR-­‐122p34).	   In	   these	   experiments,	   cells	   were	   electroporated	   with	  J6/JFH-­‐1	  Rluc	  p34	  GNN,	  which	  contains	  two	  point	  mutations	  in	  the	  miR-­‐122	  binding	  sites,	  and	  therefore	  can	  no	  longer	  bind	  endogenous	  miR-­‐122,	  but	  can	  associate	  with	  a	  synthetic	  miR-­‐122	  containing	  compensatory	  mutations	  (Fig.	  3.3D).	  Knockdown	  of	  DDX6	  attenuated	  translation	  of	  J6/JFH-­‐1	  Rluc	  p34	  GNN	  by	  34%,	  indicating	  that	  miR-­‐122	  binding	   to	   the	  HCV	  genome	   is	  not	   required	   for	   the	   influence	  of	  DDX6	  on	  HCV	  translation	   (Fig.	   3.3E,	   miControl).	   In	   addition,	   miR-­‐122p34	   stimulated	   HCV	  translation	   by	   approximately	   2	   fold	   in	   both	  DDX6	   depleted	   and	   control	   cells	   (Fig.	  3.3E,	   and	  3.4D,	  miR-­‐122p34).	  Quantitative	  RT-­‐PCR	  data	   suggest	   that	   the	  observed	  effects	   on	   translation	   of	   J6/JFH-­‐1	   Rluc	   p34	   GNN	  were	   the	   result	   of	   a	   decrease	   in	  translation	  and	  not	  a	  decrease	  in	  genome	  stability	  (Fig.	  3.3F	  and	  3.4E).	  From	  these	  results	  we	  confirmed	  that	  the	  effects	  of	  DDX6	  and	  miR-­‐122	  on	  HCV	  translation	  are	  functioning	  independently.	  	  
	  64	  
3.6.5 DDX6	  knockdown	  does	  not	  affect	  miR-­‐122	  augmentation	  of	  HCV	  









Figure	  3.5	  Augmentation	  of	  HCV	  replication	  by	  miR-­‐122	   is	  not	  dependent	  on	  
DDX6.	  	  (A)	  Representative	  northern	  blot	  analysis	  of	  HCV	  and	  GAPDH	  RNA	  from	  cells	  3	  days	  after	  electroporation	  with	   J6/JFH-­‐1	  Rluc	  RNA	  and	   the	   indicated	   siRNA	  and	  miRNA.	  (B)	  Average	  band	  intensity	  measured	  from	  3	  independent	  northern	  blots	  as	  shown	  in	  part	  A,	  and	  (C)	  the	  corresponding	  fold	  induction	  of	  RNA	  accumulation	  by	  miR-­‐122.	  	  (D)	  Relative	  luciferase	  expression	  3	  days	  post-­‐electroporation	  in	  the	  same	  experiments	  as	  shown	   in	  parts	  A,	  B	  and	  C,	  and	   (E)	   the	   fold	   induction	  of	   luciferase	  expression	  by	  miR-­‐122.	  (F)	  Relative	  cell	  numbers	  and	  (G)	  Fluc	  expression	  from	  a	  co-­‐electroporated	   capped	   mRNA	   at	   2	   hour	   post	   electroporation.	   (H)	   Western	   blot	  analysis	   of	   DDX6	   protein	   expression.	   Data	   in	   (D-­‐G)	   represents	   the	   average	   of	   8	  independent	   experiments.	   A	   one-­‐way	   ANOVA	   with	   Bonferonni’s	   multiple	  comparison	   test	  was	   performed	   on	   F	   and	   G	   to	   show	   they	  where	   not	   significantly	  different.	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3.6.6 DDX6	   silencing	   impedes	   both	   miR-­‐122-­‐independent	   and	   miR-­‐122-­‐
dependent	  HCV	  replication	  in	  Huh7.5	  cells	  	  	  






Figure	  3.6	  Both	  miR-­‐122-­‐dependent	  and	  miR-­‐122-­‐independent	  HCV	  SGR	  RNA	  
replication	  in	  Huh7.5	  cells	  is	  attenuated	  by	  depletion	  of	  DDX6.	  	  (A)	  A	  schematic	  drawing	  of	  the	  5’	  UTR	  of	  the	  JFH-­‐1	  sub-­‐genomic	  replicon	  (SGR	  JFH-­‐1)	  with	  a	  single	  point	   mutation	   in	   both	   miR-­‐122	   binding	   sites	   (SGR	   JFH-­‐1	   p3)	   that	   abolishes	  endogenous	   miR-­‐122	   binding,	   and	   the	   corresponding	   miRNA	   containing	  compensatory	   mutations	   to	   reinstate	   binding	   (miR-­‐122p3).	   	   (B)	   Time	   course	   of	  luciferase	  expression	  in	  Huh7.5	  cells	  electroporated	  with	  WT	  SGR	  JFH-­‐1	  (miR-­‐122-­‐dependent	   replication)	   and	   SGR	   JFH-­‐1	   p3	   (miR-­‐122-­‐independent	   replication)	  treated	  with	  either	  siDDX6	  or	  control	  siRNA.	   	  (C)	  Luciferase	  expression,	  relative	  to	  siControl,	  on	  day	  1,	  2,	  and	  3	  post-­‐electroporation	  for	  the	  samples	  shown	  in	  panel	  B.	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3.6.7 DDX6	   silencing	   impedes	   both	   miR-­‐122-­‐independent	   and	   miR-­‐122-­‐
dependent	  HCV	  replication	  in	  Hep3B	  cells	  	  We	   also	   confirmed	   the	   phenotype	   of	   DDX6	   knockdown	   on	   miR-­‐122-­‐independent	   and	   miR-­‐122-­‐dependent	   HCV	   replication	   in	   Hep3B	   cells.	   DDX6	  knockdown	   decreased	  miR-­‐122-­‐independent	   replication	   in	   Hep3B	   (SGR	   JFH-­‐1	   S1,	  S2:p3	  +	  miControl)	  by	  32%,	  56%,	  and	  45%	  on	  days	  1,	  2,	  and	  3	  respectively	  (Fig.	  3.7A	  and	  B)	  and	  was	  not	  significantly	  different	  from	  the	  decrease	  in	  replication	  observed	  in	   cells	   supporting	   miR-­‐122-­‐dependent	   HCV	   replication	   (SGR	   JFH-­‐1	   p3	   +	   miR-­‐122p3),	  which	  were	  49%,	  78%,	  and	  54%.	  This	  data	  confirms	   that	  DDX6	  depletion	  affects	   HCV	   replication	   independent	   of	   miR-­‐122,	   and	   demonstrates	   that	   the	  	  influence	  of	  DDX6	  on	  HCV	  replication	  is	  not	  specific	  to	  Huh7.5	  cells.	  	  
3.6.8 miRNA	   translation	   suppression	   is	   slightly	   attenuated	   by	   DDX6	  






Figure	   3.7	   Both	   miR-­‐122-­‐dependent	   and	   miR-­‐122-­‐independent	   HCV	   SGR	   p3	  
RNA	  replication	   in	  Hep3B	  cells	   is	  attenuated	  by	  depletion	  of	  DDX6.	   	  (A)	  Time	  course	  analysis	  of	  luciferase	  expression	  from	  SGR	  JFH-­‐1	  p3	  RNA	  in	  Hep3Bs	  cells	  co-­‐electroporated	   with	   either	   miR-­‐122p3	   (miR-­‐122-­‐dependent)	   or	   miControl	   (miR-­‐122-­‐independent)	   and	   the	   indicated	   siRNAs.	   	   (B)	   Luciferase	   expression	   from	   SGR	  JFH-­‐1	   p3	   RNA,	   relative	   to	   siControl,	   in	   the	   presence	   or	   absence	   of	  miR-­‐122	   p3	   at	  days	  1,	  2,	  and	  3.	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effects	   of	   DDX6	   knockdown	   on	  miRNA	   suppression	  was	   not	   due	   to	   a	   decrease	   in	  miR-­‐122	  biogenesis,	  we	  also	  tested	  DDX6	  knockdown	  using	  a	  system	  in	  which	  gene	  suppression	  was	   induced	  by	   serial	   dilutions	  of	   an	   exogenously	  provided	   synthetic	  miR-­‐122p34	  (Fig.	  3.8B).	  In	  this	  assay,	  increased	  amounts	  of	  transfected	  miR-­‐122p34	  caused	   greater	   suppression	   of	   luciferase	   expression,	   and	   DDX6	   knockdown	  attenuated	  suppression	  by	  miR-­‐122p34	  by	  11%	  and	  8%	  when	  0.5	  and	  0.125pmol	  of	  miR-­‐122p34	   was	   used,	   but	   not	   significantly	   with	   other	   dilutions	   (0.25	   and	  0.06pmol)	  miR-­‐122p34	  (Fig.	  3.8B).	  Although	  DDX6	  knockdown	  showed	  statistically	  significant	   alleviation	   of	   miR-­‐122	   silencing,	   the	   effect	   was	   modest	   and	   the	  	  physiological	   relevance	   questionable.	   To	   confirm	   that	   our	   observations	   were	   not	  specific	   to	   suppression	   by	   miR-­‐122,	   we	   also	   analysed	   the	   effects	   of	   DDX6	  knockdown	  on	  miRNA	  suppression	  by	  another	  miRNA,	  miCXCR4,	  using	  a	   reporter	  plasmid	   containing	   miCXCR4	   binding	   sites.	   This	   assay	   is	   identical	   to	   one	   used	  previously	  to	   identify	  a	   link	  between	  miRNA	  suppression	  activity	  and	  DDX6	  (153).	  We	  observed	  statistically	  significant	  alleviation	  of	  miRNA	  suppression	  by	  miCXCR4	  following	  DDX6	  knockdown	  (Fig.	  3.8C),	  but	  the	  effects	  were	  relatively	  small,	  and	  not	  as	   robust	   as	   those	   previously	   reported	   (153),	   which	   suggests	   that	   DDX6	   is	   not	  essential	  for	  miRNA	  suppression	  activity	  in	  Huh7.5	  cells.	  	  
	  








Figure	   3.8	   miRNA	   translation	   suppression	   by	   endogenous	   and	   exogenous	  
miRNA	   is	   alleviated	   by	   DDX6	   silencing.	   	   (A)	   Schematic	   diagram	   of	   the	  mRNAs	  expressed	   from	   the	   co-­‐transfected	   reporter	   plasmids	   used	   in	   this	   miRNA	  suppression	  assay.	  Expressed	  mRNAs	  carry	  the	  Fluc	  sequence	  with	  4	  WT	  miR-­‐122	  binding	  sites	  in	  the	  3’	  UTR,	  or	  a	  control	  Rluc	  sequence.	  Relative	  Fluc:Rluc	  expression	  from	   the	   reporters	   was	   assessed	   in	   control,	   DDX6-­‐depleted,	   and	   miR-­‐122	  antagonist-­‐treated	   Huh7.5	   cells.	   (B)	   Schematic	   diagram	   of	   the	   mRNAs	   expressed	  from	   the	   co-­‐transfected	   reporter	   plasmids	   used	   in	   this	  miRNA	   suppression	   assay.	  Expressed	  mRNAs	  carry	  the	  Fluc	  reporter	  gene	  and	  4	  mutant	  miR-­‐122p34	  binding	  sites	   in	   the	  3’	  UTR,	  or	   a	   control	  Rluc	   gene.	  Relative	  Fluc:Rluc	   expression	   from	   the	  reporters	  was	   assessed	   in	   control	   or	  DDX6-­‐depleted	   cells,	   co-­‐transfected	  with	   the	  indicated	  amounts	  of	  miR-­‐122p34.	  (C)	  Schematic	  diagram	  of	  the	  mRNAs	  expressed	  from	   the	   co-­‐transfected	   reporter	   plasmids	   used	   in	   this	  miRNA	   suppression	   assay.	  Expressed	  mRNAs	  contain	  an	  Rluc	  gene	  with	  4	  miCXCR4	  miRNA	  binding	  sites	  in	  the	  3’	  UTR	  or	  a	  control	  Fluc	  gene.	  Relative	  Rluc:Fluc	  expression	  from	  the	  reporters	  was	  assessed	   in	   control	   or	   DDX6-­‐depleted	   cells	   that	   were	   co-­‐transfected	   with	   the	  indicated	  amounts	  of	  miCXCR4.	  Data	   in	  A	  represents	  the	  average	  of	  6	  experiments	  and	  B	  represents	  the	  average	  of	  4	  experiments.	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on	  HCV	  replication,	  and	  miR-­‐122	  association	  with	  the	  HCV	  genome	  is	  not	  required	  for	  the	  effects	  of	  DDX6	  on	  HCV	  translation	  and	  replication.	  Our	  data	  support	  those	  of	  Jangra	  et	  al,	  who	  reported	  that	  DDX6	  was	  not	  required	  for	  miR-­‐122	  augmentation	  of	  HCV	   replication	   (259),	   and	   we	   further	   confirm	   that	   DDX6	   is	   also	   dispensable	   for	  miR-­‐122	  stimulation	  of	  HCV	  translation.	  In	  addition,	  we	  confirm	  that	  miR-­‐122	  is	  not	  required	  for	  DDX6	  to	   influence	  HCV	  replication	  by	  showing	  that	  DDX6	  knockdown	  still	  attenuates	  HCV	  replication	  in	  our	  miR-­‐122-­‐independent	  HCV	  replication	  assays.	  However,	   because	   there	   is	   a	   general	   trend	   showing	   that	  DDX6	  knockdown	  affects	  miR-­‐122-­‐dependent	   replication	   slightly	   more	   strongly	   than	  miR-­‐122-­‐independent	  replication,	   and	   at	   one	   time	   point	   the	   difference	   was	   statistically	   significant	   (Fig.	  3.7C,	  1	  day),	  we	  cannot	  exclude	  the	  possibility	  that	  a	  second	  function,	  requiring	  both	  miR-­‐122	  and	  DDX6,	  has	  a	  minor	  role	  in	  supporting	  HCV	  replication.	  	  Our	  studies	  support	   the	   findings	  of	  Scheller	  et	  al.,	   that	  DDX6	  regulates	  HCV	  translation	   (141),	   however,	   in	   experiments	   performed	   in	   a	   different	   passage	   of	  Huh7.5	   cells,	  DDX6	   silencing	  had	  no	   effect	   on	  HCV	   translation,	   and	  our	  data	  were	  similar	   to	   those	   reported	   by	   Jangra	   et	   al.	   (259).	   We	   cannot	   explain	   why	   HCV	  translation	   in	   different	   passages	   of	   Huh7.5	   cells	   has	   different	   requirements	   for	  DDX6,	  but	  variation	  in	  the	  phenotype	  and	  the	  efficiency	  by	  which	  Huh7-­‐derived	  cells	  support	   HCV	   replication	   during	   Huh7.5	   cell	   passage	   has	   been	   well	   documented	  (265,	   266).	   Regardless	   of	  whether	  DDX6	   knockdown	  does	   or	   does	   not	   affect	  HCV	  translation,	   in	   both	   cases	   miR-­‐122	   was	   equally	   capable	   of	   stimulating	   HCV	  translation	   in	  control	  and	  DDX6	  depleted	  cells,	  and	  thus	  all	  of	  our	  translation	  data	  supports	   the	   conclusion	   that	  DDX6	   is	  dispensable	   for	  miR-­‐122	  stimulation	  of	  HCV	  translation.	  	  In	   addition,	  our	  data	  does	  not	   indicate	   that	  DDX6	  plays	  a	  major	   role	   in	   the	  mechanism	   of	   miRNA	   suppression,	   which	   was	   previously	   observed	   in	   HeLa	   cells	  (153).	  DDX6	  knockdown	  resulted	  in	  a	  statistically	  significant	  attenuation	  of	  miRNA	  gene	  silencing	  activity;	  however,	  the	  physiological	  significance	  of	  a	  role	  for	  DDX6	  in	  miRNA	   suppression	   activity	   in	   Huh7.5	   cells	   is	   questionable	   since	   DDX6	   only	  attenuated	   suppression	   by	   a	   small	   amount.	   Nonetheless,	   we	   cannot	   rule	   out	   the	  possibility	  that	  other	  proteins	  present	   in	  Huh7.5	  cells	  have	  redundant	   functions	   in	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mediating	   miRNA	   suppression,	   which	   may	   explain	   the	   discrepancy	   between	   our	  results	  and	  those	  reported	  in	  HeLa	  cells.	  	  The	   mechanisms	   of	   action	   of	   DDX6	   and	   miR-­‐122	   in	   supporting	   HCV	  replication	   remain	  unclear.	  miR-­‐122	   is	  believed	   to	  modulate	   the	  efficiency	  of	  HCV	  RNA	  accumulation	  by	  stabilizing	  genomic	  RNA	  (106,	  113).	  This	  is	  likely	  mediated	  by	  miR-­‐122	  masking	  and	  thus	  protecting	  the	  uncapped	  5’	  end	  of	  the	  viral	  genome	  from	  degradation	  by	  Xrn1,	   another	  p-­‐body	  protein,	  but	  a	  direct	   role	   for	  miR-­‐122	   in	   the	  process	   of	   HCV	   replication	   has	   also	   been	   suggested	   (106,	   113).	   In	   addition,	   the	  influence	  of	  Xrn1	  knockdown	  on	  HCV	  replication	   is	  variable.	   In	  some	  cases,	   siRNA	  knockdown	   of	   Xrn1	   has	   been	   reported	   to	   increase	   HCV	   replication	   (113)	   and	   in	  other	  cases	   it	  was	  reported	   to	  have	  no	  effect	  or	   to	  decrease	  HCV	  replication	  (139,	  141,	  258).	  These	  data	  suggest	  that	  perhaps	  p-­‐body	  proteins	  have	  multiple	  functions	  in	  up-­‐regulating	  and	  down-­‐regulating	  HCV	  replication.	  	  	  HCV	   infections	   alter	   p-­‐body	   structure	   and	   recruit	   p-­‐body	   proteins	   such	   as	  DDX6,	  Lsm-­‐1,	  Pat-­‐1,	  Xrn1,	   and	  Ago2,	   to	   lipid	  droplets	  and	  sites	  of	  HCV	  replication	  (139,	   159,	   257,	   258).	   Gene	   knockdown	   studies	   indicate	   roles	   for	   several	   of	   these	  proteins	   in	   supporting	  HCV	  RNA	   accumulation	   and	   recent	   evidence	   indicates	   that	  re-­‐localization	  of	  p-­‐body	  proteins	  during	  virus	  infections	  is	  not	  unique	  to	  HCV.	  The	  yeast	  DDX6	  homolog,	  Dhh1	  is	  required	  to	  recruit	  Brome	  mosaic	  virus	  genomic	  RNA	  to	  sites	  of	  replication	   in	  a	  yeast	  model	  replication	  system	  (267).	   In	  addition,	  other	  members	   of	   the	   Flaviviridae	   family	   including	   Dengue	   and	   West	   Nile	   virus	   also	  disrupt	   p-­‐body	   structure	   and	   recruit	   p-­‐body	   proteins	   to	   replication	   sites,	   to	  positively	   regulate	   virus	   replication	   (158,	   159).	   Thus,	   DDX6	   and	   other	   p-­‐body	  proteins	  may	  have	   a	   common	   role	   in	   supporting	   virus	   life	   cycles	   (158,	   159).	   That	  other	  Flaviviruses	  utilize	  DDX6	  to	  support	  their	  life	  cycles,	  but	  are	  not	  modulated	  by	  miR-­‐122	  (or	  by	  other	  miRNAs	  that	  we	  know	  of),	  also	  supports	   the	  notion	   that	   the	  role	   of	   DDX6	   (and	   perhaps	   other	   p-­‐body	   proteins)	   is	   not	   linked	   to	   the	   activity	   of	  miR-­‐122.	   However,	   we	   cannot	   omit	   the	   possibility	   that	   re-­‐localization	   of	   p-­‐body	  proteins	  may	  support	  Flavivirus	  replication	  by	  using	  mechanisms	  that	  overlap	  those	  of	  miR-­‐122.	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Biochemical	   characterization	  of	  DDX6	  reveals	  a	  possible	   function	   in	   the	   life	  cycle	  of	  viruses.	  DDX6	  binds	  to	  mRNA	  without	  sequence	  specificity,	  and	  relaxes	  its	  secondary	   structure	   (184).	   This	   activity	   requires	   ATP	   binding	   but	   not	   ATP	  hydrolysis	  in	  a	  way	  resembling	  RNA	  chaperones	  that	  stabilize	  RNA	  (184).	  In	  a	  model	  proposed	   by	   Ernoult-­‐Lange	   et	   al.,	   DDX6	   binds	   to	   an	   mRNA,	   first	   as	   part	   of	   a	  translation	   repression	   complex,	   and	   then	   as	   individual	   proteins	   that	   coat	  translation-­‐stalled	  mRNA,	  and	  unfolds	  it	  in	  preparation	  for	  degradation	  in	  p-­‐bodies	  (184).	  DDX6	  association	  with	  Dengue	  virus	  stem-­‐loops,	  the	  DB1	  and	  DB2	  structures,	  in	   the	   3’	   UTR,	   is	   required	   for	   efficient	   virus	   replication	   (158).	  We	   speculate	   that	  DDX6	  could	  associate	  with	  and	  unfold	  virus	  genomes	  in	  preparation	  for	  initiation	  of	  genome	   replication,	   however	   thus	   far	   DDX6	   has	   only	   been	   reported	   to	   associate	  with	  HCV	  genomes	  through	  association	  with	  the	  HCV	  core	  protein.	  	  DDX6	  has	  also	  been	  implicated	  in	  the	  efficiency	  of	  HCV	  virion	  release	  and	  in	  the	   assembly	   of	   HIV	   virions	   (139,	   200).	   The	   possible	   role	   of	   DDX6	   in	   HCV	   virion	  assembly	   must	   be	   separate	   from	   its	   activity	   in	   promoting	   replication	   since	   its	  knockdown	   attenuates	   replication	   of	   sub-­‐genomic	   HCV	   replicons,	   which	   do	   not	  express	   core	   nor	   assemble	   particles.	   However,	   the	   association	   of	   DDX6	  with	   HCV	  core	  protein,	   and	  with	   lipid	   droplets,	   could	  perhaps	   suggest	   a	   role	   in	   remodelling	  viral	  genome	  in	  preparation	  for	  virion	  assembly.	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4.0 CONCURRENT	   ADVANCES	   IN	   UNDERSTANDING	   THE	   RELATIONSHIP	  
BETWEEN	  DDX6,	  P-­‐BODIES,	  miR-­‐122	  AND	  HCV	  	  At	   the	   time	  our	   research	  was	  being	  conducted,	   there	  were	  numerous	  other	  research	   groups	   evaluating	   the	   relationship	   between	   HCV,	   p-­‐body	   structures,	  proteins	  associated	  with	  p-­‐bodies,	  and	  the	  miRNA	  suppression	  pathway.	  	  Many,	  but	  not	  all	  of	  the	  findings	  of	  the	  other	  groups	  supported	  our	  on-­‐going	  observations,	  and	  a	  common	  model	  for	  the	  roles	  of	  p-­‐bodies	  in	  the	  HCV	  life	  cycle	  emerged.	  	  
	  
 DDX6	  supports	  HCV	  replication	  but	  not	  through	  miR-­‐122	  4.1 	  Concurrent	  with	  our	  work,	  five	  papers	  where	  published	  that	  reported	  DDX6	  knockdown	   decreases	   HCV	   replication	   (139,	   141,	   257-­‐259).	   All	   of	   these	   reports	  confirmed	   that	   DDX6	   silencing	   led	   to	   a	   decrease	   in	   HCV	   RNA	   accumulation	   (139,	  141,	   257-­‐259).	   	  We	   also	   confirmed	   by	   using	   several	   different	  methods	   that	  DDX6	  augments	   HCV	   replication	   in	   a	   manner	   that	   is	   independent	   from	   miR-­‐122	   and	  support	  the	  findings	  of	  Jangra	  et	  al.	  (259).	  	  Thus,	  we	  conclude	  that	  DDX6	  is	  not	  part	  of	   the	   pathway	   in	   which	   miR-­‐122	   affects	   HCV	   replication,	   and	   that	   p-­‐bodies	   and	  possibly	  p-­‐body	  proteins	  have	  an	  effect	  on	  HCV	  that	  is	  independent	  from	  miR-­‐122.	  	  One	   possibility	   is	   that	   DDX6	   supports	   HCV	   translation.	   We	   show	   data	  indicating	   that	   DDX6	   knockdown	   reduced	   HCV	   translation	   and	   supported	   the	  findings	  of	  Sheller	  et	  al.	   that	  DDX6	  supports	  HCV	  translation	  (141).	   	  These	   finding	  contradicted	  those	  of	   Jangra	  et	  al.	  who	  did	  not	  observe	  an	  impact	  of	  DDX6	  on	  HCV	  translation	  (259).	  	  However	  when	  we	  initially	  conducted	  these	  experiments	  several	  months	   earlier	  we	   found,	   similarly	   to	   Jangra	   et	  al.	   that	   DDX6	   knockdown	   did	   not	  affect	  HCV	   translation.	   	   	   In	   both	   cases,	   our	   experiments	  were	  well	   controlled	   and	  repeated	  many	  times.	  Thus,	  we	  concluded	  that	  the	  difference	  we	  observed	  between	  current	   experiments	   and	  past	  was	   the	   state	   of	   the	   cells	   given	   their	   passage.	   	   This	  conclusion	  might	  also	  explain	  the	  contradictory	  results	  in	  the	  literature	  on	  the	  role	  of	  DDX6	  on	  HCV	  translation.	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Lastly,	   our	   data	   showed	   that	   DDX6	   silencing	   had	   no	   effect	   on	  miRNA	   gene	  suppression	  and	  did	  not	  support	  the	  conclusions	  made	  by	  Chu	  et	  al.	  who	  found	  that	  DDX6	   was	   required	   for	   miRNA	   mediated	   gene	   suppression	   (153).	   	   The	   sole	  difference	  between	  our	  experiments	  and	  Chu	  et	  al.,	  was	  the	  cell	  types	  used	  (HeLa	  vs.	  Huh7.5),	  which	  suggest	  DDX6	  may	  behave	  differently	  in	  different	  cells	  or	  there	  is	  a	  pathway	   in	   Huh7.5	   which	   renderers	   DDX6	   redundant	   in	   its	   ability	   to	   enhance	  miRNA	  suppression.	  	  
 Several	  p-­‐body	  proteins,	   including	  DDX6	  support	   the	  HCV	  life	  cycle,	  but	  4.2
physical	  p-­‐body	  structures	  do	  not	  	  The	   identification	   that	  DDX6	  promotes	  HCV	  replication	  and	   translation,	  but	  not	  through	  facilitating	  miR-­‐122,	  suggests	  that	  p-­‐body	  proteins	  have	  other	  roles	  in	  the	   HCV	   life	   cycle.	   	   As	   stated	   in	   the	   literature	   review	   and	   as	   a	   rationale	   for	   my	  original	  hypothesis,	  DDX6	  is	  required	  for	  p-­‐body	  formation;	  therefore	  it	  is	  possible	  that	  the	  p-­‐body	  structures	  are	  required	  for	  HCV	  replication	  and	  translation.	   	  While	  our	  work	  regarding	  DDX6,	  miR-­‐122	  and	  HCV	  was	  being	  conducted,	  Pérez-­‐Vilaró	  et	  
al.	   demonstrated	   that	   the	   physical	   p-­‐body	   structures	   were	   not	   required	   for	   HCV	  replication	  (257).	  	  This	  conclusion	  was	  made	  since	  silencing	  Rap55,	  a	  gene	  required	  for	   p-­‐body	   assembly,	   abolished	   p-­‐bodies	   but	   had	   no	   affect	   on	   HCV	   replication.	  	  Similarly	  Ariumi	  et	  al.,	  and	  Pager	  et	  al.	  noted	  that	  over	  the	  course	  of	  HCV	  infection,	  the	  presence	  of	  p-­‐bodies	  decreased	  (258)	  and	  that	  as	  p-­‐bodies	  disappeared,	  many	  of	  the	   resident	   p-­‐body	  proteins	   including	  DDX6	  were	   recruited	   to	   lipid	   droplets	   and	  co-­‐localized	   with	   core.	   	   The	   co-­‐localization	   of	   DDX6	   and	   other	   p-­‐body	   associated	  proteins	  with	  the	  core	  and	  lipid	  droplets	  suggests	  that	  they	  may	  directly	  participate	  in	  many	   aspects	   of	  HCV	   life	   cycle	   such	   as:	   the	   formation	  of	   a	   replication	   complex,	  genome	  amplification,	  RNA	  segregation	  and/or	  virion	  assembly.	   	  However,	  a	  direct	  role	  for	  DDX6	  and	  p-­‐body	  proteins	  in	  HCV	  life	  cycle	  has	  not	  yet	  been	  demonstrated.	  The	  evidence	  that	  p-­‐bodies	  are	  not	  required	  for	  HCV	  replication	  suggests	  that	  DDX6	   is	   directly	   involved	   in	   HCV	   replication	   or	   indirectly	   affects	   HCV	   through	   a	  mechanism	  distinct	  from	  p-­‐bodies	  and	  miRNA	  mediated	  gene	  suppression.	  	  Jangra	  el	  
	  80	  
al.	   found	   that	  DDX6	   interacted	  with	  HCV	  RNA	   and	  HCV	   core	   protein	   suggesting	   a	  direct	  role	  for	  DDX6	  in	  the	  HCV	  life	  cycle.	  	  In	  addition,	  DDX6	  may	  interact	  with	  HCV	  RNA	  through	  core	  binding	  since	  DDX6	  co-­‐immunoprecipitated	  with	  full-­‐length	  HCV	  RNA,	   but	   did	   not	   co-­‐immunoprecipiate	   in	   cells	   infected	   with	   a	   sub-­‐genomic	   HCV	  replicon,	  which	  do	  not	  produce	  core.	  However,	   this	   interaction	  does	  not	  appear	   to	  be	  important	  for	  the	  influence	  of	  DDX6	  on	  HCV	  RNA	  amplification	  since	  replication	  of	  HCV	  sub-­‐genomic	  RNA	  is	  also	  impeded	  in	  DDX6	  silenced	  cells.	  	  Through	  the	  use	  of	  DDX6	   mutants,	   Jangra	   et	   al.	   also	   demonstrated	   that	   DDX6	   helicase	   domain	   was	  required	  for	  HCV	  replication	  but	  not	  its	  interaction	  with	  core	  (259).	  	  The	  role	  DDX6	  helicase	   activity	   plays	   in	   HCV	   replication	   is	   unknown,	   but	   since	   Jangra	   et	   al.	  reported,	   that	  DDX6	  does	  not	  bind	  HCV	  without	  core,	  DDX6	  helicase	  activity	  must	  affect	  HCV	  replication	  and	   translation	   indirectly.	   	  This	  could	  be	  by	  assisting	   in	   the	  folding	   or	   translation	   of	   a	   protein	   required	   to	   directly	   interact	   with	   HCV.	   	   The	  observation	   that	   DDX6	   interacts	  with	  HCV	   in	   conjunction	  with	   core	   suggests	   that	  DDX6	  may	  directly	  assist	  in	  HCV	  assembly.	  	  	  
 Future	  directions	  for	  the	  field	  of	  HCV,	  p-­‐bodies	  and	  miR-­‐122	  4.3 	  	  We	  originally	  hypothesized	  that	  DDX6	  would	  affect	  miR-­‐122	  augmentation	  of	  HCV	  based	  on	   evidence	   in	   the	   literature	   that	  DDX6	  was	   required	   for	  miRNA	  gene	  suppression	   activity.	  However,	  we	   found	   no	   relationship	   between	  miR-­‐122,	  DDX6	  and	   HCV,	   and	   found	   that	   DDX6	   did	   not	   affect	   miRNA	   suppression	   activity	   in	   our	  hands.	  Thus,	  it	  seemed	  clear	  that	  the	  role	  of	  DDX6	  is	  a	  in	  a	  different	  cellular	  function	  and	  not	  miRNA	  suppression.	  Since	  the	  focus	  of	  our	  laboratory	  is	  miRNAs	  and	  not	  p-­‐bodies	   we	   focused	   our	   subsequent	   research	   into	   better	   understanding	   the	  relationship	  between	  miR-­‐122	  and	  HCV.	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 Abstract	  5.2 	  Hepatitis	   C	   virus	   (HCV)	   has	   a	   unique	   relationship	   and	   dependency	   on	   the	  liver	  specific	  miRNA,	  miR-­‐122.	  	  Robust	  virus	  replication	  requires	  miR-­‐122	  to	  bind	  to	  two	  tandem-­‐binding	  sites	   located	  within	   its	  5’	  untranslated	  region	  (UTR),	  which	   is	  highly	   conserved	   among	  HCV	   genotypes.	   	   The	   activity	   of	  miR-­‐122	  on	   the	  HCV	   life	  cycle	   also	   requires	   incorporation	   of	   the	   miRNA	   into	   the	   host	   protein	   Ago2	   and	  binding	  of	  this	  complex	  to	  the	  viral	  genome.	  In	  this	  study,	  we	  demonstrate	  that	  the	  conserved	  nature	  of	  the	  miR-­‐122	  binding	  region,	  and	  the	  accessibility	  of	  this	  region	  to	   Ago2/miR-­‐122	   complexes	  make	   it	   susceptible	   to	   siRNA	   targeted	   cleavage.	   Our	  data	  indicates	  that	  both	  sub-­‐genomic	  and	  full-­‐length	  HCV	  RNA	  replication	  in	  Huh7.5	  cells	  is	  potently	  impeded	  by	  the	  presence	  of	  siRNAs	  that	  target	  the	  miR-­‐122	  binding	  region	  and	  we	  propose	  this	  as	  a	  novel	  HCV	  therapeutic	  strategy.	   	   Interestingly,	  the	  siRNAs	  designed	  to	  target	  the	  miR-­‐122	  binding	  region	  maintain	  their	  potency	  after	  several	   rounds	   of	   treatment,	   even	   though	   the	   presence	   of	   mutations	   within	   the	  5’UTR	  are	  detectable	  by	  sequence	  analysis.	  	  Incorporation	  of	  point	  mutations	  within	  the	  miR-­‐122	  binding	  sites	  suggests	  that	  HCV	  may	  be	  able	  to	  grow	  in	  the	  absence	  of	  miR-­‐122	  binding	  but	  we	  speculate	  that	  the	  mutant	  viruses	  will	  have	  reduced	  fitness.	  	  One	  virus	  mutant,	  containing	  a	  point	  mutation	  in	  the	  first	  miR-­‐122	  binding	  site,	  was	  tested	  for	  growth	  and	  resistance	  to	  the	  miR-­‐122	  targeting	  siRNAs.	  The	  mutant	  virus	  replicated	   less	   efficiently	   than	   WT	   virus,	   but	   interestingly	   some	   of	   the	   siRNA	  targeting	  the	  miR-­‐122	  binding	  region	  remained	  equally	  functional	  at	  inhibiting	  HCV	  replication,	   even	   though	   the	   siRNA	   sequence	   did	   not	   match	   the	   virus	   genomic	  sequence	  perfectly.	  	  This	  suggests	  that	  the	  siRNAs	  may	  have	  a	  second	  mechanism	  to	  inhibit	  HCV	  replication	  besides	  classical	  siRNA	  target	  cleavage,	  which	  may	   impede	  miR-­‐122	  binding.	   	  The	  possibility	  that	  siRNA	  targeting	  the	  miR-­‐122	  binding	  region	  have	   dual	   inhibitory	   functions	   supports	   further	   study	   and	   their	   use	   as	   a	   HCV	  therapy.	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 Introduction	  5.3
	  Hepatitis	   C	   virus	   (HCV)	   is	   a	   9.6kb	   genome,	   positive	   sense	   RNA	   virus	   that	  uniquely	   relies	   on	   the	   liver	   specific	  miRNA,	  miR-­‐122,	   for	   robust	   replication.	   	   The	  classical	  mechanism	  of	  action	  of	  miRNA	  conveys	  that	  miRNA	  bind	  to	  the	  3’	  end	  of	  an	  mRNA	  transcript	  and	  suppresses	  translation.	  However	   in	  the	  context	  of	  HCV,	  miR-­‐122	   binds	   to	   the	   5’	   end	   of	   the	   viral	   genome	   and	   promotes	   viral	   replication	   and	  translation	  (105,	  110,	  268).	  	  	  The	  5’	  untranslated	  region	  (UTR)	  of	  HCV	  encodes	  two	  miR-­‐122	   binding	   sites	   that	   are	   separated	   by	   eight	   or	   nine	   nucleotides,	   and	   these	  sites	   are	   highly	   conserved	   amongst	   HCV	   genotypes	   (104).	   	   	   Mutations	  within	   the	  miR-­‐122	   binding	   sites	   greatly	   inhibit	   HCV	   replication	   and	   translation,	   but	   robust	  replication	   can	   be	   re-­‐established	   with	   addition	   of	   synthetic	   miR-­‐122	   containing	  compensatory	   mutations,	   demonstrating	   miR-­‐122	   binds	   directly	   to	   HCV	   genome	  (104,	  105).	  	  The	  mechanism	  by	  which	  miR-­‐122	  enhances	  HCV	  replication	  and	  translation	  is	   not	   fully	   understood.	   	   The	  miR-­‐122-­‐HCV	   interaction	   requires	   the	   RNA	   induced	  silencing	  complex	  (RISC)	  associated	  protein,	  Argonaute	  2	  (Ago2)	  (111,	  114)	  and	  its	  direct	   binding	   leads	   to	   the	   stabilization	   of	   the	   genome,	   in	   part	   by	   protecting	  HCV	  from	   host	   5’	   exonuclease	   degradation	   by	   Xrn1	   (107,	   113).	   However,	   since	  knockdown	  of	  Xrn1	  does	  not	   reinstate	   replication	  of	  HCV	  genomes	   to	  which	  miR-­‐122	  binding	  has	  been	  abolished,	  then	  protection	  from	  Xrn1	  does	  not	  account	  for	  the	  observed	   augmentation	   of	   HCV	   replication	   attributed	   to	  miR-­‐122	   (110).	   	   Another	  possible	   way	   that	   miR-­‐122	   promotes	   HCV	   replication	   is	   by	   modulating	   the	  secondary	   structure	   of	   the	   HCV	   RNA	   genome.	   Some	   in-­‐vitro	   experiments	   provide	  evidence	  that	  miR-­‐122	  binding	  modifies	  RNA	  structures	  in	  and	  near	  the	  5’UTR	  (115,	  118,	  120).	   	  However,	  the	  role	  for	  a	  conformational	  change	  has	  not	  been	  confirmed	  during	  virus	  replication,	  and	   in	  one	  case	   (118)	   their	   role	   is	  questioned	  by	   the	   fact	  that	   the	  HCV	  sequences	   involved	  are	  absent	   from	  HCV	  sub-­‐genomic	  replicons	   that	  still	   respond	   to	   miR-­‐122.	   In	   spite	   of	   its	   unknown	   mechanism	   of	   action,	   miR-­‐122	  augmentation	   of	  HCV	   replication	   and	   the	   existence	   of	   conserved	  miR-­‐122	  binding	  sites	  are	  a	  promising	  target	  for	  antiviral	  development.	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HCV	   inhibition	  by	  using	  miR-­‐122	  antagonists	   that	  bind	  and	   sequester	  miR-­‐122	   effectively	   inhibit	   HCV	   in	   cell	   culture,	   in	   Chimpanzees,	   and	   have	   provided	  encouraging	   results	   in	   human	   clinical	   trials	   (103,	   243).	   	   In	  HCV	   infected	   humans,	  miR-­‐122	   antagonist	   treatment	   decreased	   HCV	   viral	   loads	   at	   all	   doses,	   and	   at	   the	  highest	  dose	  used,	  reduced	  HCV	  titers	  to	  undetectable	  levels.	  HCV	  titres	  rebounded	  following	   treatment	   cessation	   and	   longer	   treatment	   durations	   are	   currently	   being	  tested.	   	  The	  only	  side	  effect	  of	  the	  treatment	  was	  an	  anticipated	  decrease	  in	  serum	  cholesterol	  levels	  (103).	  	  Due	  to	  a	  possible	  role	  for	  miR-­‐122	  as	  a	  tumour	  suppressor,	  longer	   trials	   must	   be	   done	   with	   caution,	   and	   long-­‐term	   treatment	   with	   miR-­‐122	  antagonists	   is	   not	   advisable.	   Importantly,	   miR-­‐122	   antagonist	   treatment	   did	   not	  select	  for	  HCV	  genomes	  having	  point	  mutations	  to	  the	  miR-­‐122	  binding	  sites	  thus,	  it	  appears	  to	  not	  select	  for	  viruses	  that	  have	  escaped	  reliance	  on	  miR-­‐122.	  	  Therefore,	  miR-­‐122	  antagonism	  may	  be	  a	  treatment	  with	  a	  high	  barrier	  to	  the	  development	  of	  resistance.	  	  Given	  the	  dependence	  of	  HCV	  on	  miR-­‐122,	  the	  early	  reported	  success	  of	  miR-­‐122	  antagonist	  as	  a	   treatment,	   the	  knowledge	   that	  Ago2	   loaded	  with	  miR-­‐122	  can	  access	   the	   5’UTR,	   and	   the	   conserved	   nature	   of	   the	   miR-­‐122	   binding	   region,	   we	  speculated	  that	   the	  miR-­‐122	  binding	  region	  within	   the	  5’UTR	  of	  HCV	  constitutes	  a	  potential	  target	  for	  siRNA	  directed	  cleavage.	   	  This	  speculation	  is	  further	  supported	  by	  the	  pharmacokentic	  study	  by	  Laxton	  et	  al.	  suggesting	  that	  HCV	  can	  be	  inhibited	  by	   using	   antisense	   oligonucleotides	   targeting	   the	   5’	   terminus	   of	   the	  HCV	   genome,	  including	   the	   miR-­‐122	   binding	   region	   (269).	   Previous	   attempts	   to	   use	   siRNA	  directed	  cleavage	  at	  conserved	  regions	  of	  the	  HCV	  genome	  displayed	  a	  high	  level	  of	  success	  (244-­‐246),	  but	  over	  the	  course	  of	  several	  treatments	  their	  potency	  began	  to	  decrease.	  siRNA	  targeted	  cleavage	  of	  target	  RNAs	  requires	  perfect	  sequence	  match	  between	   the	  siRNA	  and	   the	   target.	  The	  decrease	   in	  effectiveness	  of	  HCV	   inhibiting	  siRNA	   was	   attributed	   to	   the	   evolution	   of	   escape	   mutations	   having	   nucleotide	  mutations	  within	  the	  siRNA	  target	  sequences	  that	  conferred	  resistance	  to	  inhibition	  (247,	  248).	   	  This	  illustrates	  the	  importance	  of	  targeting	  conserved	  and	  functionally	  important	  sequences	  to	  limit	  the	  possibility	  of	  evolution	  of	  resistance	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In	   this	   study,	  we	  provide	  evidence	   that	   siRNAs	  designed	   to	   target	   the	  miR-­‐122	  binding	  region	  can	  inhibit	  HCV	  replication	  in	  cell	  culture.	  We	  hypothesized	  that	  it	  would	  be	  difficult	  for	  HCV	  to	  escape	  miR-­‐122	  binding-­‐site	  targeting	  siRNA	  due	  to	  the	   conserved	   nature	   and	   essential	   function	   of	   this	   region	   and	   as	   expected	   the	  siRNAs	   continued	   to	   be	   effective	   after	   several	   rounds	   of	   treatment.	   However,	  sequence	   analysis	   did	   detect	   escape	   mutants	   but	   we	   show	   that	   a	   mutant	   virus,	  containing	  a	  point	  mutation	  in	  first	  miR-­‐122	  binding	  site	  does	  not	  abolish	  inhibitory	  activity	  of	  some	  of	  the	  siRNAs.	  	  	  
 Material	  and	  methods	  5.4
	  
5.4.1 Plasmids	  	  	  	  The	  JFH-­‐1	  FLuc	  sub-­‐genomic	  replicon	  plasmid	  (pSGR	  JFH-­‐1	  Fluc)	  was	  kindly	  provided	   by	   Dr.	   T.	   Wakita	   (262).	   	   The	   plasmid	   pJ6/JFH-­‐1	   RLuc	   (p7-­‐RLuc2A)	  encoding	   a	   full-­‐length	   HCV	   genome	   expressing	   a	   Renilla	   luciferase	   (Rluc)	   gene	  directly	   downstream	   of	   the	   p7	   gene,	   (263),	   and	   pFLneo-­‐J6/JFH-­‐1(p7-­‐Rluc2a)	  encoding	  a	  full-­‐length	  bicistronic	  HCV	  replicon	  RNA	  expressing	  neomycin	  from	  the	  HCV	  IRES	  and	  Rluc	  within	  the	  full-­‐length	  HCV	  polyprotein,	  directly	  downstream	  of	  the	   p7	   gene,	   were	   provided	   by	   Dr.	   C.	   M.	   Rice	   (herein	   called	   pJ6/JFH-­‐1	   RLuc	   and	  pJ6/JFH-­‐1	   Neo	   Rluc	   respectively).	   	   The	   miR-­‐122	   site	   1	   position	   3	   mutant	   sub-­‐genomic	   replicon	   (pSGR	   JFH-­‐1	  Fluc	   S1:P3)	  was	   generated	   as	   described	  previously	  (116),	  and	  pJ6/JFH-­‐1	  site	  1	  position	  3	  plasmid	  (J6/JFH-­‐1	  RLuc	  S1:P3)	  was	  generated	  by	  digesting	  SGR	  S1:P3	  with	  AgeI	  and	  EcoRI	  to	  isolate	  the	  5’UTR	  and	  then	  inserting	  into	  a	  partially	  digested	  J6/JFH-­‐1	  Rluc	  plasmid.	   	  The	  sub-­‐genomic	  replicon	  plasmid	  having	   both	   neo	   and	   luciferase	   genes,	   pFK	   I389	   lucubineo	   NS	   3-­‐3’	   JFH-­‐1	   (herein	  called	  SGR	  lucubineo	  JFH-­‐1	  Fluc)	  was	  kindly	  provided	  by	  Dr.	  V.	  Lohmann.	  	  pLuc	  	  JFH-­‐1	   5’UTR	   x	   2,	   a	  miR-­‐122	   suppression	   activity	   reporter	   plasmid	   having	   two	  HCV	   5’	  UTR	   sequences	   inserted	   downstream	  of	   a	   luciferase	   gene,	  was	   created	   by	  making	  two	  point	  mutations	  in	  pLuc-­‐122x2,	  a	  gift	  from	  Dr,	  P.	  Sarnow	  (104).	   	  Briefly,	  pLuc-­‐122x2	  was	  designed	  by	  cloning	  two	  5’UTR	  of	  an	  HCV	  H77	  construct	  behind	  a	  firefly	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luciferase.	   	  The	  sequence	  of	  the	  H77	  genotype	  inserts	  were	  modified	  to	  that	  of	  the	  JFH-­‐1	   genotype	   by	   using	   quick	   change	   mutagenesis	   and	   the	   primers,	   5’	  GCGACACTCCGCCATGAATCA	  and	  5’	  TGATTCATGGCGGAGTGTGTCGC	  to	  generate	  the	  plasmid	  pLuc	   JFH-­‐1	  5’UTR	  1st.	   	  The	  A	   to	  G	  swap	  required	   for	   the	  second	  UTR	  was	  achieved	  by	  digesting	  pLuc122	  x	  2	  with	  EcoR1	  and	  SalI	   to	   isolate	   the	  second	  UTR.	  Following	   ligation	   into	   BluescriptKS(+)	   and	   mutagenesis	   using	   the	   methods	  described	   above,	   the	   mutated	   second	   UTR,	   now	   having	   the	   JFH-­‐1	   sequence,	   was	  cloned	   into	   plasmid	   pJFH-­‐1	   5’UTR	   1st,	   generating	   plasmid	   pLuc	   JFH-­‐1	   5’UTR	   x	   2.	  	  Plasmid	  pT7	  and	  pRL-­‐TK	  plasmids	  were	  obtained	  from	  Promega	  Co.	  (Madison,	  WI,	  USA)	  
	  
5.4.2 Cell	  culture	  	  	  	  The	   human	   hepatoma	   cell	   lines	   Huh7.5,	   and	   Hep3B	   were	   cultured	   in	  Dulbecco’s	  Modified	   Eagle	  Medium	   (DMEM)	   supplemented	  with	   10%	   fetal	   bovine	  serum,	  0.1nM	  non-­‐essential	  amino	  acids	  (Wisent,	  Montreal,	  Canada)	  and	  100μg/ml	  Pen/Strep	  (Invitrogen,	  Burlingtion	  ON,	  Canada).	  Lunet-­‐Lucubineo	  JFH-­‐1	  cells	  (270),	  provided	   by	   Dr.	   V.	   Lohmann,	   were	   grown	   as	   described	   above	   in	   the	   presence	   of	  800μg/ml	  G418	   Sulfate	   (Wisent,	  Montreal,	   Canada)	   to	  maintain	   the	  HCV	   replicon.	  	  Huh7.5	  cells	  harbouring	  J6/JFH-­‐1	  Neo	  Rluc	  were	  provided	  by	  Dr.	  Liu	  Qiang	  	  (VIDO-­‐InterVac,	  Saskatoon,	  Saskatchewan,	  Canada)	  and	  were	  cultured	  identically	  to	  Lunet-­‐Lucubineo	   JFH-­‐1	   cells.	   	   For	   generating,	  maintaining	   and	   selecting	   cells	   containing	  HCV	  replicons,	  800μg/ml	  G418	  Sulfate	  was	  added	  to	  supplemented	  DMEM.	  	  
5.4.3 Small	  interfering	  RNAs	  (siRNA)	  design	  and	  sequence	  
	  The	  siRNAs	  designed	  which	  target	  the	  miR-­‐122	  binding	  regions	  of	  HCV	  were	  constructed	  using	  various	  software	  available	  on-­‐line	  and	  the	  target	  sequence	  were	  as	   follows:	   siRNA18-­‐36	   GCGACACUCCGCCAUGAAU,	   siRNA19-­‐37	  CGACACUCCGCCAUGAAUC	   and	   siRNA21-­‐43	   ACACUCCGCCAUGAAUCACUCCC.	   	   The	  sequence	   of	   siRNA	   JFH-­‐1	   6367	   was	   adapted	   from	   the	   highly	   effective	   siRNA	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described	  previously	   to	   inhibit	  HCV	   con1	   genotype,	   by	  modifying	   the	   sequence	   to	  match	   the	   same	   region	   in	   JFH-­‐1	   GACCCACAAACACCAAUUCCC	   (246).	   The	   control	  siRNA	  (siControl)	  target	  sequence	  was	  GAGAGUCAGUCAGCUAAUCA	  as	  was	  used	  in	  a	  previous	   study	   (111).	   	   All	   the	   siRNAs	   were	   synthesized	   by	   Thermo-­‐scientific	  (Lafayette,	  CO).	  	  
5.4.4 In-­‐vitro	  RNA	  transcription	  	  HCV	   RNA	   was	   synthesized	   using	   the	   MEGAScript	   T7	   High	   Yield	   in-­‐vitro	  Transcription	   Kit	   (Life	   Technologies,	   Burlington,	   ON,	   Canada).	   	   Firefly	   (Fluc)	   and	  Renilla	   (RLuc)	   messenger	   RNA	   (mRNA)	   where	   transcribed	   using	   a	   mMessage	  mMachine	   T7	   Transcription	   Kit	   (Life	   Technologies,	   Burlington,	   ON,	   Canada).	   	   The	  transcription	   process	  was	   conducted	   using	   the	   suggested	  manufacture’s	   protocol.	  	  In	   a	   process	   described	   previously	   (116),	  XbaI	   linearized	   plasmid	  was	   used	   as	   the	  transcription	   template	   for	  HCV	   constructs	   and	  XmnI	   linearized	  pT7	   luciferase	   and	  
BglII	   linearized	   pRL-­‐TK	   were	   used	   as	   templates	   for	   Fluc	   and	   RLuc	   mRNA	  transcription,	  respectively.	  	  
5.4.5 Non-­‐HCV	  siRNA	  knockdown	  assay	  
	  On	   Day	   0,	   6.5	   x	   104	  Hep3B	   cells/well	   were	   plated	   in	   a	   24	   well	   dish	   and	  incubated	  overnight.	  	  	  The	  following	  day	  Hep3B	  cells	  were	  transfected	  with	  100ng	  of	  pRL-­‐TK	   and	   pLuc	   JFH-­‐1	   5’UTR	   x	   2,	   along	   with	   0.1pmol	   of	   an	   siRNA	   and	   1	   μl	  lipofectamine	   2000	   (Life	   Technologies,	   Burlington,	   ON,	   Canada).	   The	   transfection	  mixture	  was	  prepared	  according	  to	  the	  suggested	  manufacture’s	  protocol.	  The	  cells	  were	  slowly	  rocked	  for	  20	  minutes	  at	  room	  temperature	  before	  being	  incubated	  at	  37°C,	  5%	  CO2.	   	  On	  day	  2,	   the	   cells	  were	   lysed	  using	  passive	   luciferase	   lysis	  buffer	  (Promega).	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5.4.6 Electroporation	  of	  Huh7.5	  cells	  	  	  	  Huh7.5	  cell	  were	  electroporated	  as	  previously	  described	  (116).	  	  	  	  
5.4.7 Transient	  HCV	  replication	  assay	  	  	  	  Briefly,	   Huh7.5	   cells	   were	   co-­‐electroporated	   with	   varying	   amounts	   of	   HCV	  RNA,	   60	   pmol	   of	   siRNA	   and	   1μg	   of	   control	   mRNA.	   	   	   Samples	   were	   plated	   and	  harvested	  for	  luciferase	  expression	  at	  2	  hour,	  and	  days	  1-­‐3.	  	  1μg	  of	  HCV	  was	  used	  in	  assays	  conducted	  with	  J6/JFH-­‐1	  RLuc	  (p7-­‐RLuc2A)	  and	  5μg	  of	  RNA	  was	  used	  in	  all	  the	  other	  replication	  assays.	  	  
5.4.8 Escape	  mutant	  selection	  assay	  	  Huh7.5	  cells	  harbouring	  J6/JFH-­‐1	  Neo	  Rluc	  and	  Lunet-­‐Lucubineo	  JFH-­‐1	  cells	  were	  electroporated	  with	  60pmol	  of	  a	  specific	  siRNA.	  	  After	  electroporation,	  a	  small	  portion	  of	   the	  cells	  was	  plated	   for	  harvest	  and	   luciferase	  assay,	  and	  the	  remaining	  cells	  were	  cultured	   in	  the	  presence	  of	  G418.	   	  After	   two	  weeks,	  ¼	  of	   the	  cells	  were	  harvested	  in	  Trizol,	  ¼	  were	  cryofrozen,	  and	  ½	  were	  electroporated	  with	  60pmol	  of	  the	  same	  siRNA	  used	  in	  the	  previous	  electroporation	  and	  the	  process	  was	  repeated.	  	  The	  cells	  continued	   in	  this	  cycle	  until	   they	  had	  been	  electroporated	  with	  the	  same	  siRNA	  seven	  times.	  	  For	  each	  siRNA,	  three	  independent	  selections	  were	  done	  unless	  otherwise	  noted.	  	  	  
5.4.9 Luciferase	  assay	  	  	  	  Cells	   were	   washed	   two	   times	   in	   Dulbecco’s	   PBS	   then	   lysed	   with	   100μl	   of	  passive	   luciferase	   lysis	  buffer	   (Promega).	   	  Luciferase	   levels	  within	   the	   lysate	  were	  measured	   by	   using	   Firefly,	   Renilla,	   or	   Dual	   luciferase	   kits	   (Promega)	   and	   light	  emission	  was	  measured	   by	   using	   a	   Glomax	   20/20	   Luminometer	   (Promega).	   	   The	  luciferase	  assays	  were	  performed	  as	  suggested	  by	  the	  manufacturer’s	  protocols.	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5.4.10 RNA	  purification	  	  Cells	  were	  harvested	   into	  1ml	  of	  Trizol	   and	   total	   cellular	  RNA	  was	   isolated	  using	  the	  suggested	  manufacturer’s	  protocol.	  	  
5.4.11 Sequencing	  of	  the	  miR-­‐122	  binding	  region	  of	  HCV	  5’UTR	  	  Purified	  RNA	  was	  converted	  to	  cDNA	  using	  iScript	  select	  cDNA	  synthesis	  kit	  (Bio-­‐Rad	   Inc.,	   Missassauga,	   On,	   Canada)	   and	   the	   manufacturer’s	   recommended	  protocol	   with	   the	   addition	   of	   a	   specific	   J6/JFH-­‐1	   Neo	   Rluc	   reverse	   transcription	  primer	   5’TGTTGTGCCCAGTCATAGCCC.	   	   The	   cDNA	   was	   then	   amplified	   using	  Herculase	   II	   Fusion	  DNA	  Polymerase	   (Agilent	   Technologies,	   Santa	   Clara,	   CA,	   USA)	  and	   the	   suggested	   manufacturer’s	   PCR	   protocol.	   	   The	   primers	   used	   for	   the	   PCR	  reactions	   were:	   forward	   primer	   5’GAATTCTAATACGACTCACTATAGACCTGCCCCTA	  ATAGG	  and	  reverse	  primer	  5’GAACCTGCGTGCTGCAATCCATC.	   	  The	  forward	  primer	  was	   designed	   to	   anneal	   directly	   to	   the	   5’	   terminus	   of	   the	   HCV	   genomic	   RNA	   and	  contains	  additional	  sequence	  of	  an	  EcoR1	  site	  and	  a	  T7	  promoter.	  	  The	  PCR	  product	  was	   gel	   purified	   using	   Qiaquick	   Gel	   Extraction	   Kit	   (Toronto,	   ON,	   Canada).	   The	  purified	  PCR	  product	  was	  ligated	  into	  pCRTM-­‐Blunt	  II-­‐TOPO®	  vector	  using	  Zero	  Blunt	  TOPO	  PCR	  Cloning	  Kit	   (Invitrogen)	  according	   to	   the	  manufacturer’s	  recommended	  protocol,	   then	   electroporated	   into	   electro-­‐competent	   TOP-­‐10	   cells	   and	   incubated	  overnight	   37°C	   on	   LB	   +	   50μg/ml	   Kanamycin	   plates.	   	   	   The	   next	   day,	   individual	  colonies	  were	  picked	  and	   sent	   for	  Templiphi	   amplification	  and	  Sanger	   sequencing	  (GE	  Healthcare,	  National	  Research	  Council	  of	  Canada’s	  Plant	  Biotechnology	  institute	  sequencing	   core,	   Saskatoon	   SK).	   Sequences	   were	   derived	   from	   3	   independent	  resistance	   selections	   for	   si18-­‐36	   treated	   cells,	   2	   independent	   experiments	   from	  si19-­‐37	  treated	  cells	  and	  1	  experiment	  from	  both	  siControl	  and	  siJFH-­‐1	  6367	  treated	  cells.	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5.4.12 Analysis	  of	  sequencing	  data	  	  All	  sequences	  where	  analyzed	  using	  Clone	  Manager	  software.	  	  	  
5.4.13 Statistical	  analyses	  	  	  	   Data	  are	  presented	  as	  the	  average	  of	  at	  least	  three	  independent	  experiments	  unless	  otherwise	  indicated.	  	  Data	  analysis	  was	  carried	  out	  with	  Prism	  6	  software.	  P	  values,	   unless	   otherwise	   indicated	   were	   calculated	   by	   using	   a	   Student	   t-­‐test,	  *P<0.05,	  **p<0.01,	  ***p<0.001,	  ****p<0.0001.	  	  
 Results	  5.5 	  
5.5.1 siRNA	  designed	  to	  specifically	  target	  the	  miR-­‐122	  binding	  region	  within	  




Figure	  5.1	  siRNA	  target	  sites	  in	  the	  miR-­‐122	  binding	  region	  and	  ability	  of	  the	  
siRNAs	   to	   function	   as	   a	   conventional	   siRNA.	   	   (A)	  A	   schematic	   diagram	  of	   how	  miR-­‐122	  bind	  the	  5’UTR	  of	  HCV	  JFH-­‐1	  and	  the	   locations	  of	  3	  siRNA	  (si18-­‐36,	  si19-­‐37,	   and	  si21-­‐43)	   that	   target	   the	  miR-­‐122	  binding	   region	  of	   the	  HCV	   JFH-­‐1	  5’	  UTR.	  	  (B)	  The	  effectiveness	  of	   the	   individual	   siRNA	   to	  decrease	   luciferase	   expression	  by	  binding	  to	  two	  seed	  sequences	  located	  downstream	  of	  a	  firefly	  luciferase	  gene.	  	  Data	  in	  B	  represents	  the	  average	  of	  four	  independent	  experiments,	  and	  significance	  was	  determined	   by	   performing	   a	   one-­‐way	   ANOVA	  with	   Tukey’s	  multiple	   comparisons	  test.	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remove	  any	  confounding	  effects	  of	   exogenous	  miR-­‐122	  binding	   to	   the	   target	   sites.	  The	  siRNAs	  si18-­‐36,	  si19-­‐37	  and	  si21-­‐43	  decreased	  firefly	  luciferase	  expression	  by	  92%,	   93%	   and	   76%	   respectively	   compared	   to	   the	   cells	   transfected	   with	   control	  siRNA	   (siControl)	   after	   normalization	   to	   the	   Renilla	   transfection	   control	   plasmid	  (Fig.	   5.1B:	   right	   panel).	   	   These	   results	   suggest	   that	   the	   designed	   siRNA,	   si18-­‐36,	  si19-­‐37	   and	   si21-­‐43	   have	   the	   potential	   to	   form	   a	   RISC	   and	   can	   bind	   to	   and	  knockdown	  mRNAs	  containing	  the	  HCV	  5’	  UTR	  and	  miR-­‐122	  binding	  sequences,	  and	  that	  si21-­‐43	  is	  less	  effective	  than	  the	  others.	  	  
5.5.2 Sub-­‐genomic	   and	   full-­‐length	   HCV	   replication	   is	   decreased	   in	   Huh7.5	  












Figure	  5.3	  siRNA	  knockdown	  of	  HCV	  sub-­‐genomic	  RNA.	  (A)	  A	  schematic	  diagram	  illustrating	  the	  SGR	  JFH-­‐1	  FLuc	  replion	  RNA.	  (B)	  Firefly	  luciferase	  expression	  at	  the	  indicated	   time	   point	   by	   Huh7.5	   cells	   co-­‐electroporated	   with	   SGR	   JFH-­‐1	   Fluc	   and	  either	   the	   siRNA	   si18-­‐36,	   si19-­‐37,	   si21-­‐43,	   JFH-­‐1	   6367	   or	   a	   control	   siRNA	  (siControl).	   	   (C)	   The	   relative	   percent	   reduction	   in	   firefly	   luciferase	   expression	  induced	   by	   siRNA	   compared	   to	   cells	   treated	   with	   siControl.	   (D)	   The	   relative	   cell	  numbers	   (E)	  and	   levels	  of	  Renilla	   luciferase	  expressed	   from	  a	   transfection	  control	  mRNA	  in	  cells	  that	  were	  treated	  with	  various	  siRNA.	  All	  data	  represents	  the	  average	  of	   four	   independent	   experiments	   and	   the	   error	   bars	   in	   B	   are	   represented	   as	  standard	  error	  of	   the	  mean,	  while	   the	  others	  are	   represent	  by	  standard	  deviation.	  Significance	   was	   determined	   by	   performing	   a	   two-­‐way	   ANOVA	   with	   Tukey’s	  multiple	  comparisons	  test.	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expected,	  decreased	  HCV	  replication	  by	  over	  96%	  during	  the	  three-­‐day	  time	  course	  (Fig.	  5.3C).	  	  The	  treatment	  of	  Huh7.5	  cells	  with	  the	  siRNAs	  did	  not	  affect	  cell	  viability	  or	  normal	  cellular	  translation	  measured	  from	  a	  co-­‐electroporated	  control	  luciferase	  mRNA	  (Fig.	  5.2D	  and	  E,	  Fig.	  5.3D	  and	  E).	  	  The	  ability	  of	  si18-­‐36,	  si19-­‐37	  and	  si21-­‐43	  to	  decrease	  luciferase	  expression	  from	  a	  full-­‐length	  construct	  and	  SGR	  indicate	  that	  the	  siRNAs	  designed	  to	  target	  the	  5’UTR	  of	  HCV	  inhibit	  HCV	  replication.	  	  
5.5.3 Cell	   lines	   stably	   harbouring	   HCV	   constructs	   remain	   susceptible	   to	  








Figure	   5.4	   Luciferase	   expression	   levels	   during	   selection	   of	   siRNA	   resistant	  
escape	  mutants.	  A	  schematic	  illustration	  of	  the	  SGR	  lucubineo	  JFH-­‐1	  FLuc	  replicon	  RNA	   (A,	   upper	   panel),	   and	   J6/JFH-­‐1	   Neo	   Rluc	   (B,	   upper	   panel).	   	   The	   bar	   graphs	  represent	  the	  %	  reduction	  in	  luciferase	  expression	  from	  SGR	  lucubineo	  JFH-­‐1	  (A)	  or	  J6/JFH-­‐1	  Neo	  Rluc	  (B)	  expressing	  cells	  following	  multiple	  rounds	  of	  treatment	  with	  the	  indicated	  siRNA	  compared	  to	  the	  same	  cells	  electroporated	  with	  a	  control	  siRNA.	  In	   all	   cases	   the	   data	   are	   presented	   as	   averages	   from	   3	   independent	   replicates	   of	  resistance	  selection	  for	  each	  siRNA,	  except	  for	  panel	  B;	  treatment	  rounds	  6	  and	  7	  of	  si21-­‐43	   and	   rounds	   5	   and	   7	   of	   JFH-­‐1	   6367	   which	   represent	   the	   average	   of	   two	  independent	  experiments.	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in	  a	  general	  decrease	  in	  effectiveness	  of	  the	  siRNA	  after	  several	  rounds	  of	  treatment	  (Fig.	  5.4B,	   lower	  right	  panel)	  but	   the	  siRNAs	   targeting	   the	  5’UTR,	   si18-­‐36,	   si19-­‐37	  and	  si21-­‐43,	  did	  not	  decrease	  in	  effectiveness	  after	  several	  rounds	  of	  treatment,	  nor	  did	   they	   demonstrate	   a	   trend	   that	   indicated	   the	   presence	   of	   resistance	   (Fig.	   5.4B	  middle	   and	   lower	   left	   panels).	   	   These	   observations	   suggested	   that	   HCV	   does	   not	  appear	  to	  generate	  resistance	  to	  siRNAs	  targeting	  the	  miR-­‐122	  binding	  region.	  	  
5.5.4 The	   5’UTR	   of	   constructs	   maintained	   in	   stable	   cells	   that	   have	   been	  
treated	   numerous	   times	  with	   the	   same	   siRNA	   contain	  mutants	  within	  
the	  miR-­‐122	  binding	  region	  	  
	  





Figure	   5.5	   Mutants	   within	   the	   miR-­‐122	   binding	   region	   of	   the	   HCV	   5’UTR	  
sequence	  yielded	  after	  seven	  rounds	  of	  treated	  with	  si18-­‐36,	  si19-­‐37,	  or	  siJFH-­‐
1	  6367	  and	  selection	  with	  G418.	  	  5’UTR	  sequences	  from	  HCV	  RNA	  extracted	  from	  cells	  harbouring	  HCV	  RNA	  after	  seven	  rounds	  of	  resistance	  mutation	  selection	  with	  (A),	   si18-­‐26	   (B),	   si19-­‐37	   (C)	   or	   siJFH-­‐1	   6367.	   	   The	   grey	   highlighted	   nucleotides	  represent	  the	  miR-­‐122	  binding	  sites,	  and	  the	  underlined	  nucleotide	  indicated	  where	  the	  siRNA	  binds.	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are	   the	   least	   conserved	   between	   HCV	   genotypes	   and	   the	   mutation	   of	   G	   to	   A	   at	  position	  28	  is	  found	  in	  the	  genotype	  1a	  H77	  sequence,	  and	  the	  mutation	  at	  position	  34	  A	  to	  G	  is	  found	  in	  genotypes	  1b	  and	  3a	  (117).	  	  We	  also	  observed	  that	  many	  of	  the	  UTRs	  isolated	  from	  cells	  treated	  with	  si19-­‐37	  contained	  paired	  mutations	  within	  the	  miR-­‐122	  binding	  region	  (Fig.	  5.5B:	  table).	   	  In	  positive	  control	  siJFH-­‐1	  6367	  treated	  cells	   we	   also	   isolated	   3	   RNAs	   out	   of	   88	   UTRs	   sequenced	   (3%)	   having	   mutations	  within	   the	  miR-­‐122	   binding	   region,	   which	   suggests	   a	   potential	   growth	   enhancing	  phenotype	  for	  these	  mutation.	  	  However,	  the	  conversion	  of	  a	  U	  to	  C	  in	  siJFH-­‐1	  6367	  treated	  cells	  at	  position	  25	  was	  only	  observed	  a	  few	  times	  in	  si18-­‐36	  and	  never	  in	  si19-­‐37	  treated	  cells.	  We	  did	  not	  detect	  any	  mutations	  in	  the	  miR-­‐122	  binding	  sites	  of	   80	  5’UTR	   sequenced	   from	  HCV	   constructs	  maintained	   in	   cells	  which	  had	  never	  been	  treated	  with	  siRNA	  (data	  not	  shown).	  	  	  	  
5.5.5 HCV	  that	  contains	  a	  point	  mutation	  in	  the	  siRNA	  targeted	  binding	  site	  is	  
more	   susceptible	   to	   si19-­‐37	   and	   si21-­‐43,	   while	   becoming	   more	  
resistant	  to	  si18-­‐36	  	  	  To	   begin	   to	   analyze	   the	   influence	   of	   the	  miR-­‐122	   point	  mutations	   on	   HCV	  RNA	  replication	  fitness	  and	  susceptibility	  to	  the	  antiviral	  siRNAs,	  we	  analyzed	  a	  full-­‐length	   virus	  bearing	   a	  point	  mutation	   at	   position	  26.	  This	  mutation	  has	   also	  been	  termed	  S1:p3	   in	  ours	   and	  other’s	  work	  and	   in	   this	   context	   is	   called	   J6/JFH-­‐1	  Rluc	  S1:p3	   (106).	  The	  point	  mutation	   is	  present	   in	   the	  1st	  miR-­‐122	  binding	  site	  of	  HCV	  5’UTR	  and	  is	  the	  result	  of	  changing	  a	  cytosine	  to	  a	  guanine	  at	  position	  26	  (Fig.	  5.6A).	  This	  mutation	  abolishes	  the	  sequence	  identified	  between	  the	  viral	  RNA	  and	  all	  three	  siRNAs,	  si18-­‐36,	  si19-­‐37	  and	  si21-­‐43	  (Fig.	  5.1A).	  	  J6/JFH-­‐1	  Rluc	  S1:p3	  RNA	  does	  not	  replicate	  as	  efficiently	  as	  WT	  virus	  (Fig.	  5.2B	  vs.	  Fig.	  5.6B:	  siControl	  and	  1μg	  vs.	  5μg	  of	  HCV	  RNA),	  but	   its	  replication	  can	  be	  reinstated	  by	  using	  a	  miR-­‐122	  mutant	  that	  reinstates	  binding	  (unpublished	  data)	  confirming	  that	   loss	  of	  miR-­‐122	  binding	  has	  an	   effect	   on	   virus	   fitness.	  Using	   this	   system	   to	   test	   the	   efficacy	   of	   our	   siRNAs,	  we	  found	  that,	  in	  spite	  of	  the	  sequence	  mismatch	  between	  this	  HCV	  genomic	  sequence	  and	  our	  antiviral	  siRNAs,	  they	  all	  retained	  antiviral	  activity.	  Surprisingly,	  some	  even	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Figure	  5.6	  siRNA	  knockdown	  of	  full-­‐length	  and	  SGR	  HCV	  RNA	  having	  miR-­‐122	  
S1:p3	   mutation.	   (A)	   A	   schematic	   diagram	   of	   the	   5’UTR	   of	   HCV	   and	   the	   S1:p3	  mutation.	   (B)	  The	   amount	   of	   luciferase	   expressed	   in	  Huh7.5	   cells	   at	   the	   indicated	  time	  points	  co-­‐electroporation	  of	  J6/JFH-­‐1	  Rluc	  S1:p3,	  or	  (D)	  SGR	  JFH-­‐1	  FLuc	  S1:p3	  with	  the	  indicated	  siRNA.	  The	  relative	  percent	  decrease	  of	   luciferase	  expression	  of	  (C)	   J6/JFH-­‐1	   Rluc	   S1:p3,	   or	   (E)	   SGR	   JFH-­‐1	   Fluc	   S1:p3	   relative	   to	   siControl	   siRNA.	  Significance	   was	   determined	   by	   performing	   a	   two-­‐way	   ANOVA	   with	   Tukey’s	  multiple	  comparisons	  test.	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had	   enhanced	   antiviral	   activity	   (Fig.	   5.6B	   and	  C).	   	  When	   J6/JFH-­‐1	  Rluc	   S1:P3	  was	  treated	   with	   the	   siRNA	   targeting	   the	   miR-­‐122	   binding	   sites;	   si18-­‐36	   reduced	  luciferase	  expression	  by	  7%,	  33%,	  and	  58%	  on	  days	  1,	  2	  and	  3.	  This	  siRNA	  was	  less	  efficient	  than	  it	  had	  been	  on	  WT	  HCV	  RNA	  as	  would	  be	  expected	  for	  an	  siRNA	  that	  does	   not	   match	   its	   target	   sequence	   perfectly	   (Fig.	   5.7A:	   top	   graph).	   	   si19-­‐37	  decreased	   luciferase	  production	  by	  40%,	  95%,	   and	  94%	  on	  days	  1,	   2	   and	  3	  while	  si21-­‐43	  inhibited	  luciferase	  expression	  by	  38%,	  81%	  and	  87%	  on	  days	  1,	  2,	  and	  3b	  (Fig.	  5.6B	  and	  C).	  	  Interestingly	  both	  si19-­‐37	  and	  si21-­‐43	  displayed	  greater	  potency	  towards	   the	  S1:P3	  mutant	  virus	   than	  the	  WT	  virus.	   	   si19-­‐37	  and	  si21-­‐43	   inhibited	  S1:P3	  1.4	  fold	  and	  2	  fold	  greater	  then	  WT	  virus	  on	  days	  2	  and	  3	  respectively	  (Figure	  5.7A:	  middle	  graphs).	   	  This	  data	  suggests	  that	  siRNAs	  19-­‐37	  and	  21-­‐44	  may	  use	  an	  alternative	  method	   of	   inhibition	   beyond	   that	   of	   siRNA	   directed	   cleavage.	   	   Similar	  results	  were	  seen	  with	  HCV	  SGR	  RNAs	  (Fig	  5.6D,	  E	  and	  Fig.	  5.7B).	  	  
 Discussion	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Figure	  5.7	  si18-­‐37	  and	  si21-­‐43	  knockdown	  of	  HCV	  S1:p3	  is	  more	  potent	  than	  
knockdown	   of	  WT	   virus.	   (A)	  The	   relative	  knockdown	  efficiency	  of	   the	   indicated	  siRNAs	   on	   J6/JFH-­‐1	   Rluc	   WT	   or	   S1:P3	   mutant	   virus	   over	   a	   3	   day	   time	   course	  compared	  to	  siControl.	  (B)	  SGR	  JFH-­‐1	  Fluc	  was	  treated	  as	  described	  in	  (A).	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harbouring	   bicistronic	   full-­‐length	   and	   sub-­‐genomic	   HCV	   RNAs	   since	   previous	  experiments	  demonstrated	  that	  sub-­‐genomic	  replicons	  can	  replicate	  independently	  of	   miR-­‐122	   (albeit	   poorly)	   and	   thus	   might	   provide	   a	   background	   with	   a	   lower	  barrier	  to	  resistance	  in	  which	  to	  isolate	  mutants	  (116).	  	  After	  selection,	  we	  identified	  several	   point	  mutations	   located	   throughout	   the	   target	   sequence,	   including	  within	  miR-­‐122	  binding	  sites.	  	  These	  data	  indicate	  that	  HCV	  can	  replicate	  efficiently	  with	  a	  single	   intact	  miR-­‐122	  site.	  This	   is	  supported	  by	  our	  analysis	  of	   the	  p3	  mutation	   in	  the	  context	  of	  the	  full-­‐length	  HCV	  RNA	  and	  previous	  work	  showing	  that	  HCV	  RNAs	  having	  point	  mutations	  to	  miR-­‐122	  binding	  site	  1	  are	  viable	  (117).	  	  It	  is	  possible	  that	  the	   use	   of	   bicistronic	   constructs	   allowed	   the	   isolation	   of	   a	   more	   diverse	   set	   of	  mutants	  than	  would	  have	  been	  seen	  using	  a	  full-­‐length	  RNA.	  Point	  mutations	  were	  present	   in	   all	   positions	   of	   the	   si18-­‐36	   target	   sequence	   that	   targeted	   the	  miR-­‐122	  binding	   region	   with	   the	   exception	   of	   the	   C	   at	   position	   24	   and	   suggests	   that	   this	  position	   may	   be	   the	   only	   non-­‐variant	   position	   in	   this	   region	   of	   the	   genome.	  	  Interestingly,	   viruses	   having	   mutations	   outside	   of	   si18-­‐36	   target	   site,	   and	   within	  miR-­‐122	   binding	   site	   2	   were	   also	   selected.	   This	   suggests	   the	   possibility	   that	   the	  siRNA	  may	  have	  been	  able	  to	  bind	  to	  the	  second	  seed	  sequence	  to	  inhibit	  replication.	  Fewer	  point	  mutations	  arose	  from	  selection	  using	  si19-­‐37.	  We	  believe	  this	  might	  be	  due	   to	   the	   fact	   that	   this	   siRNA	  spans	  both	  miR-­‐122	  sites	  and	   functions	  both	  as	  an	  siRNA	   and	   as	   a	   barrier	   to	   miR-­‐122/Ago2	   binding.	   It	   is	   also	   possible	   that	   some	  mutant	  viruses	  were	  eliminated	  due	  to	  poor	  replication,	  or	  reversion	  during	  the	  two	  weeks	  following	  siRNA	  treatment	  when	  cells	  were	  allowed	  to	  grow.	  The	  replicative	  fitness	  of	  the	  mutants	  will	  be	  explored	  in	  future	  experiments	  using	  full-­‐length	  RNA,	  and	  analysis	  of	   the	  ability	  of	   full-­‐length	  HCV	   to	   incorporate	  mutations	   in	   the	  miR-­‐122	   binding	   sites	   awaits	   future	   selection	   of	   full-­‐length	   HCV	   RNAs	   expressing	   the	  neomycin	  resistance	  gene.	  	  In	  addition,	  we	  believe	  that	  it	  is	  likely	  that	  compensatory	  mutations	  elsewhere	  in	  the	  genome	  have	  arisen	  to	   influence	  the	  replicative	  fitness	  of	   the	  RNAs	  having	  mutations	  to	  the	  miR-­‐122	  binding	  sites.	  Sequencing	   full-­‐length	  genomes	   to	   identify	   compensatory	   mutations	   could	   provide	   insight	   into	   the	  mechanism	  of	  action	  of	  miR-­‐122.	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The	  incorporation	  of	  a	  point	  mutation	  into	  the	  target	  site	  of	  a	  siRNA	  inhibits	  its	  knockdown	  efficiency.	  However,	  when	  the	  miR-­‐122	  binding	  region	  siRNAs	  were	  assayed	   for	   functionality	   against	   an	  HCV	  RNA	  having	   a	   point	  mutation	  within	   the	  target	   sequences	   for	   all	   three	   siRNAs,	   the	   effects	   on	   the	   siRNAs	   activity	   were	  variable.	   As	   one	   would	   expect,	   inhibition	   by	   si18-­‐36	   was	   attenuated	   by	   a	   point	  mutation	  in	  its	  target	  sequence	  but	  unexpectedly,	  inhibition	  by	  si19-­‐36	  and	  si21-­‐43	  was	   enhanced.	   The	   fact	   si18-­‐36	   loses	   effectiveness	   suggests	   that	   its	   main	  mechanism	   of	   inhibition	   was	   through	   siRNA	   cleavage.	   	   Given	   that	   the	   difference	  between	   si18-­‐36	   and	   si19-­‐37	   is	   a	   single	   nucleotide	   that	   extends	   into	   the	   second	  miR-­‐122	   binding	   site	   (Fig.	   5.1A)	  we	   believe	   that	   si19-­‐37	   and	   si21-­‐43	   inhibit	   HCV	  replication	  by	   blocking	  miR-­‐122	  binding	   to	   site	   2.	   Thus,	  we	  propose	   that	   si18-­‐36,	  si19-­‐37	  and	  si21-­‐43	  inhibit	  WT	  HCV	  by	  binding	  to	  and	  cleaving	  the	  5’UTR	  of	  the	  HCV	  genome.	   	  However,	   si19-­‐37	  and	  si21-­‐43	  also	  prevent	  miR-­‐122	  binding	   to	  both	   the	  first	  and	  second	  miR-­‐122	  binding	  sites.	  In	  the	  context	  of	  J6/JFH-­‐1	  Rluc	  S1:p3,	  si19-­‐37	   and	   si21-­‐43	   are	  more	   effective	   at	   inhibiting	   the	   virus,	   since	   replication	   of	   this	  RNA	   relies	   on	  miR-­‐122	   binding	   to	   site	   2	  when	   site	   1	   is	  mutated.	   	   This	   effectively	  blocks	  miR-­‐122	  from	  accessing	  HCV	  5’UTR	  and	  blocks	  HCV	  replication.	  	  	  	  That	  si19-­‐37	  may	  block	  both	  miR-­‐122	  binding	  sites	  would	  explain	  why	  fewer	  escape	  mutations	  were	  isolated	  compared	  to	  si18-­‐36,	  since	  a	  greater	  complexity	  of	  mutations	  would	  be	  required	  by	  HCV	  to	  escape.	  Similarly,	  we	  expect	  that	  the	  virus	  would	  also	  have	  difficulty	  escaping	  from	  si21-­‐43	  and	  make	  these	  two	  siRNAs	  good	  candidates	  for	  future	  HCV	  therapies,	  or	  for	  use	  in	  conjunction	  with	  si18-­‐36	  to	  limit	  the	  replication	  of	  escape	  mutants.	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6.0 LINKER	  BETWEEN	  CHAPTERS	  5	  AND	  7	  	   When	  we	   sequenced	   the	  5’UTR	  of	  HCV	  RNA	   from	  cells	   that	  had	  undergone	  positive	  selection	   for	  seven	  rounds	  of	   treatment	  with	  an	  siRNA	  targeting	   the	  miR-­‐122	   binding	   region,	   we	   observed	   mutations	   in	   the	   miR-­‐122	   binding	   region	   as	  discussed	   in	  Chapter	  5,	  but	  also	   in	  sequences	  downstream	  of	   the	  miR-­‐122	  binding	  region.	   	  These	  downstream	  mutations	  represent	  possible	  advantageous	  adaptation	  of	  the	  virus,	  and	  may	  also	  provide	  further	  insight	  into	  the	  role	  of	  miR-­‐122	  and	  HCV	  and	  thus	  are	  worthy	  of	  further	  study.	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7.0 MULTIPLE	   ROUNDS	   OF	   TREATMENT	  WITH	   siRNA	   TARGETING	   THE	  miR-­‐
122	   BINDING	   REGION	   OF	   HCV	   SELECTS	   FOR	   VIRAL	   GENOMES	   HAVING	  
MUTATIONS	   THAT	   RESIDE	   OUTSIDE	   OF	   THE	   siRNA	   TARGET	   SEQUENCE	  
AND	  miR-­‐122	  BINDING	  REGION	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 Abstract	  7.2 	  Hepatitis	  C	  virus	  (HCV)	  requires	  the	  miRNA,	  miR-­‐122	  to	  bind	  to	  its	  5’UTR	  for	  robust	   replication	   and	   translation.	   Due	   to	   this	   dependency,	   the	   miR-­‐122	   binding	  region	  of	  HCV	  is	  highly	  conserved	  across	  genotypes	  and	  has	  been	  demonstrated	  to	  be	  a	  target	  for	  efficient	  siRNA	  mediated	  degradation	  (Chapter	  5).	  	  In	  the	  past,	  siRNA	  targeting	   of	   HCV	   has	   resulted	   in	   the	   selection	   of	   escape	   mutants	   having	   point	  mutations	  to	  the	  siRNA	  target	  sequences.	  	  Sequencing	  results	  presented	  in	  Chapter	  5	  indicate	   this	   is	   also	   true	   for	   siRNA	   targeting	   the	  miR-­‐122	  binding	   region.	   	  Further	  examination	  of	  the	  5’	  UTR	  sequence	  from	  the	  selected	  HCV	  genomes	  demonstrated	  that	  not	  only	  do	  the	  selected	  viruses	  contain	  mutations	  in	  the	  siRNA	  target	  sequence	  but	   also	  mutations	   down	   stream	   of	   the	   siRNA	   target	   sequence.	   	   	   Several	   of	   these	  mutants	   occur	   in	   the	   AUG	   start	   codon	   of	   HCV	   and	   at	   conserved	   nucleotides	  predicted	  to	  have	  a	  modified	  confirmation	  upon	  miR-­‐122	  binding	  to	  the	  5’UTR.	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 Introduction	  7.3 	  Hepatitis	   C	   virus	   (HCV)	   is	   an	   enveloped	   virus	   with	   a	   positive	   sense	   RNA	  genome	   (18).	   	   The	   genome	   encodes	   10	   proteins,	   which	   are	   translated	   as	   a	  polyprotein	  from	  a	  single	  open	  reading	  frame.	  	  A	  cap-­‐independent	  process	  initiates	  translation	  of	   the	  polyprotein	  by	   the	   recruitment	  of	   the	  40S	  ribosome	  and	   limited	  initiation	  factors	  to	  a	  structured	  RNA	  element	  that	  forms	  an	  internal	  ribosome	  entry	  site	  (IRES)	  within	  the	  5’	  untranslated	  region	  (UTR)	  of	  HCV	  RNA	  genome	  (55).	  	  	  The	  5’UTR	   sequence	   is	   highly	   conserved	   across	   genotypes.	   Based	   on	   predicated	  secondary	   structure	   the	   HCV	   5’UTR	   is	   divided	   into	   four	   domains.	   	   Domain	   I	   is	  required	  for	  replication,	  domains	  III	  and	  IV	  are	  required	  for	  translation,	  and	  domain	  II	   is	   required	   for	  both	  replication	  and	   translation.	   	  Together	  domains	   II,	   III	  and	   IV	  comprise	  the	  IRES.	  The	   IRES	   coordinates	   initiation	   of	   translation.	   	   Domain	   III	   recruits	   the	   40S	  ribosome	  and	  then	  all	   three	  domains	  (II-­‐IV)	  assist	   in	  retaining	  and	  positioning	  the	  40S	  ribosome	  in	  the	  proper	  orientation	  with	  respect	  to	  the	  AUG	  start	  codon,	  located	  in	  domain	   IV.	   	  Once	   the	   ribosome	   is	  properly	  positioned,	  domain	   III	   recruits	  eIF3,	  which	  associates	  with	   the	  40S	  ribosome.	   	  The	   formation	  of	   the	  40S	  ribosome-­‐eIF3	  complex	   allows	   the	   incorporation	   of	   the	   ternary	   initiation	   complex	   eIF2-­‐GTP-­‐tRNAmet.	  	  After,	  or	  during	  the	  formation	  of	  the	  40S	  ribosome-­‐eIF3-­‐eIF2-­‐GTP-­‐tRNAmet	  complex,	   eIF5	   is	   included	   in	   the	   complex.	   	   The	   inclusion	   of	   all	   the	   factors	   in	   the	  complex	   leads	   to	   the	  phosphorylation	  of	  eIF5.	  Similar	   to	   its	   role	   in	  cap-­‐dependent	  translation,	  phosphorylated	  eIF5	  facilitates	  the	  recruitment	  of	  the	  60S	  ribosome	  and	  the	   formation	   of	   the	   translational	   competent	   80S	   ribosome	   (53-­‐55).	   	   The	  coordinated	  recruitment	  of	   factors	  required	   for	   translation	   initiation	  by	   the	  highly	  structured	   HCV	   IRES	   emphasizes	   not	   only	   the	   importance	   of	   the	   secondary	  structure,	   but	   also	   the	   ability	   for	   the	   structures	   to	   interact	   with	   each	   other.	   The	  requirement	   for	   these	   highly	   sophisticated	   interactions	   is	   exemplified	   by	  conservation	  of	  5’UTR	  sequences	  across	  genomes	  (117).	  	  Domain	  I	  of	  HCV	  5’UTR	  is	  not	  required	  for	  translation	  (55),	  but	  interacts	  with	  miR-­‐122	  and	  promotes	  both	  HCV	  replication	  and	   translation	  (104,	  105,	  108,	  110).	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Two	  miR-­‐122	  molecules,	   along	  with	  argonaute	  2	  have	  been	   shown	   to	  bind	  at	   two	  seed	  sites	   located	  within	  domain	   I	   (111,	  114,	  193).	   	  The	   interaction	  between	  miR-­‐122	   and	   HCV	   5’UTR	   protects	   the	   viral	   genome	   from	   Xrn1	   5’-­‐3’	   exonuclease	  degradation,	  and	  leads	  to	  an	  increase	  in	  viral	  translation	  and	  replication	  (113).	  	  The	  increase	  in	  viral	  translation	  is	  the	  result	  of	  the	  increase	  in	  RNA	  abundance	  provided	  by	  miR-­‐122	   protection,	   but	   the	   increase	   in	   replication	   is	   not	   solely	   linked	   to	   the	  increase	   in	   RNA	   abundance	   through	   protection	   from	   Xrn1	   (113).	   	   Another	  possibility	   is	   that	   miR-­‐122	   binding	   modifies	   the	   structure	   of	   the	   5’UTR.	   Utilizing	  selective	   2'-­‐hydroxyl	   acylation	   analyzed	   by	   primer	   extension	   (SHAPE)	   selective	  analysis,	   two	   separate	   groups	   have	   reported	   that	   miR-­‐122	   binding	   to	   the	   5’UTR	  induces	   downstream	   changes	   in	   the	   5’UTR	   (115,	   120).	   	   These	   changes	   could	  hypothetically	  increase	  or	  decrease	  HCV	  translation	  and	  replication.	  We	   have	   used	   siRNAs	   that	   target	   the	   miR-­‐122	   binding	   region	   within	   the	  5’UTR	  to	  select	  viral	  RNAs	  having	  point	  mutations	  to	  the	  miR-­‐122	  binding	  sites.	  	  We	  observed	   the	   selection	   of	   RNAs	   having	   mutations	   to	   the	   siRNA-­‐targeted	   region	  (described	   in	   Chapter	   5)	   and	   also	   RNAs	   having	   mutations	   down	   stream,	   in	   the	  conserved	  regions	  of	  the	  IRES.	  Their	  selection	  suggests	  that	  some	  of	  the	  mutations	  afford	  the	  virus	  a	  selective	  replication	  advantage	  when	  the	  miR-­‐122	  binding	  region	  is	   being	   targeted.	   We	   speculate	   that	   some	   of	   the	   mutations	   are	   general	   growth	  enhancing	  mutations,	  and	  that	  some	  may	  be	  compensatory	  mutations	  that	  allow	  the	  virus	   to	   escape	   dependence	   on	   miR-­‐122.	   	   In	   this	   chapter	   we	   will	   describe	   the	  mutations	   we	   have	   selected	   and	   compare	   them	   with	   nucleotides	   whose	  conformations	   were	   affected	   by	   miR-­‐122	   binding.	   We	   will	   also	   propose	   future	  studies	   to	   investigate	   the	   impact	   of	   the	   mutations	   on	   HCV	   replication	   and	   its	  dependence	  on	  miR-­‐122.	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 Materials	  and	  methods	  7.4 	  
7.4.1 Cell	  culture	  	  	  Huh7.5	   cells	   harboring	   J6/JFH-­‐1	   Neo	   Rluc	   were	   cultured	   in	   Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  supplemented	  with	  10%	  fetal	  bovine	  serum,	  0.1nM	  non-­‐essential	   amino	   acids	   (Wisent,	   Montreal,	   Canada),	   100μg/ml	   Pen/Strep	  (Invitrogen,	  Burlingtion	  ON,	  Canada)	  and	  800μg/ml	  G418	  Sulfate	  (Wisent,	  Montreal,	  Canada)	   to	   maintain	   the	   HCV	   replicon.	   	   This	   stable	   cell	   line	   was	   provided	   by	  provided	  by	  Dr.	  Liu	  Qiang.	  	  
7.4.2 Small	  interfering	  RNAs	  (siRNA)	  sequence	  	  	  	  The	   siRNAs	   that	   target	   the	   miR-­‐122	   binding	   region	   have	   been	   described	  previously	  in	  Chapter	  5.3.3.	  	  
7.4.3 Electroporation	  of	  Huh7.5	  cells	  harbouring	  J6/JFH-­‐1	  Neo	  Rluc	  	  	  	  The	  electroporation	  of	  cells	  was	  conducted	  as	  described	  previously	  (116)	  	  
7.4.4 Escape	  mutant	  selection	  assay	  	  	  	  The	   selection	   of	   escape	  mutants	  was	   performed	   as	   previously	   described	   in	  Chapter	  5.3.8.	  	  
7.4.5 RNA	  purification	  	  	  	  RNA	  was	  purified	  as	  previously	  described	  in	  Chapter	  5.3.10.	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7.4.6 Sequencing	  of	  the	  5’	  portion	  of	  HCV	  	  	  HCV	  was	  sequenced	  from	  the	  beginning	  of	  the	  neomycin	  gene	  to	  the	  5’end	  as	  previously	  described	  in	  Chapter	  5.3.11.	  	  
7.4.7 Analysis	  of	  sequencing	  data	  	  All	  sequences	  were	  analyzed	  using	  Clone	  Manager	  software.	  	  







Figure	   7.1	   Binding	   of	   miR-­‐122	   and	   siRNA	   designed	   to	   target	   the	   miR-­‐122	  
binding	   region	   to	   HCV	   5’UTR.	  A	   schematic	   diagram	  depicting	   how	  miR-­‐122	   (A)	  and	   (B)	   siRNA	   targeting	   the	   miR-­‐122	   binding	   region	   interact	   with	   the	   5’UTR	   of	  J6/JFH-­‐1	  Neo	  Rluc	  (C).	   	  The	  predicted	  secondary	  structure	  of	  HCV	  5’UTR	  (D).	   	  The	  underlined	   nucleotides	   indicate	   where	   miR-­‐122	   binds	   and	   the	   red	   nucleotides	  indicate	   nucleotides	   which	   accessibility	   is	   predicted	   to	   change	   upon	   miR-­‐122	  binding.	  	  The	  circled	  AUG	  represents	  the	  initiation	  codon	  for	  core	  and	  the	  blue	  AUG	  indicates	  the	  beginning	  of	  the	  neomycin	  gene.	  	   	  
	  115	  




	   	  
Figure	   7.2	   Point	   mutations	   at	   nucleotides	   predicted	   to	   be	   more	   accessible	  
when	  miR-­‐122	  is	  bound	  to	  the	  5’UTR.	  	  (A)	  The	  numbers	  and	  locations	  of	  J6/JFH-­‐1	  Neo	   RLuc	   sequences	   retrieved	   in	   cells	   treated	   with	   siRNA	   targeting	   the	   miR-­‐122	  binding	  region	  having	  a	  point	  mutation	  at	  one	  of	   the	  10	  nucleotides	  outside	  of	   the	  miR-­‐122	   binding	   region	   that	   were	   predicted	   to	   have	   differed	   accessibility	   when	  miR-­‐122	   is	   bound	   (B)	   siJFH-­‐1	  6367	  and	   (C)	   cell-­‐passage	   control.	   	   The	  nucleotides	  predicted	   to	   have	   increase	   accessibility	   are	   coloured	   green	   while	   the	   nucleotides	  predicted	  to	  be	  less	  accessible	  are	  coloured	  red.	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Figure	  7.3	  Isolated	  mutations	  within	  the	  5’UTR	  and	  their	  predicted	  interaction	  
within	   secondary	   structure.	   	   A	   schematic	   diagram	   of	   the	   5’UTR	   with	   the	   5	  nucleotides	  predicted	  to	  have	  different	  availability	  upon	  miR-­‐122	  binding	  indicated	  by	  arrows.	  	  A	  table	  demonstrating	  the	  isolated	  clones,	  the	  mutation	  that	  arose	  at	  the	  nucleotide	  predicted	  to	  have	  a	  different	  availability	  upon	  miR-­‐122	  binding	  and	  other	  point	  mutations	  found	  within	  the	  individual	  clone.	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Figure	  7.4	  siRNA	  targeting	  the	  miR-­‐122	  binding	  region	  induce	  point	  mutations	  
in	   the	   HCV	   start	   codon.	   	   (A)	   The	   numbers	   of	   J6/JFH-­‐1	   Neo	   RLuc	   sequences	  retrieved	  having	  a	  point	  mutation	  in	  the	  start	  codon	  after	  treatment	  with	  an	  siRNA	  targeting	  the	  miR-­‐122	  binding	  region,	  (B)	  siJFH-­‐1	  6367	  or	  (C)	  cell-­‐passage	  control.	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  have	   been	   used	   to	   express	   the	   neomycin	   resistance	   gene,	   but	   since	   the	  HCV	   IRES	  does	  not	   allow	   ribosome	   scanning	   this	   is	   unlikely	   (271-­‐275).	   	  Also,	   replicons	  may	  have	   been	   selected	   in	   cells	   having	   gained	   an	   alternative	   method	   to	   resist	   G418	  selection,	   or	   harbouring	   a	   second	   replicon	   expressing	   the	   resistance	   gene	   and	  perhaps	   virus	   replicate	   better	   when	   the	   5’	   end	   of	   the	   virus	   in	   not	   involved	   in	  translation	  and	  thus	  more	  available	   for	  replication.	  Since	  6	  of	   these	  mutants	  had	  a	  second	   mutation	   in	   the	   miR-­‐122	   binding	   site	   it	   suggests	   that	   it	   may	   be	   a	  compensatory	  mutation	   that	  promotes	  RNA	  replication	   in	   the	  absence	  of	  miR-­‐122	  binding.	  These	  observations	  were	  depended	  on	  the	  use	  of	  a	  bicistronic	  replicon	  to	  allow	  for	  mutations	  that	  may	  abolish	  IRES	  translation	  and	  may	  not	  be	  viable	  in	  the	  context	  of	  a	  WT	  virus,	  although	  this	  remains	  to	  be	  determined.	  	  However,	  we	  believe	  that	  this	  array	  of	  escape	  mutations	  could	  provide	  insight	  into	  the	  role	  of	  miR-­‐122.	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8.0 GENERAL	  DISCUSSION	  AND	  CONCLUSIONS	  	  
 General	  discussion	  8.1 	  This	  thesis	  work	  began	  in	  an	  environment	  were	  an	  interaction	  between	  HCV,	  miR-­‐122	   and	   components	   of	   the	   miRNA	   suppression	   pathway	   had	   only	   recently	  been	   observed	   and	   reported	   (104,	   105,	   136).	   The	   field	   was	   in	   the	   midst	   of	   an	  explosion	  of	  exploration	  in	  an	  attempt	  to	  better	  understand	  the	  link	  between	  HCV,	  miR-­‐122	   and	   the	   miRNA	   suppression	   pathway.	   In	   the	   years	   since,	   our	  understanding	   of	   how	   HCV	   interacts	   with	   miR-­‐122	   and	   the	   miRNA	   suppression	  pathway	   has	   grown	   considerably	   and	   the	   work	   presented	   in	   this	   thesis	   has	  contributed	  to	  the	  field.	  Our	  research	  conducted	  on	   the	  DEAD-­‐box	  helicase	  DDX6	  has	  demonstrated	  that	   it	   is	   required	   for	   optimum	  HCV	   replication	   and	   translation.	  We	  hypothesized	  that	   the	   effect	   DDX6	   had	   on	   augmenting	   HCV	   replication	   was	   linked	   to	   HCV’s	  dependency	   on	   miR-­‐122,	   as	   DDX6	   was	   reported	   to	   augment	   miRNA	   suppression	  through	   an	   interaction	   with	   Ago1	   and	   Ago2,	   two	   proteins	   that	   aid	   in	   miR-­‐122	  interaction	   with	   HCV	   (153).	   Contrary	   to	   our	   hypothesis,	   we	   demonstrated	   that	  DDX6’s	   effect	   on	   HCV	   replication	   and	   translation	   is	   independent	   of	   miR-­‐122.	   	   As	  these	   results	   were	   unexpected,	   and	   given	   the	   observations	   of	   others	   that	   DDX6	  affects	   the	   miRNA	   suppression	   pathway,	   we	   examined	   whether	   DDX6	   silencing	  impeded	  the	  miRNA	  suppression	  pathway	  in	  Huh7.5	  cells.	  	  Our	  findings	  indicate	  that	  in	   the	   context	   of	   Huh7.5	   cells	   DDX6	   had	   no	   effect	   on	   miRNA	   suppression.	   We	  confirmed	  this	  observation	  in	  the	  context	  of	  miR-­‐122	  suppression,	  and	  also	  using	  a	  system	   to	   measure	   suppression	   by	   miCXCR4,	   the	   identical	   assay	   used	   in	   the	  previous	   study	   conducted	   in	   HeLa	   cells	   (153).	   This	   suggests	   that	   DDX6	   does	   not	  augment	  miRNA	  targeted	  gene	  suppression,	  at	   least	   in	  Huh7.5	  cells.	   	  However,	  we	  cannot	  rule	  out	  the	  possibility	  that	  Huh7.5	  cells	  may	  have	  a	  secondary	  mechanism	  that	   is	  not	  present	   in	  HeLa	  cells	   that	  renders	  DDX6	  activity	   in	  miRNA	  suppression	  redundant.	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When	  miR-­‐122’s	  interaction	  with	  HCV	  was	  first	  reported,	  it	  was	  suggested	  to	  only	   augment	   replication	   and	   have	   no	   effect	   on	   HCV	   translation.	   However,	  contradictory	   reports	   were	   soon	   published	   demonstrating	   that	   miR-­‐122	   could	  augment	   HCV	   translation	   as	   well	   as	   replication	   (104,	   105,	   108,	   110-­‐112).	   Our	  observations	  not	  only	  strongly	  support	  that	  miR-­‐122	  promotes	  HCV	  replication	  but	  support	  its	  role	  in	  stimulating	  translation.	  	  While	   our	   data	   indicates	   that	   DDX6	   promotes	   HCV	   replication,	   our	  hypothesis	  that	  the	  mechanism	  by	  which	  DDX6	  augments	  HCV	  via	  miR-­‐122	  was	  not	  supported.	   This	   left	   us	   to	   re-­‐hypothesize	   a	  mechanism	   by	  which	   DDX6	   augments	  HCV	   replication.	   Since	  DDX6	   is	   required	   for	  p-­‐body	   formation	   and	  maintenance,	   a	  possible	  mechanism	  by	  which	  DDX6	  supports	  HCV	  replication	  could	  be	  related	  to	  p-­‐body	  formation.	  One	  possibility	   is	   that	  p-­‐bodies	  are	   important	   for	  HCV	  replication.	  	  Other	  research	  groups	  have	  demonstrated	  that	  p-­‐body	  structures	  are	  not	  required	  for	  HCV	  replication,	   and	  similarly	   to	   the	   flaviviruses,	  WNV	  and	  Dengue	  virus,	  HCV	  infection	  leads	  to	  a	  decrease	  in	  visible	  p-­‐body	  structures	  over	  time	  (139,	  157,	  159,	  257,	   258).	   However,	   we	   cannot	   rule	   out	   the	   possibility	   that	   smaller	   p-­‐body	  aggregates,	  which	   are	   not	  microscopically	   visible,	  might	   function	   to	   promote	  HCV	  replication.	   Interestingly	   as	   the	   presence	   of	   visible	   p-­‐bodies	   decrease	   during	  HCV	  infection,	   DDX6	   co-­‐localizes	   with	   other	   p-­‐body	   resident	   proteins	   at	   sites	   of	   HCV	  replication	  which,	  suggests	  that	  multiple	  p-­‐body	  proteins	  may	  facilitate	  the	  HCV	  life	  cycle	  (258),	  but	  their	  mechanism	  of	  action	  remains	  unknown.	  Since	  DDX6	  is	  an	  RNA	  helicase	  it	  is	  also	  plausible	  that	  DDX6	  directly	  interacts	  with	  the	  HCV	  genome,	  perhaps	  to	  unwind	  the	  RNA	  during	  translation	  or	  replication.	  	  DDX6	  associates	  with	  the	  HCV	  genome,	  but	  since	  the	  interaction	  requires	  HCV	  core	  protein,	  and	  core	  protein	  is	  not	  required	  for	  the	  impact	  of	  DDX6	  on	  HCV	  translation	  and	   replication,	   the	   role	   of	  DDX6-­‐core-­‐genome	   interaction	   is	   unknown	   (259).	  One	  possible	  explanation	   for	   the	   interaction	  between	  DDX6,	  core	  and	  the	  viral	  genome	  could	   be	   that	   DDX6	   is	   also	   required	   for	   HCV	   assembly.	   Although	   DDX6	   silencing	  results	  in	  a	  decrease	  in	  infectious	  particles	  released	  it	  will	  be	  difficult	  to	  determine	  if	  the	   decrease	   is	   correlated	   with	   its	   impact	   on	   HCV	   replication,	   translation,	   or	  assembly	  since	  it	  is	  difficult	  to	  design	  experiments	  that	  assess	  HCV	  RNA	  replication	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and	  translation	  separate	  from	  virion	  assembly.	  In	  addition,	  DDX6	  and	  other	  p-­‐body	  proteins	  that	  co-­‐localize	  with	  core	  at	  the	  site	  of	  HCV	  replication	  and	  assembly	  may	  also	   suggest	   a	   role	   for	   DDX6	   and	   other	   p-­‐body	   proteins	   in	   HCV	   virion	   assembly	  (258).	   Interestingly,	  DDX6	  has	  a	   role	   in	   the	  assembly	  of	  other	  viruses	  such	  as	  HIV	  and	  PFV	  (196,	  200).	  	  	  Even	   if	  DDX6	  does	  assists	   in	  HCV	  assembly,	  our	   translation	  and	   replication	  assays	  suggest	  an	  additional	  role	  in	  HCV	  replication	  and	  translation.	  	  It	  is	  currently	  unknown	  if	  the	  influence	  of	  DDX6	  on	  HCV	  translation	  is	  responsible	  for	  its	  apparent	  impact	  on	  augmentation	   in	   replication,	  or	   if	  DDX6	  augments	  both	  HCV	   translation	  and	  replication,	  perhaps	  through	  separate	  mechanisms.	  This	  question	  will	  remained	  unanswered	   until	   such	   time	   as	   experimental	   systems	   are	   designed	   that	   allow	   the	  separation	  of	  HCV	   translation	   from	  replication.	  Evidence	   suggests	   that	  DDX6	  does	  not	   function	   by	   binding	   directly	   to	   HCV	   genomic	   RNA	   since	   RNA	   was	   not	  immunoprecipitated	  with	  DDX6	  (259).	  Interestingly,	   simultaneous	   to	   our	   research	   it	   was	   reported	   that	   DDX6	   is	  recruited	  to	  WNV	  and	  Dengue	  virus	  replication	  sites	  (158,	  159).	  DDX6	  knockdown	  was	   also	   reported	   to	   lead	   to	   a	   decrease	   in	  Dengue	   virion	   release	   (158).	  However,	  whether	  DDX6	  silencing	  leads	  to	  a	  decrease	  in	  RNA	  replication	  or	  translation	  has	  yet	  to	   be	   reported	   in	   the	   case	   of	   WNV	   or	   Dengue	   virus,	   although	   DDX6	   has	   been	  demonstrated	   to	   physically	   interact	  with	   the	   3’UTR	   of	  DENV-­‐2	   (158).	   Similarly	   to	  HCV,	  during	  the	  course	  of	  infection	  with	  WNV	  and	  Dengue	  virus	  p-­‐bodies	  disappear	  (157,	   258).	   These	   similar	   observations	   between	   HCV,	   WNV	   and	   Dengue	   virus	  suggest	   that	   they	   may	   be	   utilizing	   DDX6	   in	   a	   similar	   manner	   for	   replication,	  translation,	   and/or	   assembly.	   I	   believe	   these	   observations	   also	   support	   our	  observations	  that	  the	  effect	  of	  DDX6	  on	  HCV	  is	  independent	  of	  miR-­‐122	  since	  WNV	  and	  Dengue	  virus	  have	  not	  been	  demonstrated	  to	  utilize	  a	  miRNA	  for	  replication.	  Because	  of	   the	   rapid	  progression	  of	   research	  on	   the	   role	  of	  p-­‐bodies	   in	   the	  HCV	  life	  cycle,	  and	  our	  desire	  to	   focus	  our	  research	  on	  the	  mechanism	  of	  action	  of	  miR-­‐122,	  we	  re-­‐focused	  our	  research	  to	  the	  study	  of	  a	  mechanism	  to	  inhibit	  HCV	  by	  exploiting	  its	  dependence	  of	  on	  miR-­‐122.	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Given	  HCV	  needs	  to	  bind	  miR-­‐122	  and	  the	  conserved	  nature	  of	  the	  miR-­‐122	  binding	  region	  across	  genotypes,	  we	  hypothesized	  that	  the	  miR-­‐122	  binding	  region	  would	   be	   a	   good	   target	   for	   siRNA	   mediated	   HCV	   RNA	   inhibition	   as	   a	   possible	  treatment.	  	  Our	  goals	  for	  these	  experiments	  were	  two	  fold.	  	  Firstly,	  we	  hypothesized	  that	   the	   siRNA	   could	   be	   used	   to	   knockdown	  HCV	  RNA	   levels	   in	   infected	   cells,	   but	  secondly,	  given	  the	  ability	  for	  HCV	  to	  escape	  siRNA	  treatment	  through	  incorporation	  of	   point	  mutations	   to	   the	   siRNA	   target	   sequence,	   we	   thought	   the	   siRNA	   could	   be	  used	  as	  a	  novel	  mutagenic	  tool	  to	  identify	  the	  mutational	  flexibility	  of	  the	  miR-­‐122	  binding	   region.	   These	   mutations	   could	   be	   further	   analyzed	   to	   gain	   a	   better	  understanding	   of	   the	   relationship	   between	   HCV	   and	   miR-­‐122.	   As	   expected	   our	  results	  indicated	  that	  the	  miR-­‐122	  binding	  region	  was	  susceptible	  to	  siRNA-­‐targeted	  degradation.	   	  The	  three	  siRNAs,	  designated	  si18-­‐36,	  si19-­‐37	  and	  si21-­‐43,	  designed	  to	  target	   the	  miR-­‐122	  binding	  region	  were	  able	  to	  cause	  a	  potent	  decrease	   in	  HCV	  replication	   levels	   in	   cell	   culture.	   This	  was	   observed	   in	   J6/JFH-­‐1	  Rluc,	   a	   full-­‐length	  construct	  capable	  of	  fulfilling	  the	  entire	  viral	  life	  cycle,	  and	  a	  sub-­‐genomic	  replicon	  capable	   of	   replicating	   but	   not	   assembling	   viral	   particles.	   Although	   all	   3	   siRNAs	  inhibited	  HCV	  replication,	  they	  varied	  in	  effectiveness	  with	  si18-­‐36	  being	  the	  most	  effective	  followed	  by	  si19-­‐37	  and	  si21-­‐43	  respectively.	  	  	  To	   evaluate	   the	   ability	   of	  HCV	   to	   escape	   the	   siRNAs	   targeting	   the	  miR-­‐122	  binding	   region	  we	  used	  HCV	  constructs	   that	   encoded	  a	  neomycin	   resistance	  gene.	  	  The	   neomycin	   resistance	   gene	   allowed	   us	   to	   positively	   select	   for	   cells	   containing	  replicons	   that	   were	   not	   inhibited	   by	   the	   siRNA.	   After	   seven	   rounds	   of	   treatment,	  HCV	   knockdown	   assays	   did	   not	   suggest	   the	   emergence	   of	   escape	   mutants	   to	   the	  miR-­‐122	   binding-­‐site	   targeting	   siRNAs,	   but	   they	   were	   detected	   in	   the	   positive	  control	   group	   (siJFH-­‐1	   6367).	   These	   results	   suggested	   that	   siRNAs	   targeting	   the	  miR-­‐122	  binding	  region	  could	  be	  used	  as	  potential	   treatment	   for	  patients	   infected	  with	  HCV.	  However,	  when	  we	  sequenced	  the	  5’UTR	  region	  of	  the	  selected	  RNAs	  we	  observed	  many	  genomes	  having	  point	  mutations	  in	  the	  siRNA	  targeted	  regions.	  This	  suggested	  that	  HCV	  RNAs	  could	  escape	  siRNA	  knockdown	  by	  introducing	  mutations	  into	   the	   miR-­‐122	   binding	   sites	   and	   the	   surrounding	   sequence.	   To	   determine	  whether	   HCV	   RNAs	   having	   a	   point	   mutation	   within	   the	   siRNA	   target	   site	   had	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escaped	   siRNA	   inhibition,	   we	   examined	   knockdown	   effectiveness	   of	   the	   siRNAs	  against	  a	  known	  replication	  competent	  HCV	  RNA	  having	  a	  point	  mutation	  within	  the	  miR-­‐122	  binding	  region.	  This	  HCV	  construct	  (HCV	  S1:p3)	  contains	  a	  point	  mutation	  in	  the	  first	  miR-­‐122	  binding	  site	  and	  replicates	  about	  10	  fold	  less	  efficient	  than	  WT	  virus	   constructs.	   The	   S1:p3	   mutation	   falls	   within	   the	   sequence	   targeted	   by	   all	   3	  siRNAs	   designed	   to	   target	   the	   miR-­‐122	   binding	   region.	   We	   expected	   that	   the	  sequence	  mismatch	  between	  HCV	  S1:p3	  and	  the	  siRNAs	  would	  attenuate	  or	  abolish	  siRNA	   knockdown	   ability,	   and	   this	   is	   what	   we	   observed	   for	   si18-­‐36,	   but	   the	  inhibitory	  effects	  of	  si19-­‐36	  and	  si21-­‐43	  were	  unexpectedly	  enhanced	  on	  the	  mutant	  virus.	  Specifically,	  si18-­‐36,	  which	  is	  the	  most	  effective	  against	  WT	  virus,	  lost	  most	  of	  its	  potency.	  However,	  si19-­‐36	  and	  si21-­‐43	  which,	  were	  less	  effective	  than	  si18-­‐36	  at	  inhibiting	  WT	  virus	  were	  more	  effective	  on	  the	  mutant	  virus.	  This	  observation	  was	  surprising,	  as	  we	  had	  predicted	  the	  point	  mutation	  would	  render	  all	  3	  siRNAs	   less	  potent,	   since	   the	   imperfect	   complimentary	   of	   the	   siRNA	   with	   its	   target	   would	  prevent	  siRNA-­‐mediated	  cleavage.	  	  	  	  	  A	   possible	   explanation	   for	   this	   observation	   is	   that	   si19-­‐37	   and	   si21-­‐43	   in	  association	   with	   Ago2	   are	   a	   competitive	   inhibitor	   that	   blocks	   miR-­‐122/Ago2	  complexes	   from	   binding	   to	   miR-­‐122	   binding	   site	   2.	   The	   location	   of	   the	   point	  mutation	   in	   the	   HCV	   S1:p3	   construct	   prevents	  miR-­‐122	   from	   binding	   to	   the	   first	  miR-­‐122	  seed	  sequence	  in	  the	  5’UTR,	  therefore	  replication	  of	  this	  construct	  relies	  on	  miR-­‐122	  binding	  to	  the	  second	  site.	   	  Since	  si19-­‐37	  and	  si21-­‐43	  overlap	  the	  second	  miR-­‐122	   binding	   site	   and	   si18-­‐36	   does	   not,	   I	   suspect	   that	   these	   siRNAs	   retain	  knockdown	  efficacy	  by	  blocking	  miR-­‐122	  binding	  to	  site	  2.	  	  As	  the	  administered	  siRNAs	  are	  double	  stranded,	  the	  efficiency	  by	  which	  they	  are	  processed	  and	   incorporated	   into	  Ago2/RISC	  complex	  will	  also	  affect	   inhibition	  efficiency.	  	  As	  si18-­‐36	  and	  si19-­‐37	  were	  demonstrated	  to	  function	  equally	  well	  as	  a	  siRNA	  when	  suppressing	  mRNA	  expression	  in	  a	  control	  assay,	  we	  conclude	  that	  they	  are	  processed	  and	   incorporated	   into	  a	  RISC	  with	   similar	   efficiency.	  Therefore	   it	   is	  reasonable	   to	  expect	   the	  difference	   in	   their	   function	  against	  HCV	   is	  not	  a	   result	  of	  their	   ability	   to	   be	   incorporated	   into	   the	   RISC.	   On	   the	   other	   hand,	   si21-­‐43	   was	  observed	  to	  be	  less	  effective	  at	  suppressing	  a	  control	  mRNA	  than	  si18-­‐36	  and	  si19-­‐
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37	  and	  we	  concluded	   that	   it	  was	   less	   functional	   against	  WT	  HCV	  because	   it	   is	  not	  processed	  into	  a	  RISC	  as	  efficiently.	  	  	  	  We	  propose	  that	  si18-­‐36	  is	  more	  effective	  at	  inhibiting	  WT	  HCV	  than	  si19-­‐37	  because	   of	   differences	   in	   how	   they	   physically	   interact	   with	   the	   5’UTR.	   	   The	  difference	  between	  the	  two	  siRNA	  is	  1	  nucleotide	  and	  we	  believe	  that	  it	  is	  significant	  that	  the	  one	  different	  nucleotide	  targets	  the	  first	  nucleotide	  of	  the	  second	  miR-­‐122	  seed	  sequence	  on	  HCV	  5’UTR.	  	  Thus,	  si18-­‐36	  targets	  only	  the	  first	  miR-­‐122	  binding	  site	  and	  the	  space	  between	  the	  two	  seed	  sequences,	  while	  si19-­‐37	  targets	  the	  first	  miR-­‐122	  seed	  sequence,	  the	  space	  between,	  and	  1	  nucleotide	  of	  the	  second	  miR-­‐122	  seed	  sequence.	  Therefore	  we	  speculate	  that	  si18-­‐36	  is	  competing	  with	  just	  one	  miR-­‐122	  for	  binding	  to	  the	  5’UTR,	  while	  si19-­‐37	  is	  less	  efficient	  since	  it	  is	  competing	  with	  two	   miR-­‐122s	   for	   the	   5’UTR.	   In	   the	   case	   of	   WT,	   we	   assume	   that	   the	   siRNA	  interaction	   with	   the	   5’UTR	   leads	   to	   a	   cleavage	   of	   the	   genome,	   which	   prevents	  replication.	   In	   the	   case	   of	   the	   mutant	   construct,	   we	   speculate	   that	   si18-­‐36	   is	  ineffective	  since	  it	  does	  not	  induce	  cleavage	  due	  to	  the	  sequence	  mismatch,	  and	  does	  not	  block	  miR-­‐122	  binding	  to	  the	  second	  seed	  site,	  and	  that	  si19-­‐37	  is	  effective	  since	  it	   competitively	   inhibits	  miR-­‐122	   binding	   to	   site	   2.	   This	  model	   also	   explains	  why	  si21-­‐43	   is	  more	  potent	   against	   the	  mutant	  HCV	   construct	   than	   the	  WT,	   since	   it	   is	  predicted	   to	   also	   compete	   with	   miR-­‐122	   for	   binding	   the	   second	   miR-­‐122	   seed	  sequence.	   This	   observation	   suggests	   that	   siRNA	   targeting	   the	   miR-­‐122	   binding	  region	   has	   a	   potential	   dual	   mechanism	   of	   inhibiting	   HCV	   replication:	   first	   by	   the	  classical	   siRNA	   mediated	   target	   cleavage	   and	   second	   by	   acting	   as	   a	   competitive	  inhibitor	  for	  the	  miR-­‐122	  binding	  sequences.	  Currently	   a	   promising	   treatment	   for	   HCV	   is	   utilizing	   LNA-­‐122	   to	   bind	   and	  sequester	  miR-­‐122,	   thus	  preventing	   it	   from	  being	  used	  by	  HCV.	   It	   is	   possible	   that	  combination	   treatment	   of	   LNA-­‐122	   with	   siRNA	   targeting	   the	   miR-­‐122	   binding	  region	  could	  be	  an	  even	  more	  efficient	  treatment.	  The	  combination	  treatment	  would	  have	   three	   modes	   of	   action,	   miR-­‐122	   sequestration,	   HCV	   RNA	   cleavage,	   and	   by	  blocking	   any	   residual	   miR-­‐122	   from	   binding	   to	   the	   5’	   UTR.	   The	   combination	  treatment	   may	   also	   function	   synergistically,	   since	   firstly,	   siRNA	   knockdown	   may	  enhance	   degradation	   of	  HCV	   genomes	   to	  which	  miR-­‐122	   does	   not	   bind,	   secondly,	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sequestration	   of	   miR-­‐122	   may	   enhance	   siRNA	   cleavage	   of	   the	   naked	   5’UTR,	   and	  thirdly,	   the	   siRNA	   could	   out	   compete	   any	   residual	  miR-­‐122	   that	   LNA-­‐122	   did	   not	  sequester.	  Synergism	  between	  LNA-­‐122	  and	  siRNAs	   targeting	   the	  miR-­‐122	  sites	   is	  currently	  being	  assessed.	  	  Another	   surprising	  outcome	   from	  these	  studies	  was	   that	   in	   si18-­‐36	   treated	  cells	   escape	  mutants	   were	   viable.	   Viral	   RNAs	   isolated	   and	   sequenced	   after	   seven	  rounds	   of	   treatment	   with	   si18-­‐36	   and	   selection	   with	   G418	   had	   mutations	  throughout	   the	   5’UTR	   including	   the	   miR-­‐122	   binding	   region	   and	   siRNA	   target	  sequence.	   The	   5’UTR	   of	   the	   si19-­‐37	   treated	   cells	   also	   contained	   mutations	  throughout.	  	  With	  further	  analysis	  we	  concluded	  that	  the	  potency	  of	  si18-­‐36	  against	  a	  miR-­‐122	  binding	  site	  1	  point	  mutant	  S1:p3	  was	  substantially	  decreased	  compared	  to	  WT	  explaining	  why	  viruses	  having	  point	  mutations	  were	  selected.	  	  Each	   mutation	   observed	   within	   the	   miR-­‐122	   binding	   region	   represents	   a	  possible	   escape	  mutant	   and	  will	   be	   cloned	   into	   J6/JFH-­‐1	   Rluc	   and	   assayed	   for	   its	  effect	   on	   replication	   and	   its	   ability	   to	   replicate	   in	   the	   presence	   or	   absence	   of	   the	  siRNA	  and	  miR-­‐122.	   	  We	  observed	  several	  mutations	  downstream	  of	   the	  miR-­‐122	  binding	  region	  whose	  confirmation	  were	  found	  previously	  by	  SHAPE	  analysis	  to	  be	  modified	   by	   miR-­‐122	   binding	   to	   the	   5’UTR	   (115).	   These	   mutations	   will	   also	   be	  cloned	   into	   J6/JFH-­‐1	   Rluc	   and	   assayed	   for	   their	   functionality	   in	   the	   presence	   or	  absence	  of	  miR-­‐122.	  Of	  note,	  we	  observed	  several	  mutations	  in	  HCV	  initiation	  codon,	  suggesting	   that	   some	   escape	   mutants	   had	   adaptive	   mutations	   in	   which	   reporter	  gene	   translation	  may	  have	  been	  abolished.	  Evidence	  suggested	   that	   these	  mutants	  enhanced	   RNA	   replication	   independent	   from	   an	   effect	   on	   miR-­‐122	   activity	   since	  they	  were	  also	  isolated	  in	  a	  control	  experiment	  to	  select	  for	  siRNA	  escape	  mutants	  against	  a	  siRNA	  that	  did	  not	  target	  the	  miR-­‐122	  binding	  sites.	  These	  mutations	  are	  certainly	  due	  to	  the	  bicistronic	  construct	  used,	  since	  if	  these	  mutations	  abolish	  virus	  polyprotein	   translation	   in	   a	   full-­‐length	  monocistronic	   construct,	   replication	  would	  also	  be	  abolished.	  Thus,	  we	  also	  plan	  to	  isolate	  escape	  mutants	  in	  the	  context	  of	  full-­‐length	  monocistronic	  HCV	  RNAs	  in	  the	  future.	  	  	  Utilizing	  siRNAs	  targeting	  the	  miR-­‐122	  binding	  region	  we	  have	  achieved	  both	  of	  our	  objectives.	  Firstly,	  we	  have	  shown	  a	  proof	  of	  principle	  experiment	  that	  they	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can	   be	   used	   as	   a	   possible	   treatment	   for	   HCV,	   and	   surprisingly,	   their	   inhibition	   of	  HCV	  is	  potentially	  though	  two	  mechanisms.	  Secondly,	  the	  siRNAs	  induced	  potential	  escape	   mutants	   with	   unique	   sequences,	   which	   upon	   further	   analysis	   will	  demonstrate	  the	  mutational	  flexibility	  of	  the	  miR-­‐122	  binding	  region	  that	  could	  lead	  to	  the	  evolution	  of	  a	  virus	  that	  can	  grow	  independent	  from	  miR-­‐122	  which	  would	  be	  a	  valuable	  tool	  to	  study	  the	  mechanism	  of	  action	  of	  miR-­‐122.	  	  	  
 General	  Conclusions	  8.2 	  
• DDX6	  augments	  HCV	  translation.	  
• DDX6	  augments	  HCV	  replication.	  
• The	  mechanism	  of	  DDX6	  augmentation	  of	  HCV	  translation	  and	  replication	  is	  separate	   from	   that	   of	   miR-­‐122	   augmentation	   of	   HCV	   translation	   and	  replication.	  
• DDX6	  does	  not	  promote	  miRNA	  directed	  gene	  silencing	  in	  Huh7.5	  cells.	  
• miR-­‐122	  augments	  HCV	  translation.	  
• siRNAs	   designed	   to	   target	   the	   miR-­‐122-­‐binding	   region	   inhibit	   HCV	  replication.	  
• The	   siRNA	   targeting	   the	   miR-­‐122	   binding	   region	   have	   variable	   inhibitory	  effects	   on	   viral	   RNA	   having	   point	   mutations	   within	   the	   target	   sequences	  which	  suggests	  that	  they	  may	  inhibit	  HCV	  replication	  by	  two	  mechanisms.	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